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There are many protein-protein interactions that are vital for cellular processes such as signal 
transduction, structural organisation and apoptosis. In this study we decipher the role of the 
protein-protein interaction of C-terminal Binding Proteins (CtBPs). CtBPs function as 
transcriptional co-repressors in the nucleus playing key roles in tumorigenesis and metastasis by 
regulating cellular processes, critical to cell survival, cell migration and senescence. CtBP 
proteins also play a role in the cytoplasm in regulating mitotic Golgi membrane fission Studies 
in which the expression or function of CtBPs has been inhibited have independently identified 
roles for CtBPs in both suppressing apoptosis and promoting cell cycle progression.  
  Modulation of these interactions with small molecules is a potential therapeutic strategy with 
benefits over current methods. Our approach in studying protein-protein interactions and 
uncovering potential inhibitors involves constructing a bacterial Reverse Two Hybrid System 
(RTHS) linking the dimerisation of the target protein partners to the expression of reporter 
genes, whose regulation can be monitored via host survival.  Subsequent screening of a cyclic 
peptide library for potential inhibitors was then carried out. The libraries were produced using 
Split Intein-mediated Circular Ligation Of Peptides and Proteins (SICLOPPS) technology, 
developed for intracellular synthesis of cyclic peptides. We have used this methodology to 
identify inhibitors of CtBP dimerisation and better understand the roles of this protein 
interaction in cell cycle regulation. 
  Chapter 1 provides an introduction to the work carried out to study protein-protein interactions 
and finding potential inhibitors. Since our investigations involved the extensive use of the 
RTHS and SICLOPPS system, the background and work performed by others has been 
described in detail. A detailed review of CtBPs has also been carried out. 
  Chapter 2 details our work investigating the homodimeric and heterodimeric protein-protein 
interaction of CtBPs using the RTHS. This work allowed us to optimise selection conditions 
and find cyclic peptide inhibitors of the homodimerisation of CtBP1 and CtBP2 using the 
SICLOPPS process. The synthesis of these inhibitors is described. 
  Chapter 3 details our work carried out to develop ELISAs for in vitro analysis of the selected 
cyclic peptides. This involved the purification of His- and GST-tagged CtBP1 and CtBP2 
proteins. The ELISA conditions were optimised to carry out CtBP homodimeric and 
hetrodimeric analysis. This work showed that the peptides lead to a reduction in CtBP 
homdimerisation and heterodimerisation in vitro. 
  Chapter 4 details the in vivo effects of the uncovered CtBP dimerisation inhibitors. Using these 
cyclic peptide inhibitors we have demonstrated that CtBP dimerisation is essential for the 
regulation of mitotic fidelity, and that inhibition of CtBP dimerisation by the cyclic peptides 
leads to aberrant segregation of chromosomes during mitosis. We have also shown that 
inhibition of CtBP dimerisation leads to a reduction in migration of MCF-7 breast cancer cells. 
Chapter 5 details the experimental procedures used in this work and presents spectroscopic and 
analytical data for the compounds prepared.   
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Abbreviation 
A    adenine 
aa    Amino acids   
3-AT    3-amino-1, 2, 4-triazole 
Amp    Ampicillin 
ARF    Alternative reading frame  
Arg    Arginine 
Asp    Aspartic acid 
ATP    adenosine triphosphate 
Aq    Aqueous 
Bcl-2     B cell lymphoma 
BARs    brefeldin A-ADP ribosylation substrate 
BKLF    basic Krüppel-like factor 
bp     base pair   
BRCA1  breast cancer 1 
BSA    Bovine serum albumin 
C    cytosine 
CoREST  REST corepressor 
CtBP    C-terminal Binding protein 
  hCtBP human CtBP 
  mCtBP mouse CtBP 
  dCtBP drosophila CtBP 
Cys     Cysteine  
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DAPI    (4,6-diamidino-2-phenylindole) 
DBD    DNA binding Domain 
DCC    N,N'-dicyclohexylcarbodiimide 
DCM    Dichloromethane 
DIC    N,N'-diisopropylcarbodiimide 
DIPEA   N,N-diisopropylethylamine   
DMAP   4-dimethylamino pyridine 
DMEM  Dulbecco’s modified Eagle’s medium 
DMF     N,N-dimethylformamide 
DMSO   dimethyl sulphoxide 
DNA     deoxyribonucleic acid 
dNTP    deoxyribonucleotide triphosphate 
EBNA3C  Epstein-Barr virus 
EC50    half maximal effective concentration 
EDC    1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EDT    Ethane dithiole 
EDTA   Ethylenediaminetetraacetic acid 
EMT    epithelial-mesenchymal transition  
ELISA   Enzyme-linked immunosorbent assay 
Et2OH   Ethanol 
eq    equivalents  
FCS    Fetal Calf Serum 
FITC    fluorescein isothiocyanate  
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Fmoc    9-Fluorenylmethyloxycarbonyl chloride 
FPLC    Fast protein liquid chromatography 
G    guanine 
Gly    Glycine 
GST    Glutathione S-transferase 
HAT    Histone acetyl transferase 
HDAC   Histone Deacetylase 
Hdm2    Human double minute 2 gene 
Hdm2    Human double minute 2 protein 
His    Histidine 
HM ESI  High mass electrospray ionisation 
HMTase  Histone methyltransferase 
HOBt    Hydroxybenzotriazole 
HPLC   High-performance liquid chromatography 
HPSS    Hank's Balanced Salt Solution 
hr    hour 
HRP    Horseradish peroxidise 
IC    C-Intein 
Ig    Immunoglobulin 
IN    N-Intein 
IPTG    isopropyl β-D-1-thiogalactopyranoside 
IR    Infrared 
Kan    Kanamycin  
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kB     kilo base pair 
kDa    kilo Dalton 
LB    Luria-bertani Broth  
LCI    Live Cell Imager 
LSD1    Lysine-specific demethylase 
M    Molar concentration 
MCS    multiple cloning site 
mAb    monoclonal antibody 
MCF-7   Michigan Cancer Foundation – 7 (breast cancer cell line) 
Mdm2   murine double minute 2 gene 
Mdm2   murine double minute 2 protein 
MeCN   Acetonitrile 
MeOH   Methanol 
Met    Methionine 
mFIP    Multiple fluorescence  
min    minutes 
mmol    millimole 
mol    moles 
MS    Mass spectrometer 
MTS  (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) 
MW    molecular weight 
m/z    mass to charge ratio  
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NADH   Nicotinamide adenine dinucleotide 
NBD    Nucleotide binding domain 
NLS    Nuclear localisation signal 
NMP    1-methyl-2-pyrrolidinone 
NMR    nuclear magnetic resonance  
OD    optical density 
o/n    overnight 
ONPG   ortho-Nitrophenyl-β-galactoside 
p300    E1A binding protein p300 
PAK1    p21-activated kinase 1 
PBS    Phosphate buffered saline 
PCR    polymerase chain reaction 
pI    isoelectric point 
pRB    Retinoblastoma protein 
Pro    Proline 
PTac    Tac promoter 
PyBop   benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
Pyr    Pyridine 
PXDLS  Proline-X- Aspartic acid-Leucine- serine (X = any amino acid) 
RBS    ribosome binding site 
RNA    Ribonucleic acid 
RNAi    RNA interference 
RRT    Arginine-Arginine-Threonine   
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rt    room temperature  
RTHS   Reverse two-hybrid system 
SBD    Substrate Binding domain 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Sec    seconds 
Ser    Serine 
Sumo    small ubiquitin-like factor 
SICLOPPS  Spilt-intein circular ligation of peptides and proteins 
siRNA   Small interfering RNA 
SOC    Super Optimal broth with Catabolite repression 
Spec    Spectinomycin 
SPPS    solid phase peptide synthesis 
SRC    steroid receptor coactivator 
T    thymine 
TAE    Tris-acetate-EDTA 
Tat    Trans-activator of transcription 
TBS    Tris buffered saline 
Temp    temperature 
TFA    Trifluoroacetic acid 
Thr    Threonine 
TIS    Triisopropyl silane   
TLC    Thin layer chromatography 
TNF-α     Tumour necrosis factor alpha  
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tRNA    transfer RNA 
Trp    Tryptophan 
Tyr    Tyrosine 
Ubc9    Ubiquitin carrier protein 9   
UV    Ultra violet 
Val    Valine 
VMA    Vacuolar Membrane ATPase 
wt    wild type 
Y2HS    yeast two-hybrid system 
ZEB    Zinc finger E-box-binding homeobox 
ZnF217  Zinc finger protein 
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1  Introduction 
 
1.1   Protein-Protein interaction 
There are a large number of protein-protein interactions that control and regulate many 
cellular processes, for example metabolic pathway, signal transduction and programmed 
cell death. For this reason, there is significant current interest in studying the potential 
of this class of interaction as a general drug target. Low molecular weight chemical 
compounds that are bound to a protein may prevent the formation of protein dimers. 
Although typically large and featureless, protein-protein interfaces display an overall 
match between polar residues through large hydrogen bond networks, often mediated by 
water molecules and hydrophobic interactions between aliphatic and aromatic patches. 
Correctly identifying the role of a protein-protein interaction can help assign the true 
cellular function of a given proteins, investigate the mechanism of intracellular 
biochemical pathways, understand the primary courses of diseases and could lead to the 
development of drugs to treat diseases.
1  
Large scale siRNA screening can be used to investigate the function of genes 
individually in a high throughput manner with respect to biological function and cellular 
processes. Treatment with siRNA leads to gene silencing by destroying mRNA that 
encodes a protein therefore preventing the protein from being synthesised. Methods of 
introducing siRNA into the cells include introducing an expression vector, which allows 
the cells to express the siRNA. An advantage of this method is that it allows persistent 
gene silencing after stable integration of the vector into the host genome. This leads to 
complete knock out of the protein. This process is complicated, time consuming and 
more expensive than other methods. Another method involves the synthesis and 
transfection of long double stranded (ds) siRNA (200 nt). Once introduced into the cell 
ds siRNA can be cleaved by the DICER complex forming siRNA. This method is easier 
and more cost effective. Small siRNA can be created in vitro and transfected into the 
cells once present in the cells ds siRNA is denatured and bound by the RISC complex. 
Small siRNA can be purchased directly, complete knock down is not guaranteed.
2, 3 
There are many therapeutic uses of siRNA, for example treatment of cancer, viral and 
genetic diseases.
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Advantages of siRNA screening include: 
•  Quick method to knock down a specific gene. 
•  siRNA can be labeled. 
•  Ease of transfection. 
•  Chemical modifications to enhance stability are possible. 
•  Allows the depletion of any protein as long as the sequence is known. 
•  Perfect drug for the specific blocking of unwanted or disease causing genes 
Disadvantages of siRNA screening include: 
•  May not work in cell lines difficult to transfect. 
•  Is expensive for larger experiments. 
•  Short-term, transient knock down only. 
•  Chemically synthesized siRNA is short lived. 
•  Results in transient inhibition of gene expression. 
•  Off-target effects resulting in knock down unintended genes due to mismatches 
and gaps between small RNA and target RNA sequences. 
•  Degree of knock down is variable. 
•  The protein is removed from the system, therefore further analysis is required to 
identify the underlying mechanism of the cellular process of interest. 
Manipulation of protein-protein interactions has proven challenging. Unlike enzyme 
based drug discovery, there is a no clear starting point for drug design, because in 
nature, few small molecules bind at protein-protein surfaces. Protein-protein interfacial 
surface areas are typically large, suggesting that macromolecules may be better suited as 
inhibitors (as opposed to small molecules).
5 Other difficulties include the fact that 
interacting surfaces are often shallow and featureless compared to the well-defined 
binding pockets for enzyme active sites. This may cause problems with selectivity, 
because on such surfaces there is not enough contact to achieve specificity through 
shape recognition for a small molecule, as typically observed in deep binding enzyme 
pockets. Studies focusing on protein interfaces have shown that binding energies are not 
uniformly distributed, but instead there are certain important residues called hot spots. 
These residues comprise a small fraction of  interfaces but account for the majority of 
the binding energy.
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However, in most cases there is only one hot spot present at the interface and on 
average it has a surface area of 1560 ± 340Å upon binding.
7 It is therefore difficult to 
know where on the interface these hot spot areas are and often there is no associated 
crystal structure, which makes rational design very difficult.
8 
A great deal of work has gone into understanding protein-protein interactions and trying 
to find potential inhibitors. Traditional drug development involves random screening of 
molecules this process is very lengthy, expensive and gives low yields. Computational 
methods have been proposed to predict protein-protein interactions, for example 
computer-aided drug design (CADD). The CADD method refers to the application of a 
variety of computational methods to drug discovery and design. It is possible to identify 
appropriate binding sites to be targeted during virtual database screening. CADD 
exploits state-of-the-art technology to speed up the drug development process. 
Advantages of CADD process are as follows: It is target specific and structure based, 
fast, automatic and has a low cost.
9 Disadvantages of the process are as follows: due to 
combinatorial attachment, a number of diverse chemical components arise that in 
reality, may be synthetically unfeasible structures; many ligands are produced that are 
chemically unstable and although a diverse set of chemical building blocks are used, the 
manner of attachment depends entirely on the developer of the software. 
Another methodology used to identify interacting proteins or to study protein 
interactions is the yeast two-hybrid system (YTH), which is used to identify mutations 
that affect protein-protein interactions. YTH is also used to find proteins that interact 
with a single protein of interest and used to confirm suspected interactions and to define 
interacting domains.
10 It provides direct evidence of physical protein-protein 
interactions in high-throughput analysis.
11 Detection of protein-protein interactions in 
the YTH is based on the reconstitution of transcription factors divided into a DNA 
binding domain (DBD) and a DNA activation domain (AD). One of the proteins is 
fused to the DBD and the other to the AD. Productive interaction of the proteins of 
interest will bring the two domains together and will trigger the transcription of an 
adjacent reporter gene for example lacZ. However, there are some limitations to this 
process: the location of the interaction is restricted to the nucleus, which is not suitable 
for the study of membrane proteins and large size proteins. Also transcription factors 
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cannot be targeted to the nucleus may not yield a transcription signal even though it 
may potentially interact, causing false negatives. 
12 
The bacterial two-hybrid (BTH) system is similar to the yeast two-hybrid system. It 
allows the identification of protein-protein interactions in Escherichia coli. This 
technique enables a fast and simple approach to identifying protein-protein 
interactions.
12a Both the YTH and BTH system are limited to positive selection for 
protein-protein association events and do not allow the detection of dissociation events 
for examples mutations in one of the interacting proteins or introduction of an inhibitor. 
 
1.2  Reverse Two Hybrid Systems (RTHS) 
The original forward two hybrid systems can be altered to couple cell growth to the 
disruption of protein complexes, and this methodology is referred to as the reverse two-
hybrid system (RTHS). An important feature of the RTHS is the incorporation of 
reporter genes to monitor the protein-protein interaction, whose product is toxic to 
growing cells. Allowing selective pressure against the formation of the two-hybrid 
complex, Vidal et al developed a RTHS in yeast where URA3 was used as a reporter 
gene. The URA3 gene encodes an enzyme required for the biosynthesis of uracil. Yeast 
cells that express URA3 fail to grow on media containing 5-fluoro-orotic acid (5-FOA) 
because the URA3 enzyme transforms 5-FOA into a toxic compound.
13, 14 When the 
proteins of interest interact the URA3 gene is expressed leading to the death of yeast cell 
on media containing 5-FOA. When the protein-protein interaction is disrupted either by 
a mutation or the presence of an inhibitor the URA3 gene is no longer expressed 
therefore cells are able to survive on media containing 5-FOA. This process allows the 
screening of libraries of randomly generated mutation and potential drugs. 
Another reporter gene used was LacZ, which allows quantification of the 
protein-protein interactions through β-galactosidase assays. Hannick et al 
15 reported 
that biochemical assays for LacZ expression were relatively insensitive and lead to high 
frequency of false positives. They therefore developed a system dependent on cell 
viability, for example the introduction of a selective marker HIS3. The HIS3 genes 
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synthesis of histidine and is able to complement the growth defect of cells bearing a 
deletion in the homologous.
16  
The RTHS
17 can be used for both studying protein-protein interactions and for rapid 
screening of inhibitors of protein-protein interactions. The RTHS used in this study is 
based on the bacteriophage regulatory system, linking the disruption of the interaction 
between the two target proteins, expressed as hybrid fusion of a chimeric repressor 
complex, to the expression of three reporter genes. The λ phage active repressor is a 
homodimer formed by 2 cI molecules. The λ cI is a transcriptional repressor that 
controls the lytic/lysogeny cycle of bacteriophage λ, the N-terminal domain is 
responsible for DNA operator, recognition and binding. The C-terminal domain 
mediates dimerisation. The N-terminal domain alone can not form an active repressor, 
but if bound to a protein able to dimerise a functional chimeric repressor can be 
restored.
18 The bacteriophage 434 is a close relative of bacteriophage λ and encodes a 
regulatory protein that both activates and represses transcription.
19 Repressor dimers 
bind cooperatively to a region of the phage chromosome called (OR) that contains three 
repressor binding sites (OR1, OR2, OR3). PR and PRM are promoter regions present with 
in OR. The Salmonella phage P22 and the coli-phage 434 and λ repressor all share 
sequence similarities within the C-terminal domain.
19, 
20, 
21 These proteins can only 
form homodimers. The dimerisation interface of the 434 repressor is located within 15 
amino acids of the C-terminal end of the protein. In order to study protein 
heterodimerisation G. Di Lallo et al 
22 generated a chimeric operator in which the DNA 
sequence coding for the amino acids in this region were replaced with the homologous 
region of p22 repressor. The operator can be recognised and bound only by a hybrid 
repressor formed by two chimeric monomers. Only proteins, which allow dimerisation 
of the two chimeric reporters allow the formation of a functional repressor able to bind 
the P22-434 hybrid operator and prevent synthesis of down-stream reporter genes.                                                                  Chapter 1:  Introduction   
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Figure 1.1  (A) Chimeric 434 and P22 promoter, (B) Wild-type 434 promoter.
17b 
 
Our homodimeric RTHS uses the 434 binding protein and the heterodimeric RTHS uses 
a mutant 434, p22 and the wild-type 434 binding protein (Figure 1.1). A plasmid, which 
codes for two fusion proteins, is constructed. Each fusion protein consists of one of the 
protein partners of the protein-protein interaction under investigation and one half of the 
repressor. Once the plasmid is introduced into the cell and transcribed, protein partners 
are able to come together forming the protein complex. This brings the two halves of 
the repressor into contact, reconstituting the active repressor that will bind its 
corresponding operator sequence that has been incorporated onto the chromosome. The 
repressor has control over downstream reporter genes that are essential for the life of the 
cell on minimal media; the formation of the active repressor prevents their transcription 
and leads to cell death.
17b In this system, potential inhibitors of the dimerisation can be 
introduced and cells containing active inhibitors can easily be identified on selective 
media, as they are the ones able to survive (Figure 1.2).
17a, 23 
The reporter construct is engineered onto the chromosome of the E.coli host cell strain 
containing a HisB deletion.  HisB codes for imidazole glycerol-phosphate (IGP) 
dehydratase and histidinol-phosphate (HOL-P) phosphatase which catalyse the sixth and 
eighth step of histidine biosynthesis, respectively
24.  The reporter construct consists of 
three reporter genes: HIS3. The second reporter is Kan
R, which codes for 
aminoglycosidase 3’-phosphotransferase for kanamycin resistance. These two reporters 
are chemically tuneable and conditionally selective for reporter genes. The third 
reporter gene is Lac Z (β-galactosidase).
13 Formation of the protein complex inhibits the 
growth on minimal media by blocking HIS3 expression. Residual background can be 
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glycerol phosphate dehydratase and so inhibits histidine biosynthesis and growth) and 
kanamycin. Figure 1.2 shows an example of how the RTHS system works.
17 
 
Figure 1.2 RTHS, (A), homodimerisation of two fusion proteins leads to the 
transcription of an active repressor protein, preventing the transcription of HIS3 
reporter gene, therefore causing non-growth of phenotypes on the plate without 
histidine. (B), Mutation or introducing a small molecule allows HIS3 expression 
and survival of cells as the repressor is not formed.
17a 
 
The RTHS has been used to decipher interactions used by the influenza virus non-
structural protein1 (NS1) protein to silence the host antiviral sensor protein, retinoic 
acid inducible gene-1 (RIG-1). NS1 is widely regarded as a factor that antagonises the 
host’s immune responses. RIG-1 acts as a sensor for influenza and other negative strand 
RNA viruses. The gene encoding the Influenza A NS1 was cloned into the N-terminal 
fusion with 434, while RIG-I or tripartite motif protein 25 (TRIM25) was cloned as an 
N-terminal fusion with P22. The resulting plasmids were integrated into the 
chromosome of the RTHS strain (SNS126). The protein-protein interaction was 
quantified using o-nitrophenol-β-galactoside (ONPG) assays. A direct interaction 
between NS1: RIG-I and NS1: TRIM25 was observed.
25  
In this study we have combined the RTHS with a biosynthetic library of ~10
8 cyclic 
peptides, produced using split intein-mediated circular ligation of peptides and proteins 
(SICLOPPS). The advantage offered by this approach is the ability to link both the 
Histidine Auxotroph
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434 434
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cyclic peptide inhibitor and target protein to DNA encoding and compartmentalise the 
entire assay with cells, which allows for genetic selection to be performed instead of a 
screen. This has previously been used to indentify small molecule inhibitors of the 
homdimeric interaction of ATIC
17a which is involved in the production of purines and 
the heterodimerisation of p6 and UEV involved in HIV budding
26. This current study 
looks into the protein-protein interaction of C-terminal binding proteins (CtBPs) using 
the RTHS (Figure 1.3). This will then be combined to SICLOPPS to uncover potential 
cyclic peptide inhibitors.  
 
Figure 1.3 RTHS constructs for CtBP heterodimerisation, CtBP1 and CtBP2 
homodimerisation. 
 
1.3   Split intein-mediated circular ligation of peptides and proteins 
(SICLOPPS): 
Both synthetic and genetic methods have been extensively employed to generate 
molecular libraries. Both methods have their advantages and disadvantages. Synthetic 
methods readily generate libraries of small, drug-like molecules rich in chemical 
diversity. Moderate library sizes of 10
3-10
5 members are attainable by these approaches. 
Genetic encoding enables the generation and screening of large libraries (10
6-10
10) in 
vivo.
27 Many genetically encoded libraries have been developed for the discovery of 
potential drug targets. DNA-encoded chemical libraries allow the discovery of small 
molecules ligands against target proteins of biological or pharmaceutical importance. 
This involves the covalent attachment of individual compounds to unique DNA                                                                  Chapter 1:  Introduction   
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fragments. These libraries can then go through affinity-based selection; this involves the 
incubation of the library with a target protein of choice immobilised on a solid support. 
The non-binding molecules can be removed by washing the solid support. The DNA 
code of the bound molecule can be amplified via PCR. High throughput sequencing 
allows for the identification of the compound. Which can then be synthesised for 
biological or biochemical assays. A disadvantage of this process is that it is difficult to 
discriminate between ligands with different binding affinities, which depends on the 
coating densities of the target protein on the solid support.
28 
DNA-encoded chemical libraries share features with biological and biochemical display 
technologies such as phage display technology, which allows the isolation of billions of 
polypeptides. The gene encoding a specific protein is inserted into the genome of a non-
lytic phage. After production of the phages in bacteria the DNA encoded polypeptide is 
displayed on a defined coat protein of the respective phage. This can also be applied to 
ribosome display and yeast display. A drawback of these methods is that they are 
limited to the display and selection of polypeptides and proteins. Display of small 
molecules showed to be more complex and led to smaller library sizes.
29, 28 
In this study we use cyclic peptide libraries encoded by split inteins (SICLOPPS). Cyclic 
peptides are an important class of therapeutics with pharmacological function ranging from 
immunosuppressants to antineoplastic, antibacterial and antiviral agents. Many natural 
products with a wide range of pharmacological activities are derived from cyclic 
polypeptides. Production of cyclic peptides is advantageous in that they are more resistant to 
cellular catabolism such as degradation by proteases than their linear counterparts therefore 
have a longer drug half-life.
23 Like peptide aptamers and disulfide-linked peptides, the 
constrained scaffolds of cyclic peptides enhances their binding affinity compared to the 
linear counter-part and that improves the binding ability for target sites. Giebel et al showed 
that cyclic peptides had 100-fold to 1000-fold higher affinity than the liner counterpart.
30 
Peptides are particularly well suited to be modulators of protein-protein interface as they are 
themselves composed of amino acids.
23, 31 
Post-translational rearrangement was discovered in the Saccharomyces cerevisaiae 
vascular ATPase where a segment of over 400 amino acids was excised out of the VMA 
host protein (extein) and the two flanking halves were ligated to form the functional 
VMA subunit.
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other cellular entities via a self catalysed post-translational process in which an 
intervening sequence (intein) excises itself out of precursor polypeptide resulting in 
linkage of the flanking sequence (extein) by a native bond. There is little homology in 
the extein sequence, therefore it can be replaced with a foreign sequence without major 
effect on the splicing and cleavage process.
23 However, the efficiency of the intein-
mediated protein ligation is known to depend on the identity of the extein amino acid 
residues immediately adjacent to IC and IN. The extein residue immediately adjacent to 
the C-intein (IC+1) serves as a nucleophile for the transesterification reaction, 
generating the branched and lariat intermediates in protein splicing and circular ligation, 
respectively. Only three residues occupy the IC+1 position in active inteins: cysteine, 
serine and threonine. Cysteine serves as the transesterification nucleophile for the wild-
type Ssp DnaE intein. C.P. Scott et al. evaluated the dependence of circular ligation on 
the identity of the transesterification nucleophile. The cyclic peptide production was 
evaluated following in vitro incubation and elution from the chitin affinity column. All 
three constructs were well expressed and showed evidence for the post-translational 
processing by PAGE (Polyacrylamide gel electrophoresis) analysis.
33 Inteins catalyze a 
highly specific N-(S/O) acyl shift at the N-terminal splice junction followed by 
transesterification, which joins the N-extein to the C-extein (Figure 1.4). Cyclisation of 
the intein C-terminal asparagine results in breakage of the C-terminal splice junction 
yielding free intein and (thio) ester linked extein. A spontaneous (O/S)-N acyl shift 
restores the natural amide bond. Trans-acting split intein follow the same reaction 
pathway after the N- and C- terminal intein fragment rapidly associate to form active 
intein.
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Figure 1.4  Mechanism of intein mediated protein splicing. X represents either 
oxygen or sulfur in the side chain of either serine, threonine or cysteine.
32 
 
Application of inteins for the in vivo production of cyclic peptides by Scott et al.
34 and 
Evans et al. has improved the feasibility of developing peptide-base therapeutics. Cyclic 
peptides are created by inverting the placement of the N- and C- domains of a naturally 
occurring split-intein found in the Synechocystis sp. PCC6803 DnaE gene. Similar 
cyclic peptides can also be obtained using the TWIN system, which employs two inteins 
on the N- and C- terminus of the target protein.
32 The Methodology of Split-Intein 
Circular Ligation of Peptides and Proteins (SICLOPPS) allows for genetic encoding of 
libraries by introducing random peptide sequences as the extein sequence via 
oligonucleotide synthesis using error prone PCR, followed by cloning into plasmids that 
code for the rearranged intein. After translation of intein:peptide:intein:fusion, the intein 
catalyses the formation of a peptide bond between the first and last amino acid thereby 
creating a cyclic peptide (Figure 1.5).
35 SICLOPPS libraries were designed by 
introducing codons for five variable amino acids between the C- and N- intein genes. 
The variable region was encoded by NNS where N represents any of the four DNA 
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(4X4X2) and encodes all 20 amino acids while eliminating both ochre (UAA) and opal 
(UGA) stop codons from the library. Amber stop codons (UAG) are represented in the 
library at a frequency of 1/32. 
SICLOPPS may be used for the cyclisation of peptides of a variety of sizes, even protein.
34 
Benkovic et al. were able to synthesise the cyclic octapeptide pseudostellarin F in E.coli and 
demonstrated its inhibitory effect on tyrosinase in vivo. An advantage of SICLOPPS is that 
libraries of up to 10
8 members are rapidly generated and screened in vivo using standard 
molecular biology techniques and genetic selection, it has proven large flexibility towards 
peptide length and composition. Library sizes are several orders of magnitude larger than 
those possible by conventional synthetic methods.
31 
17a  
 
Figure 1.5 An expressed fusion protein folds to form an active intein, which 
undergoes a series of rearrangements to generate a cyclic peptide with randomly 
encoded amino acids. Z = S or O (cysteine or serine).
26   
 
This methodology also has some drawbacks. A particularly difficult challenge is that 
molecules attainable by SICLOPPS are limited both by the specificity of the intein and the 
ability of the peptide to form a tight loop structure. Although the Ssp DnaE intein shows a 
usefully broad specificity, it is far from random in the sequence it will cyclise. Since less 
than 70% of randomly selected clones generally showed detectable levels of in vivo 
cyclisaton, it is impossible to correlate library size with the cyclic peptide sequence space 
actually tested. Growth phenotypes may reflect active component expression levels and not 
necessarily the inhibitor with the best binding affinity or efficacy because in vivo 
requirements for growth are often threshold based. Additionally, genetic selection and 
screens often produce false positives, so target molecules require further validation to 
confirm the mode of activity. Similar results are found in all types of genetic selections and 
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selections and screens to eliminate false positives. Solid phase synthesis of peptides is 
straightforward and cyclisation of small peptides is facile. The ability to synthesise large 
quantities of the selected peptides assures the availability of sufficient quantities for in vitro 
and in vivo testing. 
Despite the above drawbacks, SICLOPPS has successfully identified inhibitors of E. coli 
Dam methyltransferase,
36 C1pXP
37 as well as inhibitors of HIV Gag protein recognition of 
the human endocytotic protein TSG101.
26 This technology has also proven useful for the 
discovery of cyclic peptides that disrupt the dimerisation domains of ribonucleotide 
reductase and 5-aminoimidazole-4-carboxyamide-ribotide transformylase. SICLOPPS 
coupled with genetic selection has facilitated the rapid identification of numerous cyclic 
peptides with micromolar IC50 values that serve as valuable leads for further drug 
development.  
SICLOPPS has also been used for the production of libraries of random cyclic peptides 
in mammalian cells using retroviral technology to enable the intracellular delivery. This 
led to the identification of cyclic peptide inhibitors that block interleukin-4 mediated 
IgE class switching in B cells.
38 Deschuyteneer et al
35 have also evaluated the 
possibility to perform split intein-mediated polypeptide cyclisation in the periplasm of 
E.coli and further secrete the peptides in the extracellular medium. They created various 
libraries of randomised precursors, and a large proportion of the clones were shown to 
efficiently produce backbone cyclic peptides in periplasm. They also postulated that 
using an SXXXXXG library, with a G at the splice junction would greatly improve the 
efficiency of the random libraries. By expressing a phage pore protein in the outer 
membrane of E.coli, they showed that cyclic peptides could diffuse in the extracellular 
medium. These new possibilities of producing libraries of cyclic peptides either in the 
periplasm or outside the bacteria opens a wide potential of development of selection-
based strategies for identifying compounds that would act on exported or membrane 
proteins or that would interfere with competing organisms. The target sequence for 
cyclisation is cloned in frame between genes encoding the two fragments of the Ssp and 
DnaB split intein (DnaBIC and DnaBIN) in a permuted order and behind the arabinose 
controlled pBAD promoter. The pPBla construct in Figure 1.6 illustrates the intein-
TEM-1 β-lactamase precursor. Splicing will occur in the linker region containing the N- 
and C-termini of the enzyme and that’s made possible by imposing a serine (+1) and a 
glycine (-1) at the splicing junction. The pPL6-8 constructs for cyclisation of hexa-, and                                                                  Chapter 1:  Introduction   
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octa-peptides libraries in the periplasm of E.coli. The randomised codons encoding four, 
five, or six amino acids are cloned between the fixed codons of the serine and glycine 
residues. The degeneracy of the codons is NNB (B encodes C, T, or G).
35 
 
Figure 1.6 Construct for protein and peptide cyclisation in the periplasm of E.coli.
35 
 
This project was conducted jointly with the Faculty of Medicine to uncover cyclic 
peptide inhibitors of the C-terminal binding proteins homodimerisation. 
 
1.4  C-terminal Binding Proteins: 
The adenovirus E1A proteins are expressed during the early phase of the viral life cycle 
and they induce cell proliferation. The N-terminal region of E1A along with the 
conserved region 1 (CR1) interacts with histone acetyl transferases (HATS) to modulate 
chromatin modification and transcription, whereas CR2 interacts with the tumour 
suppressor protein pRb and related proteins, p130 and p107. Through these interactions, 
E1A exon 1 drives cell cycle into the S-phase and cooperates with other oncogenes to 
transform primary cells. C-terminal Binding Proteins (CtBPs) were first identified in 
1993 as a 48 kDa protein that bound the C-terminal CR4 domain of the adenovirus E1A 
oncoprotein containing the conserved PLDLS motif.
39 Interaction of CtBP with E1A C-
terminal region was found to negatively modulate oncogenic transformation by E1A.  
CtBP family proteins are highly conserved among invertebrates and vertebrates. 
Invertebrates contain a single CtBP whereas vertebrates contain two highly homologous 
CtBP proteins (CtBP1 and CtBP2). CtBPs show distinct functions according to their 
cellular localization. In the nucleus, CtBPs act as transcriptional co-repressors 
modulating the activity of a large number of transcriptional repressors. They form 
compounds. Using a bacterial reverse two-hybrid sys-
tem (RTHS), a strategy for selecting cyclic peptides that
modulate protein–protein interactions has been devel-
oped (11, 12). This strategy has been validated for the
disruption of the ATIC homodimer (13)a n df o rt h ei n h i -
bition of the Gag-TSG101 interaction that prevent the
HIV budding event (14). In combination with, respec-
tively, a ﬂuorescent reporter substrate or an in vivo se-
lectable transposase activity, cyclic peptide inhibitors
of, respectively, the ClpXP protease (15)a n dt h e
EcoDam DNA methyltransferase (16)w e r ei d e n t i ﬁ e di n
Escherichia coli. Libraries of random cyclic peptides
were also produced in mammalian cells with retroviral
technology and a genetic screen has been set up to test
their functionality (17).
With the aim of expanding the scope of applications
of cyclic peptide libraries, we have evaluated the possi-
bility to perform split intein-mediated polypeptide cy-
clization in the periplasm of Escherichia coli and further
secrete the peptides in the extracellular medium. First,
we demonstrated that a wide variety of intein-
polypeptide precursors can be translocated in the
periplasm prior to splicing. Second, we showed that
minimal sequence determinants in the polypeptide pre-
cursors are sufﬁcient for cyclization to occur prior to in-
tein inactivation by oxidation of its essential cysteine in
the periplasm. Various libraries of randomized precur-
sors were created, and a large proportion of the clones
were shown to efﬁciently pro-
duce backbone cyclic peptides
in the periplasm. Finally, by ex-
pressing a phage pore protein in
the outer membrane of E. coli,
we showed that cyclic peptides
could diffuse in the extracellular
medium. These new possibili-
ties of producing libraries of
cyclic peptides either in the
periplasm or outside the bacte-
ria opens a wide potential of de-
velopment of selection-based
strategies for identifying com-
pounds that would act on ex-
ported or membrane proteins or
would interfere with competing
organisms.
RESULTS AND DISCUSSION
Intein Splicing in the Periplasm. We initially decided
to work with an artiﬁcially permuted mini-intein derived
from the DnaB intein of Synechocystis sp. PCC6803
strain (called Ssp DnaB) because it appears to be well
appropriate for producing high levels of cyclized target
proteins (18). The TEM-1  -lactamase (Bla) was chosen
as the model periplasmic protein since its activity and
stability in the cyclic form has been already demon-
strated in the cytoplasm (19)a n db e c a u s ei t sl o c a l i z a -
tion in the periplasm can be easily demonstrated by am-
picillin resistance phenotype.
On the basis of the work of Liu et al. (20), the cen-
trally located endonuclease domain of the Ssp DnaB in-
tein was deleted to create a mini-intein of 154 aa split
into two parts, a 106 aa N-terminal fragment (DnaBIN)
and a 48 aa C-terminal fragment (DnaBIC). The two frag-
ments were arranged in the order DnaBIC-DnaBIN and
cloned into an expression vector behind the arabinose-
controlled pBAD promoter (Figure 1). To avoid a poten-
tial problem of oxidation in the periplasmic space, the
nonessential Cys50 of the DnaBIN gene was mutated to
alanine. The gene encoding Bla was then introduced be-
tween the two fragments by ﬁxing a serine and a gly-
cine codon as the ﬁrst extein residue at the N-splicing
junction and the last extein residue at the C-splicing
junction (position  1a n d 1i nF i g u r e1 ) .I n d e e d ,t h e
serine is an essential residue involved in the splicing re-
action (21)a n dt h eg l y c i n ew a sr e p o r t e dt ob ei m p o r -
Figure 1. Constructs for protein and peptide cyclizations in the periplasm of E. coli.
The target sequence for cyclization is cloned in frame between genes encoding the
two fragments of the Ssp DnaB split intein (DnaBIC and DnaBIN)i nap e r m u t e do r d e r
and behind the arabinose controlled pBAD promoter. The pPBla construct illus-
trates the intein-TEM-1  -lactamase precursor. Splicing will occur in the linker re-
gion connecting the N- and C-termini of the enzyme and is made possible by
imposing a serine ( 1) and a glycine ( 1) at the splicing junctions. The pPL6-8
constructs for the cyclization of hexa-, hepta-, and octa-peptides libraries in the
periplasm of E. coli.T h er a n d o m i z e dc o d o n se n c o d i n gf o u r ,ﬁ v e ,o rs i xa m i n oa c i d s
are cloned between the ﬁxed codons of the serine and glycine residues. The degen-
eracy of the codons is NNB (B   C, T, or G).
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functional interactions with multiple cellular proteins, allowing them to act as 
transcriptional co-repressors that can regulate many cellular processes including 
development, proliferation, differentiation, transformation and apoptosis. The 
transcriptional activity of CtBPs is regulated by NAD(H)-binding and metabolic status 
of the cell. In the cytoplasm they are involved in maintenance of the Golgi playing a key 
component of the machinery controlling Golgi tubule fission and endocytic membranes. 
CtBP fission inducing activity was shown to participate in the fragmentation of the 
Golgi complex during mitosis and in intracellular membrane traffic. They also perform 
diverse function associated with central nervous system synapses and in regulation of 
the microtubule cytoskeleton. The control of CtBP nuclear vs. cytosolic localisation 
involves posttranslational modifications such as phosphorylation and sumoylation.  
There are four CtBP isoforms that are generated from the two distinct mammalian 
genes, CtBP1 and CtBP2.  The CtBP1 gene is located on chromosome 4 of humans and 
on chromosome 5 of mice. The CtBP1 locus codes for two protein isoforms: CtBP1-L 
and CtBP1-S (CtBP3/brefeldin A-dependent ADP ribosylation substrate (BARS) 
protein). Both are identical except for a thirteen amino acid region at the N-terminus. 
The CtBP2 gene maps to chromosome 10 of humans and in chromosome 7 of mice. The 
CtBP2 gene codes two protein isoforms, CtBP2 and the second isoform, designated as 
RIBEYE is a 120 kD protein that is predominantly expressed in sensory neurons. CtBP1 
and CtBP2 are very similar in sequence; they share 78% in amino acid identity and 83% 
in similarity.  
CtBPs exhibit homology to NAD-dependent 2-hydroxy acid dehydrogenase. This 
homology includes the conserved NAD binding motif (GXGXXG) and a catalytic His 
residue at the active site.
40 The CtBP central domain (∼ 195 residues) plays an important 
role as the dimerisation site (Figure 1.7), allowing the formation of homo- and 
hetrodimerisation between CtBP1 and CtBP2 that would act as an aggregation scaffold 
for multimeric nuclear protein complexes.
41 Each monomer in the CtBPs dimer is 
divided into large and small domains. The dimerisation interface is extensive, burying 
~3368 Å
2 of solvent accessible surface area per monomer.
42 Dimerisation is stimulated 
by occupation of the dinucleotide-binding site within the central domain. The preferred 
ligand is NADH, which binds to the site with greater than 100-fold higher affinities than 
NAD
+.  CtBP has been postulated to be a redox sensor that links the cellular metabolic 
status to transcription regulation. The unique NADH-dependence of CtBP1’s action not                                                                  Chapter 1:  Introduction   
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only highlights the importance of hypoxia and an aerobic glycolysis in promoting 
tumour formation through the activation of CtBP1, but also reveals a potential 
therapeutic approach. 
 
Figure 1.7 CtBP structure: (A) the dehydrogenase domain contains a substrate-
binding domain linked via flexible hinge to NAD
+ binding domain. NAD
+ 
(yellow) binds in the active site cleft. (B) The van der Waals surface of CtBP 
dimer, one monomer in green the other in grey.
42 
 
Binding NAD(H) promotes the stabilization of a compact dimeric form of the protein, 
with the substrate- and nucleotide-binding domains tightly wrapped around the bound 
NAD(H), which is required for providing a stable core for the formation of multimeric 
repression complexes (Figure 1.8).
43 Loss of NAD/NADH binding induced a dramatic 
decrease in the homodimerisation efficiency and transcriptional repression activity in 
both CtBP1 and CtBP2. Studies by Nardini et al showed a mutation of the Gly172 to 
Glu which resulted in complete disruption of the dimer.
44 Mutation of the NAD(H)-
binding motif (G183A/G186A) in CtBP1 leads to a  protein that is deficient in 
dimerisation compared to the wild type.
45 Also, the amino acid substitution at G189, in 
the conserved NAD(H) binding motif, abrogates the ability of CtBP2 to homodimerise 
and leads to a dramatic decrease in corepressor activity. The ability of NADH to 
stimulate CtBP dimerisation contributes indirectly to the enhanced binding of PXDLS 
CtBP Is an NAD -Regulated Dehydrogenase
861
Figure 2. CtBP Structure
(A) The dehydrogenase domain contains a substrate binding domain linked via a flexible hinge to the NAD  binding domain. NAD  (yellow)
binds in the active site cleft in a bent L-shaped configuration.
(B) The van der Waals (vdw) surface of a CtBP dimer. One monomer is drawn in gray and the other in green. The gray monomer is related to
the monomer in (A) by rotation of  81 , roughly along the vertical axis of the paper, to give a view of the CtBP dimer down the 2-fold axis.
The NAD  molecules are hidden from view by the vdw surface; their approximate positions are indicated by dashed ovals. Note, the NAD 
binding domain makes the majority of dimeric interactions.
strate binding pocket (Figure 3B), hydrogen bonded to corresponding to a 7.5  rotation around the hinge region
(Lamzin et al., 1994). Similar rigid body motion has been His315 (2.8 A ˚ ), Arg266 (2.8 and 2.9 A ˚ ), and Arg97 (2.8 A ˚ ).
described for other NAD -dependent dehydrogenases, This prompted us to test whether CtBP could catalyti-
where the apo form has been termed the “open” confor- cally modify an acetyllysine residue on a histone H3-
mation and the NAD -bound form as the “closed” con- derived peptide, but we found no evidence. An acetate
formation (Grau et al., 1981; Lamzin et al., 1994). In ion is similar to a 2-hydroxyacid substrate in containing
comparing our structure against other NAD -bound D2- a terminal carboxylate group, but it lacks the 2-hydroxyl
HDHs, the active site cleft is particularly narrow. For group. The acetate ion, present in the crystallization
example, the average distance across the cleft (mea- mix and critical for CtBP crystallization, is bound in an
sured between residues 101 and 266, and 78 and 294) orientation different from what we expect for a real sub-
is  10 A ˚ , as compared to  16 A ˚ in D-LDH and  13 A ˚ strate:itssecondcarboxylateoxygenoccupiestheposi-
in D-HicDH. Only FDH has a narrower active site cleft tion anticipated for oxidation/reduction of the 2-hydroxyl
( 8A ˚ ), which may reflect the small size of its formate (Figure 3B). Theacetate’s small size andstructuralsimilar-
ion substrate (Lamzin et al., 1994). ity to 2-hydroxyacids appear to permit tight binding in
A comparison with apo-D-GDH structure—based on the CtBP active site.
the alignment of NAD  binding domains—suggests that
the CtBP substrate binding domain moves toward the
E1A Is Recruited through a NAD -Dependent closed conformation by a rotation of  5  (Figure 4A).
Conformational Change To evaluate the potential role of NAD -induced confor-
ConformationalchangeonNAD bindingisakeyfeature mationalchangeinprotein-proteininteractions,weeval-
of NAD -dependent dehydrogenases (Eklund and Bran- uated the effects of adding NAD  to binding of E1A to
den, 1987). In the majority of cases, NAD  binding CtBP. We found that in the presence of NAD , CtBP
causes a narrowing of the active site cleft due to a bound to E1A much more efficiently (Figure 5A). This
movement of the substrate binding domain toward the NAD  dependency was observed both with the full-
cleft. The structures of holo- and apo-FDH, for instance, length CtBP, as well as with the isolated dehydrogenase
domain(Figure5A).ThesedatastronglyimplythatNAD  differ in the location of the substrate binding domain,
A  B                                                                  Chapter 1:  Introduction   
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motif containing transcription factors. A double mutant G189R/R272L which also 
introduces an amino acid substitution at a highly evolutionarily conserved arginine 
residue implicated in substrate binding for bacterial 2HAD family members, completely 
inhibited mCtBP transcriptional repression activity.
46 
 
Figure 1.8 CtBP mediated transcriptional repression. CtBP is recruited to the 
chromatin by its interaction with negative regulators of transcription. NADH is 
involved in dimerisation and repressor activity of CtBP. Transcription repression 
is brought about by its interaction with CtIP, polycomb complex and involves 
HDACs and HMTases (G9a). CtBP and its interaction with HDAC1/2, 
CoREST/LSD1 and Ubc9 also form a multiprotein complex involved in 
SUMOylation of transcriptional regulators.
43 
 
Both CtBP1 and CtBP2 contain a conserved substrate binding domain (consisting of 
∼155 residues that are mainly N-terminal) involved in the binding of transcription 
factors possessing consensus Pro-X-Asp-Leu-Ser (PXDLS) peptide motif (where X is 
any amino acid).
41 This motif was identified within the C-termini of E1A and EBNA3C. 
Deletion of these regions from either of these two proteins markedly alters their ability 
to transform cells into cooperation with mutant RAS, providing evidence for the key 
role of CtBP in cellular transformation. Subsequent work has confirmed that the vast 
majority of DNA-binding factors that recruit CtBP family proteins that contain related 
motifs (Figure 1.9). Peptides as small as 15 residues encompassing this motif can bind 
CtBP in vitro. Quantitative binding assays have confirmed the importance of the Pro, 
Asp/Asn, Leu and Ser/Thr residues, through the mutations in any one of these residues 
does not usually eliminate binding. There is evidence that the binding of CtBP proteins 
to NADH significantly increases their affinity for PXDLS motif containing nuclear 
transcription factors, and so it is possible that this serves to drive CtBPs to the nucleus.                                                                   Chapter 1:  Introduction   
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Figure 1.9  Models of CtBP dimers with PXDLS partners. (A) Model of CtBP as a 
bridging molecule linking a transcription factor (TF) and an effector. An 
elongated dimer of CtBP as a link between a promoter-bound transcription 
factor containing a PIDLS and the effector molecule HDAC4, which also 
contains a PIDLS motif. (B) Model where a CtBP dimer is localised to a 
promoter by binding two PIDLS motif-containing transcription factor and then 
recruits effectors through a different surface.
47  
 
The C-terminus of CtBP1 contains a PDZ-binding motif, which is implicated in nuclear 
export of CtBP1 in association with PDZ domain containing partners. CtBP is thought 
to act as a molecular bridge between DNA binding proteins and enzymes associated 
with transcriptional repression such as histone deactylases. Various DNA-binding 
repressors recruit CtBP through this region. A second protein interaction groove has 
been identified which interacts with a RRT motif. Even though the RRT binding site 
has no direct contact with the nucleotide-binding site, the close proximity of the two 
sites in the same domain may influence interaction of RRT-containing proteins with 
CtBP in the presence of NAD(H). While DNA-binding proteins such as ZEB1/2 interact 
with CtBP primarily through PLDLS-like motifs, factors such as ZnF217 interact 
through both PLDLS-like and RRT motifs.
48 
Attempts to crystallise full length CtBP have been unsuccessful. A possible explanation 
for this could be the high mobility, or disorder, of the C-terminal region in the full-
length protein that, contrary to the substrate- and nucleotide-binding domains, may 
maintain an unstructured conformation, which prevents the formation of productive 
crystal contacts. Analysis of CtBP C-terminal sequence illustrates the presence of bulky 
hydrophobic residues, and a high proportion of ‘disorder promoting’ residues, in 
particular Gly and Pro. The lack of order-promoting residues and of aromatic amino 
effectors. In this case, the critical effectors would be likely to be
non-PIDLS-containing molecules (Fig. 1B).
Importantly, a number of CtBP partner proteins do not have
canonical PIDLS motifs. Some of these probably have related
motifs that can presumably bind the PIDLS cleft (10, 40, 42, 52,
61, 62), but others may bind different surfaces of CtBP. Dis-
tinguishing between the two types of partners may help differ-
entiate between partners involved in recruiting CtBP to pro-
moters and those involved in mediating or regulating CtBP
activity. Interestingly, the effector proteins in the CtBP repres-
sion complex, HDAC1, HDAC2, histone methyltransferase
G9, and histone demethylase LSD1, have not been shown to
contain PIDLS motifs. Thus, it seems that these proteins either
bind a separate surface of CtBP or associate with it indirectly,
via additional bridging molecules (47, 53, 60).
In this study, we have investigated the importance of the
PIDLS cleft for CtBP’s physical interaction with partner pro-
teins and also for CtBP’s repression activity. We used a num-
ber of different CtBP cleft mutants. We disrupted the cleft
by mutation, and we also produced a CtBP fusion protein
that contains a C-terminal PIDLS peptide that appears to
ﬁll CtBP’s own cleft, termed the cleft-ﬁlled mutant protein.
With these mutant proteins, we conﬁrmed that several rec-
ognized PIDLS-dependent partners rely on the cleft for bind-
ing to CtBP. We also conﬁrmed that some proteins without
recognizable PIDLS motifs do not require an intact CtBP cleft
for binding and therefore presumably contact other faces of
CtBP. Finally, we observed that certain protein domains that
interact with CtBP but do not have recognizable PIDLS motifs
do, nevertheless, rely on the PIDLS cleft and therefore pro-
pose that PIDLS-type motifs that cannot be recognized by
visual sequence inspection may exist.
In terms of functional gene repression, our assays with Gal4
DNA-binding domain (Gal4DBD)–CtBP or zinc ﬁnger-CtBP
fusions revealed that signiﬁcant repression activity remains
even when the PIDLS cleft is mutated. In contrast, the cleft is
required for repression when CtBP is not fused to a heterol-
ogous DNA-binding domain. These results suggest that the
cleft plays an essential role in recruiting CtBP to PIDLS-con-
taining transcription factors.
MATERIALS AND METHODS
Plasmid constructs. Full-length murine CtBP2 was ampliﬁed by PCR
(mCtBP2Xma.F, TCCCCCCGGGAAAAAGAATGGCCCTTGTGGATAA
GCA; mCtBP2NotStopSal.R, ACGCGTCGACCTATGCGGCCGCTTGCTCG
TTGGGGTGCTCTC), and the product was cloned into the XmaI/SalI pGBT9
(Clontech) vector. This resulting construct, pGBT9-mCtBP2, was used as wild-
type CtBP2 in yeast experiments. Secondly, murine BKLF residues 1 to 84, 1 to
75, and 30 to 75, each containing the
61PVDLT
65 motif, were ampliﬁed by PCR
(for example, BKLF 30-75 with mBKLF.30.Not.F [ATAAGAATGCGGCCGC
AAAGCCCAACAAATATGGGGT] and mBKLF.75.Sal.R [ACGCGTCGACC
TATGCAGCAGGCGGGGAGCCCC]) and cloned into the NotI/SalI sites of
pGBT9-mCtBP2. The resulting yeast two-hybrid constructs expressed the BKLF
segments fused to the C terminus of CtBP2. The pGBT9-mCtBP2-BKLF 30-75
construct is referred to as cleft ﬁlled. The control  DL fusion, which contains a
DL-to-AS mutation in the PVDLT motif in the BKLF 30-75 portion of the
fusion, was generated from the pGBT9-mCtBP2-BKLF 30-75 construct by over-
lap PCR mutagenesis (BKLFdeltaDL.F, CAGGTGGAGCCGGTGGCCAGCA
GGTGAACAAGCGG; BKLFdeltaDL.R, CCGCTTGTTCACCGTGCTGGCC
ACCGGTCCACCTG). The mCtBP2, mCtBP2-BKLF 30-75, and mCtBP2-
BKLF 30-75  DL inserts were subcloned into the XmaI/SalI sites of the
pGAD10(new) (derived from pGAD10 from Clontech) vector to allow them to
be expressed in the yeast two-hybrid system as both Gal4 activation domain
(Gal4AD) and Gal4DBD fusions.
A58E and V72R mutations were introduced into murine CtBP2 by overlap
PCR mutagenesis (mCtBP2.A58E.F, GACCTGGCCACTGTGGAATTCTGTG
ATGCACAG; mCtBP2.A58E.R, CTGTGCATCACAGAATTCCACAGTGGC
CAGGTC; mCtBP2.V72R.F, GAAATCCATGAGAAGCGGTTGAATGAAG
CTGTG; mCtBP2.V72R.R, CACAGCTTCATTCAACCGCTTCTCATGGAT
TTC). BglII/SalI-digested mutant inserts were ligated into the BamHI/SalI sites
of the pGBT9 and pGAD10(new) vectors to generate pGBT9-mCtBP2-A58E,
pGBT9-mCtBP2-V72R, pGAD10(new)-mCtBP2-A58E, and pGAD10(new)-mCtBP2-
V72R.
Amino acids 1 to 362, 32 to 445, 32 to 362, 10 to 445, 20 to 445, 26 to 445, 1
to 55, 50 to 362, and 70 to 362 of murine CtBP2 were ampliﬁed by PCR with
appropriate oligonucleotides, and BglII/SalI-digested products were ligated into
the BamHI/SalI pGBT9 and pGAD10(new) vectors to generate pGBT9-mCtBP2
32-362, pGBT9-mCtBP2 50-362, pGBT9-mCtBP2 70-362, pGAD10(new)-
mCtBP2 1-362, pGAD10(new)-mCtBP2 32-445, pGAD10(new)-mCtBP2 32-362,
pGAD10(new)-mCtBP2 10-445, pGAD10(new)-mCtBP2 20-445, pGAD10(new)-
mCtBP2 26-445, and pGAD10(new)-mCtBP2 1-55. pcDNA3-rCtBP1-S, encoding
full-length rCtBP1-S, was kindly provided by Daniela Corda (Department of Cell
Biology and Oncology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti,
Italy) and has been described previously (50). From this template and with appro-
priate oligonucleotides, rCtBP1-S 1-430 (full length) and 15-345 were ampliﬁed by
PCR and ligated into the EcoRI/SalI sites of the pGBT9 and pGAD10(new) vectors
to generate pGBT9-rCtBP1-S 1-430, pGBT9-rCtBP1-S 15-345, pGAD10(new)-
rCtBP1-S 1-430, and pGAD10(new)-rCtBP1-S 15-345. pCMV5 FLAG-hCtBP1-L,
encoding full-length hCtBP1-L, was kindly provided by David Wotton (University of
Virginia, Charlottesville) and has been described previously (20). From this template
and with appropriate primers, hCtBP1-L 1-440 (full length) and 26-440 were am-
pliﬁed by PCR and ligated into the EcoRI/SalI sites of the pGBT9 vector to generate
pGBT9-hCtBP1-L 1-440 and pGBT9-hCtBP1-L 26-440.
The yeast two-hybrid assay vectors pGAD10-BKLF 1-268 and pGBT9-BKLF
1-268, encoding murine BKLF, have been described previously (57). pcDNA3-
FHL3 was kindly provided by Ju Chen (University of California at San Diego, La
Jolla) and has been previously described (7). Full-length murine Four-and-a-Half
LIM Domain Protein 3 (FHL3) was ampliﬁed from this vector by PCR
(mFHL3.Bam.F, CGGGATCCATGAGCGAGGCATTTGAC; mFHL3.Eco.R,
CGGAATTCTCAGGGGCCTGCTTGGC), and the product was cloned into
the BamHI/EcoRI sites of the pGBT9(new) vector, allowing expression of
Gal4DBD-FHL3 in yeast two-hybrid assays. The yeast two-hybrid assay vector
for murine Ubc9, pGAD10-Ubc9, has been described previously (39). Murine
homeodomain-interacting protein kinase 1 (HIPK1) amino acids 619 to 1040 and
619 to 1083 were ampliﬁed by PCR (5x HIPK Frag, GGAATTCTCGTCGGC
AGCGCCAGTTCCT; 3x HIPK1Frag-PLNLS, CGGGATCCCTACACCGCGC
TGGCTCCCCCT; 3x HIPK1 Frag, CGGGATCCCTAGAAGGCGTAGGGG
GCTTGGGA) and cloned into the EcoRI/BamHI sites of the pGAD10 vector to
generate pGAD10-HIPK1 619-1040 and pGAD10-HIPK1-619-1083. The NL-
to-AS mutation was introduced into the
1042PLNLS
1047 motif of the pGAD10-
FIG. 1. Models of CtBP dimers interacting with PXDLS partners.
(A) Model of CtBP as a bridging molecule linking a transcription
factor (TF) and an effector. An elongated dimer of CtBP as a link
between a promoter-bound transcription factor containing a PIDLS
motif and the effector molecule HDAC4, which also contains a PIDLS
motif. (B) Model where a CtBP dimer is localized to a promoter by
binding two PIDLS motif-containing transcription factors and then
recruits effectors through a different surface.
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acids undermines one of the basic contributions to the thermodynamic stabilisation of 
the protein hydrophobic core. 
1H-NMR analysis carried out by Nardini et al 
41 indicates 
that large portions of the C-terminal protein backbone experiences dynamic fluctuation, 
lacking a well-defined 3D structure. 
There is strong evidence that CtBP1 and CtBP2 are found in transcriptional complexes 
in the nucleus, indicating that CtBP proteins must be imported into the nucleus from the 
cytoplasm. Control of subcellular localisation is emerging as an important mechanism 
whereby CtBP1 functions are regulated. It is possible that this translocation of the 
vertebrate CtBP may be a regulatory event by which the transcriptional regulatory 
activity of CtBP in the nucleus may be disrupted. Alternatively, it may also play a role 
in providing CtBP for the cytoplasmic functions such as those observed in Golgi.
49 
Phosphorylation of CtBP1 at Ser158 by p21-activated kinase 1 (PAK1) results in 
cytoplasmic localisation and inhibition of its corepressor activity under certain growth 
conditions. Pak1 regulation of CtBP represents a new transcriptional regulatory 
pathway whereby a signalling kinase can inactivate a corepressor and stimulate 
dissociation of a corepressor regulatory complex from an endogenous gene promoter. In 
the presence of NADH, Pak1 super-phosphorylated CtBP and inhibited CtBP 
dehydrogenase activity, suggesting that preferential phosphorylation of active CtBP 
may alter secondary structures and influence protein-protein interaction, enzymatic and 
corepressor function.
50  
Certain PxDLS-containing transcriptional repressors are able to recruit CtBP1 to the 
nucleus, for example Ets family member NET, tumour suppressor protein HIC1 and 
transcription factor BKLF (basic Krüppel-like factor). CtBP is also modified by 
covalent addition of the small ubiquitin-like modifier (Sumo). HPC2 has been shown to 
enhance SUMOylation of CtBP at a single K428 of CtBP1 by functioning as SUMO E3 
ligase activity of the polycomb protein PC2. This in conjunction with protein-protein 
interactions involving C-terminal PDZ-binding domain, regulates the nuclear 
localisation and is critical for the repression activity of CtBP1.
41, 51 It has been reported 
that neuronal nitric oxide synthase binds and causes translocation of CtBP1 from the 
nucleus into the cytoplasm.
49 CtBP2 lacks both this sumoylation site and the PDZ 
binding domain. However, CtBP2 contains a unique nuclear localisation signal (NLS, 
amino acids 8-13) located in the N-terminus that plays a key role in controlling the 
nuclear-cytoplasmic distribution of the protein.
52 When expression constructs encoding                                                                  Chapter 1:  Introduction   
20 
 
amino acids 1-119 of CtBP2 fused to EGFP are transfected into MCF-7 cells, the fusion 
protein localises primarily to the nucleus. This localisation is dependent upon the NLS, 
as a protein lacking amino acids 4-14 is localised primarily in the cytoplasm.
52 Zhao et 
al demonstrated that this region does not, in fact, function as classical NLS, but rather 
that it is necessary for the lysine 10 within it, to be acetylated for it to direct localisation 
into the nucleus. They specifically showed that the lysine in this sequence is acetylated 
in vivo and this is likely to be through the action of the p300 acetyltransferase, a known 
CtBP binding protein. CtBP1 lacks the NLS region but CtBP2 can heterodimerise with 
CtBP1and direct both proteins into the nucleus. Transcriptional reporter assays have 
shown that CtBP2 repressed E1A transcriptional activity whereas CtBP1 did not.  
CtBP2 mediated repression not only requires PLDLS-dependent interaction with E1A 
C-terminal domain and also the NLS of CtBP2. 
 
Figure 1.10  Domain structure of mammalian CtBP family protein. Shows the two 
proteins CtBP1 (top) and CtBP2 (bottom).
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1.5  Nuclear Function 
1.5.1  Transcriptional Repression 
The vertebrate CtBPs, and the Drosophila homolog, dCtBP function as a transcriptional 
corepressor in the nucleus. A large number of DNA-binding transcription repressors 
G. Chinnadurai / The International Journal of Biochemistry & Cell Biology 39 (2007) 1593–1607 1595
Fig. 1. Domain structure of mammalian CtBP family proteins. Two protein isoforms of CtBP1 (CtBP1-L and CtBP1-S) generated by two mRNA
splice variants of CtBP1 are indicated. A splice variant of CtBP1-S also codes for an extra Ser residue (S369 in CtBP1-S). The two CtBP1 protein
isoforms are highly homologous to the corresponding CtBP2 isoforms (CtBP2-L and CtBP2-S). The third isoform of CtBP2, RIBEYE contains a
largeN-terminaldomain(A-domain,unrelatedtoCtBP)linkedtoCtBP2(B-domain,residues20to445).TheA-domainofRIBEYEisnotindicated
in the ﬁgure. The residues of the catalytic triad for the D2-HDH activity are indicated in ﬁlled circles. The sequences that form the PLDLS-binding
cleft at the N-terminal region and the C-terminal region are indicated. The dimerization interface and the region that forms the RRT-binding surface
groove in the dinucleotide binding domain are also indicated. In CtBP2, the N-terminal residues acetylated by p300 are indicated. The residues
subjected to phosphorylation by various kinases in CtBP1 and the corresponding residues in CtBP2 (not experimentally demonstrated) are shown.
The SUMOyaltion site in CtBP1 is shown. CtBP2 lacks the PDZ-binding motif present in the C-terminus of CtBP1.
their roles in various cellular processes. Here, recent
advances in our understanding of the mechanisms of
transcriptional regulation by animal CtBP proteins are
reviewed.
2. CtBP in gene-speciﬁc repression
A large number of sequence-speciﬁc DNA-binding
transcriptionalrepressorsofDrosophilaandmammalian
species mediate their activity in a CtBP-dependent man-
ner (Chinnadurai, 2002; Turner & Crossley, 2001).
In Drosophila, several short range repressors (which
function <100–200bp from the enhancer/promoter)
such as Snail, Knirps, and Kr¨ uppel exert their transcrip-
tional activity during embryo development primarily
by recruiting CtBP (reviewed by Aihara, Perrone, and
Nibu (2006)). Several other ﬂy repressors such as
Brinker (Hasson, Muller, Basler, & Paroush, 2001)
and Hairless (Barolo, Stone, Bang, & Posakony, 2002;
Morel et al., 2001; Nagel et al., 2005) exert their
repressive activity by recruitment of both dCtBP and
Groucho (Gro). At present, more than thirty different
vertebrate transcriptional regulators have been reported
to modulate their activity through recruitment of
CtBP. Most of the CtBP-dependent transcriptional
regulators are sequence-speciﬁc DNA-binding proteins
suggesting that CtBPs repress transcription as core-
pressors (Chinnadurai, 2002; Turner & Crossley, 2001).
However, the C. elegans homolog, ceCtBP may bind
directly to promoter regions via its N-terminal THAP
(Thanatos-associated protein) Zn-ﬁnger (C2CH-type)
domain. A solution structural study of the ceCtBP
THAP domain has revealed that it contains a large
positively charged surface patch which can bind to
double-stranded DNA (Liew, Crossley, Mackay, &
Nicholas, 2006). The THAP domain is found in proteins
involvedintranscriptionalregulation,cell-cyclecontrol,
apoptosis, and chromatin modiﬁcation. Thus, while                                                                 Chapter 1:  Introduction   
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mediate their activity by recruiting CtBP through the PLDLS motif (0). The Mouse 
basic Krüppel-like factor (BKLF) interacts with mCtBP through the PXDLS motif. 
When mCtBP2 was targeted to the promoter through the BKLF Zn-finger domain, the 
chimeric protein repressed transcription efficiency, demonstrating that CtBP has direct 
transcriptional repressor activity.
49 As a corepressor, CtBPs primarily function as a 
scaffold to recruit chromatin modifying enzymes including histone deacetylases, histone 
methyltransferases, and polycomb-group proteins to DNA-binding transcription factors. 
The precise mechanism by which CtBP mediates transcriptional repression remains to 
be elucidated. Repression of transcription plays a critical role in the regulation of 
cellular processes, with various repressor proteins exerting their effect through protein-
protein interactions with corepressor that in turn bind chromatin-modifying enzymes.  
Transcription Factor  Family  Adapter  CtBP 
mBKLF, hKLF8  Krüppel-type Zn finger  Direct  mCtBP2  
mIkaros,   Krüppel-type Zn finger  Direct  hCtBP1 
hZEB, mδEF1  Homeodomain Zn finger  Direct  hCtBP1, mCtBP1, 2 
hTGIF  TALE family 
homeodomain  
Direct  hCtBP1 
mFOG1, mFOG2, 
hFOG2 
Zn finger  Direct  mCtBP2 
xFOG  Zn finger  Direct?  Not none 
hEvi-1, mEvi-1  Zn finger  Direct  hCtBP1, mCtBP2 
mNet  Ets  Direct  mCtBP1 
xTcf-3  HMG-box  Direct  xCtBP 
hPc2, xPc  Polycomb  Direct  hCtBP1, 2, xCtBP 
mSOX6  HMG-box  Direct  mCtBP2 
hHuntingtin  Polyglutamine  Direct  hCtBP1 
hBRCA-1  Ring finger  hCtIP  hCtBP1 
hE2F4, 5  E2F/DP  pRb/p130-
hCtIP 
hCtIP 
mMEF2  MADS family  mMIRT, 
hHDAC4, 5, 
mHDAC7 
mCtBP1, 2 
NHR  Nuclear receptor  mRIP140  hCtBP1 
 
Table 1.1. Vertebrate CtBP-Interacting Transcriptional Factors.
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One of the best-characterised mechanisms of gene repression is the recruitment of 
histone deacetylase enzymes (HDACs). These are thought to remove acetyl groups from 
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DNA, and facilitating the compaction of chromatin, thus preventing gene expression in 
the targeted region. CtBPs link DNA-binding repressors and histone-modifying 
enzymes to mediate transcriptional repression. HDAC contains a PXDLS motif that 
allows them to bind CTBP (Figure 1.11). This observation suggests a simple model by 
which the dimerisation of CtBP enables it to serve as a link between DNA-binding 
protein, containing a PXDLS motif, and a histone deacetylase protein with a similar 
motif. It has been documented that CtBP can interact with multiple HDACs both in vivo 
and in vitro. The addition of trichostatin A, a specific inhibitor of HDACs blocked 
CtBP-dependent repression. It has also been shown that CtBP-dependent repression can 
still occur in the presence of trichostatin A and there is no detectable HDAC activity 
associated with CtBP. This suggests that CtBP may utilize multiple mechanisms to 
regulate transcription.
54  
Other proteins shown to interact with CtBP include co-REST, histone methyltransferase 
(G9a and HMTase), and a polyamine oxidase. The association of CtBP with polycomb 
protein PC2 led to its sumoylation. Polycomb (Pc) is part of a Pc group (PcG) protein  
that are involved in the stable and heritable repression of gene activity during 
Drosophila and vertebrate development. PcG proteins do not typically bind DNA 
directly but are components of chromatin and are thought to repress gene expression by 
co-ordinating the formation of densely packed heterochromatin.
55 PcG protein HPC2 
recruits CtBP1 and Ubc9 to the PcG bodies resulting in sumoylation of CtBP1 at a 
single Lys (K428) residue. Ubc9 recruited by CtBP1 and HPC2 may also target other 
transcription factors and histone H4.  
Repression by CtBP1 has been suggested to play a key role in cell survival. Decreased 
CtBP1 expression allows cancer cells to become hypersensitive to apoptosis. A decrease 
in the level of CtBP1 proteins is sufficient to trigger apoptosis in p53-null cells. Upon 
apoptotic stimuli, CtBP1 undergoes proteasome-dependent degradation, which results in 
derepression of pro-apoptotic genes and allows apoptosis to proceed. The p160/steroid 
receptor coactivator (SRC) family is a well-studied family of transcriptional 
coregulatory proteins that function through histone tail modification, altering chromatin 
structure, and facilitating transcription initiation. SCR1 and SCR3 have been shown to 
have histone acetyltransferase (HAT) activity, which is necessary for the formation of 
an open chromatin structure. SCR coactivators also interact with general coactivators 
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to recruit more HAT enzymes to the vicinity of target sites upon ligand binding.
50 
Additionally, the CtBP complex contains the corepressor CoREST. The CoREST 
protein complex also contains HDAC1/2 and LSD1 (lysine specific demethylase-1). 
 
Figure 1.11  Transcriptional repression by CtBP1.  
 
1.5.2  Transcriptional Activation 
Although CtBPs function predominantly as transcriptional corepressors linking various 
chromatin-modifying components to DNA-binding repressor, under certain conditions 
they may function as transcriptional activators. CtBP-null mouse embryos which exhibit 
axial truncation phenotypes have revealed that expression of one of the target genes of 
Wnt3A, Brachyury (T), is lower in E10.5 embryos
54 compared to normal looking E9.5 
embryos. That suggests that CtBP2 may function as a transcriptional activator of 
Brachyury. The Brachyury promoter contains a consensus-binding site for the Wnt 
transcription TCF as well as for the E box transcription regulator. The potential effect of 
CtBP2 on Brachyury expression is due to trans-activation function encoded by CtBP2 
or due to interaction between CtBP2 and factors simultaneously recruited by both TCF 
and E-box transcription factor. CtBP2 undergoes post-translation modification such as 
acetylation by p300 and a lower level of SUMO modification, which contribute to the 
context-dependent transcriptional activation function.
48 
Studies by Fang et al have demonstrated that dCtBP can directly activate transcription 
of certain Wnt target genes after stimulation with Wnt, while repressing others in the 
absence of Wnt. Upon Wnt stimulation, stabilised β-catenin binds to TCFs, converting 
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animal development to control a variety of cell fate decisions and promotes oncogenesis 
by maintaining a proliferative, stem cell fate.
48, 56  
 
1.6  Role in Oncogenesis and Apoptosis 
The mammalian CtBPs modulate oncogenesis by regulating the activities of tumor 
suppressor genes and cellular and viral oncogenes, consistent with a role in tumor 
suppression as well as tumor promotion. CtBPs promote tumorigenesis by inhibiting 
genes involved in the epithelial to mesenchymal transition. CtBP transcriptional 
repressors are attractive cancer targets since they encode a potentially “druggable” 
dehydrogenase domain and their silencing by RNAi results in anti-cancer effects, 
including apoptosis and abrogation of cancer cell migration or invasion.
57 CtBP dimers 
and CtBP repression complexes are also detectable in cancer cells in the absence of 
hypoxic or nutrients, and siRNA-mediated knockdown of CtBPs in cancer cell lines 
leaves them hypersentive to p53-independent apoptosis.
58,59,60 The multiple pro-
oncogenic activities of CtBPs are well established, with CtBP being the target of 
multiple tumour suppressors. CtBP-dependent transcriptional regulation also plays an 
important role in the control of tumor cell migration. The pro-survival role of CtBPs has 
recently been shown to arise from their role in maintaining mitotic fidelity. CtBP 
siRNA results in reduced association of aurora B with mitotic chromatin and an increase 
in the frequency of aberrant mitosis.
58 This results in cell death, particularly in cells 
containing mutant p53, which fails to undergo a protective post-mitotic cell cycle arrest.    
 
1.6.1  E1A Model 
A biological role for CtBP was first demonstrated by genetic dissection of the 
oncogenic activity of E1A. Mutation in the conserved PLDLS motif causes enhanced 
transformation phenotype in ras cooperation assays. Tumors expressing the E1A 
mutants are also highly metastatic, while tumors expressing wt E1A are not. These 
results are consistent with the concept that the interaction of CtBP with E1A negatively 
regulates oncogenesis. 
49, 61 It has been postulated that the interaction of CtBP with E1A 
would restrain the cell proliferation activity of the N-terminal region of E1A. E1A 
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for E1A to up-regulate cellular genes. Cells from CtBP knockout mice were 
hypersensitive to a wide variety of apoptotic stimuli, mimicking the effect of E1A.
62 
 
1.6.2  CtBP1/Bcl-3 
Bcl-3 is a proto-oncogene that belongs to the IкB family. Elevated levels of Bcl-3 have 
been detected in a number of cancers, including breast cancer and anti-apoptotic effects 
of Bcl-3 in cancer have been reported. Bcl-3 is also responsible for the down regulation 
of p53 activity by enhancing the transcription of Hdm2 in normal and cancer cells, 
leading to inhibition of DNA damage induced apoptosis. Bcl-3 can also negatively 
regulate lipopolysaccaride (LPS)-induced tumour necrosis factor alpha (TNF-α) 
synthesis in macrophages when bound to histone deacetylase 1 (HDAC1) and HDAC3. 
Bcl-3 prevents the degradative polyubiquitination of p50 inhibitory homodimers.  
CtBP was identified as a binding partner of Bcl-3 via nano-flow liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) analysis; direct binding was 
confirmed via GST pull-down assay. A PXDLS/R sequence located in the N-terminal 
region of Bcl-3 was recognised. This motif found within CtBP1-binding proteins allows 
them to associate with CtBP1. CtBP is crucial in the biology of Bcl-3: this corepressor 
is required for the stabilisation of Bcl-3 and for Bcl-3 to repress gene transcription. Both 
Bcl-3 and CtBP1 are known to exert anti-apoptotic effects. Binding of Bcl-3 to CtBP1 
blocked ubiquitination of CtBP1 leading to its stabilisation. Therefore, over expression 
of Bcl-3 made cells resistant to apoptotic stimuli due to sustained maintenance of 
CtBP1-mediated repression of pro-apoptotic genes.  This role of Bcl-3 is independent of 
p53 since the repression was maintained in H1299 cell, where functional p53 is absent. 
 
1.6.3  CtBP/BRAC1 
Breast cancer is one of the leading causes of death in women worldwide. BRAC1 
(breast cancer 1) is a human tumour suppressor gene, which produces a protein called 
breast cancer type 1 susceptibility protein, responsible for DNA repair, cell regulation 
and transcriptional regulation. Deficiency in BRAC1 leads to accelerated proliferation, 
aberrant mitosis, tumorigenesis and reduced genome stability. It also leads to impaired 
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DNA repair following genotoxic insults. Individual harbouring germline mutations in 
the BRAC1 carry an 80% lifetime risk of developing breast cancer. Li-Jun Di et al have 
demonstrated that CTBP assembles at BRAC1 promoter as part of a dynamic, 
multicomponent co-repressor complex containing p130, BRAC1 and HDAC1 that 
represses local histone acetylation at the BRAC1 promoter and BRAC1 transcription. 
Disruption of this complex by estrogen stimulation and/or changes in NAD+/NADH 
ratio leads to CtBP dismissal, HDAC1 eviction, increased histone acetylase and 
subsequently increased BRAC1 transcription from the BRAC1 promoter.
63 
Patients with germline mutations in Fanc/Brca genes have high incident of head and 
neck squamous cell carcinomas (HNSCCs) at a young age. The BRAC1 promoter is 
controlled by a complex and dynamic array of DNA binding proteins, transcriptional 
co-activators and co-repressors. Knocking down CtBP1 expression via siRNA led to a 
three-fold increase in BRAC1 mRNA, suggesting that CtBP1 on its own regulates 
BRAC1 expression in HNSCC cells. Y Deng et al investigated whether CtBP1-
mediated repression of BRAC1 gene is sensitive to NADH levels. They showed that 
hypoxia increases free cellular NADH levels, which affects CtBP1 activity without 
affecting its levels. Cells exposed to hypoxia showed a 2.5-fold increase in CtBP1 
recruitment to the proximal region of BRAC1 promoter resulting in a decrease in 
BRAC1 mRNA levels.
64       
 
1.6.4   CtBP in Epithelial-Mesenchymal Transition (EMT) 
Carcinomas, representing the majority of human cancers, develop from epithelial cells.  
Epithelial cells possess prominent cell-cell and cell-matrix adhesion that partly regulate 
critical functions such as selective permeable barrier assembly, cell polarity, 
developmental pattern formation, and epithelial gene expression. High turnover cells are 
programmed to undergo apoptosis on their release from the extracellular matrix, 
preventing the colonization of mislocalised cells. As carcinoma cells progress to 
malignancy, the cells lose expression and self-differentiation of certain epithelial-
specific genes in a process known as epithelial-mesenchymal transition (EMT).
65 A 
hallmark event in the EMT is the downregulation or loss of the E-cadherin, a homotypic 
cell-to-cell interaction molecule ubiquitously expressed on epithelial cells.
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E-cadherin-mediated cell-cell adhesion is essential for maintaining the homeostasis and 
structure of epithelial tissues; its function is lost in a majority of epithelial cancers. E-
Cadherin (encoded by CDHI gene), serves as a widely acting suppressor of invasion and 
metastasis by epithelial cancers.
67 The E-cadherin promoter contains two E-box 
elements, which are thought to be involved in silencing it in E-cadherin non-expressing 
cells. The rapid growth and poor vascularisation of solid tumours exposes cancer cells 
to hypoxia leading to increased levels of NADH in the cells enhancing CtBP-mediated 
repression of the E-cadherin promoter as a result of increased interaction with cellular 
repressors such as ZEB. Consistent with the results on E-cadherin repression, hypoxia 
was reported to increase tumor cell migration (Figure 1.12).
68 CtBP dependent 
recruitment of E-box repressors such as ZEB1/2 and methylation (HMTases, G9a-GLP) 
has been linked to repression of E-Cadherin promoter, suggesting that CtBP is 
important in promoting epithelial-to-mesenchymal transition (EMT). This is a step that 
contributes to the malignant property of tumour cells due to loss of intracellular 
adhesion in tumours, acquisition of motile and invasive phenotypes and increased 
resistance to apoptosis.
69 Cell mobility was reduced by siRNA-mediated depletion of 
CtBP, suggesting that the effect was independent of HIF-1α or other E-cadherin 
repressors. CtBP1 and hypoxia-inducible factor transcription factor are thought to be 
involved in the activation of cell migration. Like hypoxia-inducible factor CtBP 
corepressors directly sense and respond to the intracellular metabolic changes that 
accompany hypoxia. CtBP-mediated stimulation of hypoxia-induced cancer cell 
migration may be due, in part, to repression of epithelial adhesion genes such as 
E-cadherin.  
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Figure 1.12  CtBP mediates the hypoxia-induced migration of H1299 lung 
cancer cells. H1299 cells grown for 20 h in 20% O2 (Control) or 1% O2 
(hypoxia) were assayed for their migration onto the matrix deposited by cells 
scraped away at the beginning of the assay.
68 
 
ZEB1 and ZEB2 are transcriptional repressors that contain zinc-finger motifs in their 
DNA binding domains, and both recognise the same E-boxes in their target genes. 
ZEB1 and ZEB2 are transcription factors that control key regulatory genes during 
embryonic development and cell differentiation. ZEB1 is expressed in many tissues 
including immune system and plays an important role in regulating both muscle and 
lymphoid differentiation. ZEB1 has also been shown to block the function of a range of 
transcription factors involved in the regulation of immune genes and has been shown to 
have two means of repression: direct competition for binding of activators to certain E-
box sites and trans-repression involving both an N-terminal region and the (PXDLS) 
motif region of the protein.
70 ZEB1 represses E-cadherin transcription by binding to two 
E box sequences in its promoter region. Expression of ZEB1 in epithelial cells induces 
an EMT and promotes tumour invasiveness in vitro and in vivo models.
71  
ZEB1 contains an N-terminal region that binds the coactivator p300 and P/CAF, 
acteyltransferases that loosen chromatin structure. Moreover binding of P/CAF to ZEB1 
acetylates several lysine residues close to the CtBP interaction domain of ZEB1, 
displacing CtBP and switching ZEB1 from a repressor to an activator. ZEB2 does not 
interact with p300 or P/CAF and thus only serves as a transcriptional repressor. 
Experimental results obtained by Pena et al illustrated that CtBP and p300 levels are 
important factors in the control of the expression of genes crucial for EMT, and 
therefore, for tumor progression, at least in human colon cancer.
72 Wang et al 
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promoter activity. IL-2 is a key cytokine for T cell proliferation and homeostasis. The 
cooperation of ZEB1 with HDAC1 requires the co-expression of CtBP2 leading to the 
speculation that CtBP2 may behave as a scaffold protein in repressor complexes.
70 
Other E-cadherin repressors include δEF1; knockout of δEF1 in mice causes severe 
skeletal defects. Another human member of this family, slug causes epithelial to 
mesenchymal transition when overexpressed.
73 Expression of Drosophila ZEB 
homologue zfh-1 is controlled by members of the SNAIL family of transcription 
factors. SNAIL has been proposed as an alternative E-cadherin repressor. Vitamin D 
induces the expression of CDHI in cells expressing vitamin D receptor (VDRs). SNAIL 
also represses VDR expression in tumor cell lines and its induction in human colorectal 
carcinomas is associated with CDHI and VDR down regulation.
72 
Epithelial cells are sensitive to ‘anoikis’ (a form of apoptosis mediated by the loss of 
contact from the extracellular matrix), wherein apoptosis is triggered by the loss of 
appropriate integrin-mediated cell-matrix contacts, causing cell survival to be 
anchorage-dependent. E1a-CtBP interaction was required for the induction of epithelial 
gene expression. In the case of E-cadherin promoter, this resulted from E1a’ disruption 
of a complex involving CtBP and δEF1/ZEB, a zinc finger-homodomain repressor 
protein that controls muscle and lymphoid differentiation. Anoikis-sensitivity resulted 
from the interaction of E1a-CtBP.
73   
 
1.6.5  CtBP as an Apoptosis Antagonist 
It is thought that apoptosis might be regulated through changes in cellular CtBP. Work 
on E1A has also revealed a potential apoptosis antagonist activity of CtBP. Tumor cell 
lines expressing E1A mutants defective in interaction with CtBP were less sensitive to 
anoikis. Genetic knockdown of the transcriptional co-repressor CtBP in mouse 
embryonic fibroblast results in up regulation of several genes involved in apoptosis such 
as PERP (p53-effector related to pmp-22), P21, Bax and NOXA.
69, 74  
Additionally, HIPK2 mediates the phosphorylation of p53 in the response to UV 
irradiation, thereby activating p53 function and promoting apoptosis. Studies by Wang 
et al showed that HIPK2 also promotes apoptosis through its effect on CtBP. UV 
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promotes apoptosis in cells. The mitogen-activated protein kinase (MAPK) family 
member-Jun NH2 terminal kinase 1 (JNK1) plays an important role in triggering 
apoptosis in response to cellular stresses such as UV irradiation and cytokines.  JNK1 
phosphorylate Ser 422 of CtBP and triggers CtBP degradation. Both UV and cisplatin 
induced sustained JNK activation and decreased CtBP levels. This pathway promotes 
p53-independent apoptosis in tumor cells, suggesting a possible novel cancer therapy by 
targeting JNK1 mediated CtBP degradation.
74 Pro-apoptotic effects have been 
demonstrated to occur indepentantly of p53, however recently Birts et al have 
demonstrated that loss of CtBP1 and CtBP2 does lead to p53 activation, and this can 
protect against CtBP siRNA-induced chemosensitisation in breast cancer cells.
75 
 
1.6.6  ARF/CtBP   
ARF (p19
ARF in mouse [mARF] and p14
ARF in human [hARF]) is a potent tumour 
suppressor that antagonises the oncoprotein Hdm2. ARF is also a negative regulator of 
p53, inhibiting the interaction of p53 with transcriptional co-activators, driving its 
export from the cytoplasm and degradation by proteosome. Under hypoxic conditions 
that would favour an increase intracellular NADH concentration, a decrease in 
interaction between Hdm2 and CtBP2 resulted in the relief of p53 mediated repression. 
ARF exerts tumour suppression function utilizing both p53 dependent and independent 
pathways. CtBP is a putative target for p53 independent ARF function, where ARF-
dependent CtBP degradation correlated with ability of ARF to physically interact with 
CtBP. ARF expression in human colon cancer cells lacking p53 induced efficient 
apoptosis.
76  
ARF can also downregulate CtBP by targeting it for proteasomal degradation, inducing 
Bik-dependent apoptosis. However apoptosis was also observed after CtBP knockdown 
alone, suggesting that CtBP lies directly downstream of ARF in its pathway of 
apoptosis induction.  Loss of ARF has been linked to tumour invasiveness and 
metastasis in mouse and skin models. Notably, an antiapoptotic survival signal(s) is 
necessary for tumour cells to escape their normal microenvironment, invade and 
metastasise.
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ARF is also capable of blocking CTBP mediated repression of PTEN and by doing so, 
ARF can inhibit CtBP-dependent hypoxia-induced, cancer cell migration.
57 Suppression 
of tumour invasion and metastasis by ARF, especially in a setting of p53 inactivation, 
might therefore be explained by its ability to induce apoptosis through inhibiting targets 
of CtBP. CtBP transcription factors have been shown to induce epithelial-to-
mesenchymal transition and to stimulate cell migration. Therefore regulation of CtBP’s 
activity is an important tumour suppressor function.
40,78 Depletion of CtBP1 or CtBP2 
reduces cell invasion. Ectopic CtBP2 expression enhances tumour cell migration and 
invasion. The Evi-1 oncoprotein responsible for acute myelogenous leukaemia requires 
interaction with CtBPs to mediate transformation. Therefore, agents designed to disrupt 
this interaction may be useful therapeutically.
79 Various studies carried out suggest that 
CtBP maintains a certain antiapoptotic “tone” in cells through repression of 
proapoptotic gene transcription. Such repression might be abrogated via ARF-induced 
CtBP degradation, resulting in derepression of such genes. 
The CtBP dehydrogenase substrate 4-methylthio-2-oxobutyric acid (MTOB) can act as 
CtBP inhibitor at high concentration, and is cytotoxic to cancer cells . Treatment with 
MTOB induced p53-independent apoptosis in a variety of human cancer cell lines. 
MTOB displaced CtBP from the promoter of the pro-apoptotic gene Bik, increasing Bik 
expression in a dose dependant manner. MTOB induces apoptosis in human colorectal 
cancer cell lines. In vivo test by Straza et al showed that MTOB in colon cancer 
peritonaeal xenograft demonstrated it to be a safe, well-tolerated therapy, with an ability 
to limit tumor growth and ascites production and possibly prolong survival.
57 
 
1.6.7  CtBP/Bcl-2 
Mitochondria are essential organelles that are responsible for cellular energy production 
and cell death by regulating the balance between pro-apoptotic and anti-apoptotic 
proteins such as Apoptosis Inducing Factor (AIF), Smac/Diablo and cytochrome C. 
These factors are released from the mitochondria following the formation of a pore in 
the mitochondrial membrane called permeability Transition pore, or PT pore. These 
pores are thought to form through the action of the pro-apoptotic members of the bcl-2 
family of proteins which are often found in the cytosol where they act as sensors for 
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factor deprivation they relocate to the surface of the mitochondria where the anti-
apoptotic proteins are located
80. Bcl-2 family members play a critical role in regulation 
of the mitochondrial pathway that leads to apoptotic cell death by directly targeting 
mitochondria and are frequently over-expressed in many tumors. J H Kim et al found 
that mitochondria-dependent apoptosis occurred in response to glucose deprivation and 
this apoptosis was mediated by the activation of Bcl-2 associated X protein (BAX) gene 
expression. They also found that CtBP associated with and repressed BAX promoter 
and was dissociated from the promoter in response to glucose deprivation. In addition, 
mitochondrial morphological changes and decreased mitochondrial activities were 
observed in ctbp-knockout cells, and the knockdown of Bax in CtBP-knockout cells 
recovered the mitochondrial morphology and function.
60 
 
1.6.8  CtBP/ACP, Wnt signalling 
CtBP plays an important role in modulating the Wnt signalling pathway during 
development and oncogenesis in mammals. The activation of Wnt signalling results in 
an increase in the levels of β-catenin. In the absence of this signalling, the level of β-
catenin is downregulated by the tumour suppressor protein, adenomatous polyposis coli 
(ACP). ACP gene is a key tumour suppressor gene, which promotes degradation of β-
catenin.
49 During human colon carcinogenesis,
57 inactivation of the ACP/β-catenin 
pathway services to block the progress of enterocytes in the colonic crypt into a 
differentiated, post mitotic state.
67 Genetic studies using mutant mouse models have 
demonstrated that mutations in the Acp gene are responsible for intestinal 
tumorigenesis. Homozygous Acp mutation in mice leads to embryonic lethality, and 
conditional deletion of the gene in the adult mouse disrupts homeostasis not only in the 
intestine but also in other tissues. ACP inhibits β-catenin/TCF transcription through 
interaction of β-catenin or CtBP.
79 The APC protein has also been demonstrated to 
control CtBP protein turnover and may be involved in the auto-regulation of CtBP 
abundance. APC is known to regulate the abundance of CtBP1 but did not have this 
effect on CtBP2 suggesting a CtBP2-selective regulatory mechanism, or it could be that 
CtBP1 may be more abundant in cells than CtBP2, so that knockdown of CtBP2 results 
in undetectable relative increase in CtBP1 abundance to restore total CtBP protein 
levels.
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1.7  Role in Membrane Fission and Transport 
The Golgi complex in mammalian cells is composed of stacks of flattened membrane 
disks that in mammals are connected laterally to form a single ribbon. The Golgi ribbon 
is localised to perinuclear area, and it has an essential role in secretory trafficking, lipid 
biosynthesis, protein modification and the sorting and transport of protein.
81 Many 
factors contribute to the formation and maintenance of the structure of the Golgi 
complex, including Golgi ‘matrix’ proteins and GTPase, specialised cytoskeleton-base 
motors, determine the Golgi perinuclear location and a constant membrane input from 
the endoplasmic reticulum (ER). When cells divide they must segregate not only their 
genetic material but also their cytoplasmic or organelles equally between two daughter 
cells.  During cell division, the Golgi undergoes extensive fragmentation that begins 
prophase and initially involves the severing of tubules connecting adjacent stacks. The 
isolated Golgi stacks are shortened and transformed into tubular networks that fragment 
into clusters of vesicles and tubules. A number of molecular proteins have been 
characterised through in vitro assays of Golgi mitotic fragmentation reassembly. These 
include numerous kinases, such as Cdc2, RAF/MEK1/ERKc1, PlK1 and plK3 (Figure 
1.13).
82 
 
Figure 1.13  The Golgi ribbon undergoes sequential fragmentation steps 
during mitosis in mammalian cells. Schematic representation of the Golgi 
complex partitioning during mitosis.
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A third CtBP homologue (CtBP3) was identified initially as a 50 kD protein that is 
ribosylated when rat cells are treated with the fungal toxin Brefeldin-A. Hidalgo 
Carcedo et al report that the protein CtBP3/BARS [C-terminus binding protein 
3/brefeldin A (BFA) adenosine diphosphate-ribosylated substrate], has homology to 
CtBP1 and 2 but lacks the first 11 amino acids relative to CtBP1. CtBP3 remodels lipid 
bilayers, which is an essential regulator of Golgi membrane fission, fission of vesicles 
involves in basolateral transport from the Golgi to plasma membrane, in dynamin-
independent endocytosis and in transcriptional regulation. The fragmentation of the 
Golgi complex by CtBP is required for cells to enter mitosis and both CtBP3 and CtBP1 
possess this activity. Spyer et al showed that a sub-population of CtBP migrates to and 
associates with centrosomes during the transition from G2 to mitosis or in very early 
prophase. CtBP then remains localised with the centrosomes throughout mitosis. It 
reassociates with chromatin when daughter nuclei are forming during late 
telophase.
51,81This suggests that drugs acting on BARS should have the potential to 
control G2-propase transition stage of this cycle and prevent the proliferation of cancer 
cells. Anti-sense and siRNA directed against CtBP causes a reduction of mitotic index 
and accumulation of cells in G2 of the cell cycle. 
Golgi fission is required for proper entry of cells to start dividing suggesting the 
existence of a novel ‘Golgi mitotic checkpoint’ dedicated to linking the state of 
assembly of the Golgi complex with the process of entry into mitosis. The main 
evidence for this checkpoint is that the inhibition of Golgi fragmentation via a 
functional block of the proteins involved in this process. Immunodepletion of BARS 
inhibited Golgi fragmentation by more than 80%, and the addition of recombinant 
BARS to depleted extracts completely restored their fragmentation activity.
82 Moreover, 
in cells that already have Golgi membranes that are organised as isolated stack, 
microinjection of the BARS blocker does not affect G2/M transition, indicating that the 
absence of a ribbon organisation of the Golgi, BARS becomes necessary for mitotic 
entry.
81 BARS are active also in the fission of transport carriers during interphase 
traffic, but this activity may be enhanced by mitotic phosphorylation. CtBP/BARS-
dependent fission requires long-chain acyl-CoAs as essential cofactors. These acyl-
CoAs were originally proposed to be acyl donors for a lipid specific acyl-transferase 
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into phosphatic acid (PA). This activity facilitates, but is not essential for several 
fission-requires activities of BARS.  CtBP1 exhibits fissioning activity when it binds 
acyl-CoA and assumes an open structural configuration as a monomer and participates 
in transcriptional regulation when in the dimeric form bound to NAD(H). 
BARS is involved in membrane fission at several transport steps, including that from 
the Golgi complex to the basolateral membrane in epithelial cells, fluid-phase 
endocytosis and retrograde transport of the KDEL receptor to the ER by COPI-coated 
vesicles. The later requires an interaction between BARS and the COPI-vesicle 
component ARFGAPI, which is in turn regulated in an opposite fashion by palmitoyl-
CoA and NAD
+, the cofactor of BARS.
82 The core complex of Coat Protein I (COPI), 
coatomer, is sufficient to induce coated vesicular-like structures from liposomal 
membrane. Coat proteins play a key role in intracellular transport by coupling the 
deformation compartmental membrane from vesicle formation with cargo sorting that 
involves coats binding to specific sequences in the cytoplasmic domain of cargo 
proteins for their proper packaging into nascent vesicles. Upon activation of the small 
GTpase ADP-Ribosylation Factor 1 (ARF1), coatomer becomes recruited onto Golgi 
membrane. J-S Yang et al showed that BARS plays a critical role in the fission step of 
COPI vesicle formation by multiple approaches.
83 
 
1.8  Mitotic Fidelity 
The pro-survival role of CtBPs has recently been shown to arise from their role in 
maintaining mitotic fidelity. During mitosis aurora B first localises to centromeres in 
prophase and remains concentrated at centromeres until it relocalises to the central 
spindle at the start of anaphase where it subsequently concentrates at the midbody. 
CtBPs are required for the optimal association of aurora B with the chromatin during 
mitosis. CtBP siRNA results in reduced association of aurora B with mitotic chromatin 
and an increase in the frequency of aberrant mitoses. This results in cell death, 
particularly in cells containing mutant p53, which fail to undergo a protective post-
mitotic cell cycle arrest. Bergman et al found three mitotic phenotypes in CtBP siRNA 
treated cells: 1) lagging chromosome during mitosis and, interphase cells, micronuclei 
that contain primarily centromere-containing chromatin; together indicative of entry 
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to microtubules; 2) an extended average time spent in mitosis, mitosis being delayed 
predominantly at the prometaphase stage and 3) failure of cytokinesis in a proportion of 
cells, resulting in the generation of binucleate cell progeny. Bergman et al analysed the 
phenotype of CtBP depleted cells by morphological analysis of DAPI-stained cell 
nuclei and identifying multiple morphological defects consistent with aberrant transit 
through mitosis. There was a significant increase in occurrence of binucleate cells, 
suggesting that a portion of cells undergo cell division without segregating their DNA 
and is consistent with the modest increase in cells with 4N DNA content which was also 
seen in flow cytometry.  CtBP siRNA also caused a three- to four-fold increase in 
micronuclei. Micronuclei can arise from whole chromosomes that lag at mitosis due to, 
for example, a damaged kinetochore or faulty spindle apparatus or from acentric 
chromosome fragments created by DNA breaks. There was no gross effect of CtBP 
siRNA on Golgi morphology, suggesting that the aberrant mitotic phenotype might not 
be a consequence of abnormal Golgi maintenance.
84 CtBP siRNA causes both an 
extended period of transit through mitosis, and a post-mitotic G1 arrest.
85 Birts et al 
microinjected GST-CtBP
DN, into the cytoplasm of MCF-7 cells, which
 also caused a 
significant increase in aberrant mitosis (showed in the montage in Figure 1.14). CtBP 
function in the nucleus is critical for the regulation of mitotic fidelity, as are its 
interaction with cellular factors that associate with the PxDLS-binding cleft.  
 
Figure 1.14  Microinjection of GST-CtBP2(1–110) (CtBP
DN) induces aberrant 
mitosis. At 20  h post-release, cells were microinjected into the cytoplasm with 
the indicated proteins plus FITC-Dextran. Cells were then monitored by 
fluorescent time-lapse imaging for the subsequent 65  h. Representative time-
lapse montages of cells.
86 
 
the cells. The ability of cells to complete at least one
mitosis in the imaging period was also not substantially
affected by the GST microinjections (Figure 4A), nor
was the time at which mitosis occurred substantially
affected (not shown). Compared with injection with
GST, neither GST-CtBP
DN nor GST-CtBP
DNDNLS
further increased cell death or reduced the ability of
cells to enter a ﬁrst mitosis. However, of the mitotic
events that did occur, GST-CtBP
DN caused a signiﬁcant
(Po0.0001) increase in those that were aberrant, that is
27.7% compared with only 2.5% in non-injected or
GST-injected cells (Figure 4B). Mitotic events were
scored as aberrant if there was failed abscission,
extended rounding during mitosis or the death of one
or both daughter cells directly after mitosis (Figure 4C).
This mitotic phenotype was dependant upon amino
acids 4–14 in CtBP
DN as only 5.9% of the mitoses were
aberrant when GST-CtBP
DNDNLS were injected
(Po0.0001 compared with CtBP
DN) (Figure 4B). Thus,
either functions of CtBPs within the nucleus or protein–
protein interactions made by amino acids 4–14 of CtBP2
are critical for mitotic ﬁdelity. Finally, when the fate of
the daughter cells from the ﬁrst mitosis was analysed,
we found that, although in GST-injected cells, at
least one of the two cells went on to divide again within
the imaging period in 25.6% of cases; this ﬁgure
was reduced to 3.5% in the GST-CtBP
DN-injected cells
(Figure 4B). This was also seen with the siRNA
experiment (Figure 3c), and is consistent with CtBP-
compromised MCF-7 cells undergoing a post-mitotic,
p53-dependent G1 arrest with 2–4N chromosome con-
tent (Bergman et al., 2009).
Figure 4 Microinjection of GST-CtBP2(1–110) (CtBP
DN) induces aberrant mitosis. (A, B) At 20h post-release, cells were
microinjected into the cytoplasm with the indicated proteins plus FITC-Dextran. Cells were then monitored by ﬂuorescent time-lapse
imaging for the subsequent 65h. (A) The ﬁrst event undergone by each injected cell is recorded. (B) The outcome of each cell that
underwent a ﬁrst mitosis. The denominator for the calculation of percentage is shown in parenthesis. (C) Representative time-lapse
montages of cells from (A, B). See also Supplemental videos.
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The cell cycle transition from interphase into mitosis requires several dramatic cellular 
events, which include chromosome condensation. Reversible chromosome condensation 
limits transcriptional machinery access to chromosomal DNA and inactivates 
chromatin-remodelling complexes.
87 D. Cimini et al supports this idea that chromatin-
remodelling process is strongly altered when histones are hyperacetylated during 
mitotic condensation, producing mitotic chromosomes with altered three-dimensional 
structure. Inhibition of histone deacetylation shortly before mitosis produces defects in 
chromosome condensation in living cells. A complex of chromosomal passenger 
proteins, notably aurora B kinase and its regulators surviving, borealin and INCENP 
regulates many aspects of mitosis. Inhibiting the expression and/or activity of 
chromosomal passenger proteins results in severe mitotic defect. Cell death may occur 
as a consequence of such defects, and thus proteins such as survivin and aurora B kinase 
are currently under investigation as targets for potential anti-cancer therapeutics. Aurora 
B-depleted Drosophila cultured cells showed altered chromosome condensation and 
defective association of the condensing Barren protein together with reduced H3 
phosphorylation.
88  
The mitotic check points maintain the fidelity of this process by sensing proper 
microtubule attachment with the kinetochores and the tension between the kinetochores 
of sister chromatids.
87 The spindle assembly checkpoint is the cell cycle control 
mechanism that acts during mitosis to ensure the fidelity of chromosome segregation by 
preventing premature entry into anaphase. Thus preventing the chromosome instability 
and polyploidy associated with cancer.
89 This checkpoint is activated for longer in CtBP 
compromised cells compared to controls. 
Histone modification also plays a key role in regulating mitotic checkpoint activation,
87 
with inhibition of HDAC activity prolonging mitotic arrest leading to chromosomal 
stability and segregation defects.
88, 90 As cell cycle checkpoints are often defective in 
cancer, HDAC inhibitors are often selectively cytotoxic to tumour cells, causing rapid 
and extensive apoptosis. HDACs are therefore increasingly viewed as holding much 
potential for development of novel therapeutics for a variety of diseases (including 
cancer) with the majority of current approaches focused on inhibiting individual 
HDACs with small molecules. The use of HDAC inhibitors has shown the ability of 
CtBPs to repress transcription in a partially HDAC dependent way. Along with their 
effect on gene transcription, HDAC inhibitors also induce effects on mitotic fidelity that                                                                  Chapter 1:  Introduction   
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are highly comparable to those observed upon inhibition of CtBP expression or 
targeting of the CtBP chromatin modifying complex. These effects include activation of 
the spindle assembly checkpoint, aberrant chromosomal segregation, failure of 
cytokinesis and reduced association of chromosomal passenger proteins with mitotic 
chromatin. Mitotic fidelity is thus dependent upon both HDACs, and an intact CtBP 
chromatin modifying complex; further dissection of the mechanism of regulation of 
mitosis by these proteins will be required to establish whether recruitment of HDACs 
by CtBPs is required for a normal mitotic phenotype. 
 
1.9  CtBPs in central nervous system synapses 
Chemical Synapses are highly specialised cell-cell contacts that mediate efficient 
communication between nerve cells. The release and reception of neurotransmitters 
occurs at the pre- and postsynaptic region.  A unique type of chemical synapse, 
structurally specialised for the tonic release of neurotransmitter in the dark, is the 
photoreceptor ribbon synapse. The presynaptic ribbon constitutes an electron-dense 
band of large surface area that extends from the site of transmitter release into the 
presynaptic cytoplasm and is covered by hundreds of synaptic vesicles. The ribbon is 
defined and organised by a scaffold of proteins. One of these proteins is the kinesin 
motor protein KIF3A and is enriched at ribbons. Two other integral components of 
photoreceptor ribbon synapses are Bassoon and Piccolo.
91 Another protein is RIBEYE, 
which is a protein that is enriched in dense bodies at ribbon synapses and is likely to 
function in synaptic vesicle exocytosis through the interaction with active zone proteins. 
CtBP is also present at the synaptic terminals (Figure 1.15). 
The N-terminal A domain can form aggregates in cultured cells and bears no 
recognisable similarity to other proteins or protein domains. The C-terminal B domain 
is identical to a transcriptional corepressor, C-terminal binding protein 2, but without 
the first 20 residues encoded by the first coding exon.
91-92 The A domain mediates 
assembly of RIBEYE into large structures whereas B domain binds NAD
+ with high 
affinity, similar to 2-hydroxyacid dehydrogenases.
93 RIBEYE lacks the N-terminal 20 
amino acid domain of CtBP2 and is localised to the cytoplasm. Ultra structural studies 
have revealed that both RIBEYE and CtBP1 may meet the need of tonic rate release of 
neurotransmitter. CtBP1/BARS is present at photoreceptor ribbon synapses and at                                                                  Chapter 1:  Introduction   
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conventional synapses of retina and brain and has been identified as a constituent of the 
conventional chemical synapses that do not express RIBEYE. CtBPs play a role in the 
molecular assembly and function of central nervous system synapses.
94 Depletion of 
RIBEYE in zebra fish has shown to result in shorter synaptic ribbons.
95 
 
Figure 1.15  CtBPs in ribbon synapse. The RIBEYE protein is postulated to be 
the predominant constituent of the ribbon. Other constituents of the ribbon 
include CtBP1 and the kinesin motor molecule KIF3A.
 The ribbon is anchored 
to the presynaptic membrane by the protein Bassoon, which is associated with 
voltage-gated Ca
2+ channels. CtBP1 is suggested to play a role in membrane 
turnover during exocytosis and endocytosis of the synaptic vesicles. 
 
1.10 Role of CtBP in developmental processes 
Tightly regulated gene expression is critical for the correct embryonic development and 
adult growth. CtBP plays a crucial role during early embryo development and during 
later development processes in Drosophila, they have been found in complex with 
several known DNA-binding transcription factors that participate in a wide variety of 
developmental and adult biological pathways and processes. These include Wnt and 
BMP/TGFβ signalling, the action of GATA factors, cell-cell adhesion and apoptosis, 
myogenesis and vascularisation and segmentation in flies.
54 In Drosophila, the single 
CtBP gene encodes two major isoform generated through alternative RNA splicing. 
These isoforms, termed CtBPL and CtBPS are highly conserved in insects. The proteins 
are identical at the N-terminus but differ in the C-terminal region: CtBPL has an                                                                  Chapter 1:  Introduction   
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extended C-terminus, which is lacking in CtBPS. These two isoforms have similar 
repression activity, but distinct development expression profile.
96 
Reduction in the level of maternal dCtBP results in severe segmentation and patterning 
defects, and homozygous mutations are embryonic lethal.
97 Gene dosage experiments in 
Drosophila have shown that CtBP is required for the activity of the repressors Krüppel, 
SNAIL, Knirps and biochemical assays have confirmed these genetic interaction.
49 
Knirps is a nuclear receptor protein that controls the segmentation of the abdomen, 
whereas SNAIL is a zinc finger protein that establishes a boundary between the 
presumptive mesoderm and neurogenic ectoderm.
98 The Notch signalling pathway is 
important in cell fate decisions during Drosophila development. During Notch 
signalling, the intracellular domain of Notch associates with DNA binding protein 
suppressor of Hairless.
49 Hairy is another Drosophila pre-cellular repressor that has 
shown to bind dCtBP. Hairy is also known to recruit the Groucho co-repressor. Mouse 
embryos lacking CtBP1 are small but viable, whereas CtBP2 deficient embryos die 
mid-gestation and display defective development of several tissues. This shows the 
importance of CtBPs in mammals and drosophila.
40, 99, 
100  
In addition to the identified functions in Drosophila, CtBP has also been implicated in 
human development. Mutation in the human TGIF (which maps to the HPE4 locus) 
leads to holoprosencephaly, a condition resulting from defects in craniofacial 
development. One of the HPE4 alleles encode a protein with a single amino acid 
substitution I a consensus binding site for CtBP, suggesting that CtBP-dependent branch 
of TGIF-mediated transcriptional repression is required for proper craniofacial 
development in humans. The full repressor activity of TGIF is dependent on its ability 
to bind both CtBP and histone deacetylase (HDAC).
54 In animal models CtBPs are 
widely expressed during numerous developmental processes, as well as in adult cells. 
Indeed homozygous knockout Drosophila (dCtBP-/-) exhibits lethal phenotypic 
abnormalities. Similar effects have been demonstrated in mouse embryo models, 
CtBP1-/- animals are small and have a significantly shorter life expectancy while 
CtBP2-/- embryos die in utero. In addition, the phenotypic defects seen in the 
neurological, cardiovascular and musculoskeletal systems of CtBP2-/- embryos are 
worsened if they are also CtBP1-/-, indicating that the two proteins, while having 
distinct roles, may share considerable functional overlap. These differences suggest that 
the two proteins have different roles in vivo or they are expressed in slightly different                                                                  Chapter 1:  Introduction   
41 
 
places during the course of development. Hildebrand et al have shown that there are 
clear differences in the expression of CtBP1 and CtBP2 during placental 
morphogenesis. Specifically, CtBP2 is readily detected in the forming placenta while 
CtBP1 is not. CtBP1 is expressed throughout embryogenesis and into adulthood.
54, 97, 101 
CtBP2 interacts physically with key factors in the stem cell regulatory network. 
Embryonic stem cell (ESC) assays carried out by Tarleton and Lemischka indicate that 
a knockdown of Ctbp2 expression affects the balance between self-renewal and 
differentiation towards self-renewal even when differentiation is forced. There are only 
two mechanisms by which a stem cell could increase in prevalence, these being to 
divide more rapidly or to experience a change in symmetry of fate decisions. It was 
hypothesised that the later mechanism was responsible for this observation, as cell cycle 
assays verified that this change was not due to changes in the rate of cell division. 
 
1.11 Control of Plant Microtubule Cytoskeleton 
The genome of terrestrial plants also codes for a CtBP family member, 
ANGUSTIFOLIA (AN). The AN gene was first identified in Arabidopsis thaliana and 
this gene controls N polarity-dependent leaf cell expansion, possibly through 
controlling the arrangement of the microtubule cytoskeleton. The N-terminal region of 
the AN protein shares sequence similarity with three protein classes, which also show 
similarities with each other in the region: dehydrogneases, CtBPs and BARS. AN 
proteins lack amino acid residues important for the D2-HDH catalytic function and also 
lacks the consensus NAD(H)-binding motif. It has been shown that AN was thought to 
repress transcription similar to the function of CtBP; however AN lacks some of the 
structural features that are conserved in animal CtBPs.
102 Mutations in AN gene results 
in leaves that are narrower and thicker than normal.
103 
1.12 The aim of the project 
The aim of this project was to combine the RTHS with SICLOPPS in order to study the 
protein-protein interaction of CtBP and uncover cyclic peptide inhibitors. This will help 
us further understand the role of these proteins in the cell. CtBPs exist as both monomer 
and dimers in cells and they dimerise in response to NADH levels. Current tools do not 
allow us to know whether the effect of CtBP on mitotic fidelity, reduced proliferation                                                                  Chapter 1:  Introduction   
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and colony forming potential is due the loss of CtBP or the break up dimerisation. 
siRNA leads to a loss off protein abundance in the cell where as the peptides do not.  
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2.1.  Construction of RTHS 
 
The pTHCP16 plasmid constructed by Horswill et al
17b (Figure 2.1) was used to build a 
homodimeric Reverse Two Hybrid System (RTHS) construct for CtBPs. This plasmid 
contains the sequence for wild type 434 repressor, under the control of Ptac promoter 
induced by isopropyl-β-D-thiogalactopyranoside (IPTG). The multiple cloning sites 
(MCS) have been placed to allow for construction of C-terminal fusion with the 434 
repressors. The MCS consists of SacI, BamHI, NruI and SacI restriction sites.  
 
Figure 2.1.  pTHCP16 plasmid. 
 
The pTHCP14 plasmid constructed by Horswill et al
17b (Figure 2.2) was used to build 
our heterodimeric RTHS construct for  CtBPs . As shown, this plasmid contains the 
sequences for the wild-type 434 repressor and a mutant 434 repressor (referred to as 
P22) with P22 binding specificity, under the control of a PTAC promoter induced by 
IPTG. Multiple cloning sites (MCS) have been placed to allow for construction of 
C-terminal fusions with the repressors. The MCS following P22 contains XhoI, SpeI, 
SmaI, and KpnI, while 434 is followed by SalI, BamHI, NruI, and SacI. 
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Figure 2.2.  pTHCP14 plasmid  
 
Two primers were designed for PCR: a forward primer to extend from the start codon 
(ATG) towards the stop codon (TAG) of template DNA, and a reverse primer that 
extends from the stop codon towards the start codon. Appropriate restriction enzymes 
were chosen that do not cut within the gene of interest. The distance between restriction 
sites is also considered, and where feasible sites were chosen to be as far apart as 
possible to improve efficiency of digestion by allowing more efficient binding of the 
restriction enzyme to the DNA.  
For the forward primer, 21bp from the beginning of the desired gene were taken and for 
the reverse primer the reverse complement from the end of the gene was taken. Ideally a 
cytosine or guanine was taken as the last 3’ nucleotide as this allows for stronger 
binding interaction and a more efficient PCR reaction. A stop codon (TAG) was 
introduced for the reverse primer. A GTTGTT sequence was introduced at the start of 
the primer, to act as a handle to allow the restriction enzyme to bind more efficiently to 
the DNA. The general sequence for the forward primer was GTTGTT-sequence of 
restriction enzyme-21bp and for the reverse primer the general sequence was 
GTTGTT-Complementary reverse of restriction enzyme-CTA-reverse complement of 
21bp. 
The next step was to amplify the gene that codes for the protein of interest; this was 
done via the polymerase chain reaction (PCR). PCR was carried out using a high 
fidelity polymerase with exonuclease activity for example Deep Vent (New England 
Biolabs) or Pfu (Promega). The annealing temperature was calculated using pDRAW 
software. It is important to note that when calculating the annealing temperature, only 
bases that are complementary to template DNA were used, and the restriction site was 
not incorporated in the calculation.                                                                 Chapter 2:  Screening and Selection of Peptides   
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After the PCR reaction the length of the amplified DNA was determined by gel 
electrophoresis. The PCR product was then purified and stored ready for the next step. 
Bacterial strains containing pTHCP16 was grown overnight and the plasmid was then 
isolated and purified. The Plasmid and PCR product were then digested with the 
relevant restriction enzymes (which were chosen when designing the primers), using 
standard condition (section 6.1.2.5). Digestion was followed by purification with 
QIAGEN QIAquick Spin Columns. The digested PCR product and plasmid were then 
ligated using NEB T4 ligase; this resulted in the insertion of the target gene into the 
RTHS plasmid. This plasmid was then transformed into DH5α cells, and grown on agar 
plates containing the appropriate antibiotic marker for the plasmid (ampicillin). For 
maximum transformation efficiency, the cells were thawed on ice and resuspended by 
carefully agitating the tube. It was found that cold and dry plates lower transformation 
efficiency and therefore the plates were pre-warmed at 37 °C. Colony PCR was run to 
identify colonies with the correct insert.   
 
Nitrophenyl-β-D-Galactoside (ONPG) assay 
The SNS118 cell strain constructed by Horswill et al
17b contains the RTHS reporter 
construct as a chromosomal insert, composed of the lacZ gene encoding ß-
galactosidase, under the control of the binding region of the reconstituted 434. The use 
of the lacZ reporter gene in the RTHS allows the targeted protein-protein interaction to 
be monitored by ONPG assay. IPTG is used to induce the production of the fusion 
proteins, increasing the levels of IPTG produces a higher concentration of fusion 
protein, which potentially reduces levels of β-galactosidase because its transcription is 
hindered by the increase in dimerised repressor. This links protein dimerisation to the 
levels of β-galactosidase present and can be quantified by ONPG assays. ONPG is a 
colorimetric substrate used for the detection of β-galactosidase activity. β-galactosidase 
hydrolyses ONPG to otho-nitrophenyl (ONP), which is yellow in colour. Enzyme 
activity can be measured by the rate of appearance of the yellow colour using a 
spectrometer and measuring the absorbance at OD420.  If excess ONPG is added, the 
amount of ONP formed is proportional to the amount of β-galactosidase and time of 
reaction. The reaction is stopped by the addition of Na2CO3, which shifts the reaction                                                                 Chapter 2:  Screening and Selection of Peptides   
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mixture to pH 11. At this pH, ONP is converted to a coloured anionic form and 
β-galactosidase is inactivated.  
 
Figure 2.3.  Hydrolysis of ONPG by β-galactosidase to ONP and galactose. 
 
2.2.  Construction of CtBPs RTHS 
The plasmids containing cDNA of CtBP1 and CtBP2 were available in house. The gene 
encoding full-length human CtBP1 and CtBP2 was cloned into the RTHS as a 
C-terminal fusion of the bacteriophage 434-repressor DNA binding domain under the 
control of an IPTG inducible promoter. The whole protein was used in the RTHS in 
order to include any regulatory domains as well as the dimerisation domain. 
 
2.2.1.  CtBP1 RTHS 
The CtBP1 coding sequence was amplified via PCR using designed primers, which 
allows the introduction of restriction sites into the sequence. The gene contained a SalI 
site near the end of the sequence, which was removed by a silent mutation (GUC to 
GUU) to allow SalI to be used to clone the gene into the RTHS. The CtBP1 gene was 
incorporated between the SalI and NruI restriction sites (Figure 2.4). As the NruI 
restriction enzyme is unable to cleave DNA methylated with Dam methyltransferase, a 
Dam negative strain was used to incorporate CtBP1. The pTHCP16 plasmid was 
therefore transformed into GM2929, a dam negative strain, which is maintained by 
chloamphenical resistance gene within the dam gene. The isolated plasmid was cut once 
with HpaI to confirm its length (~7103) and a PCR was carried out to confirm the insert 
was present (Band at 1320bp) (Figure 2.5). The presence and fidelity of the cloned 
sequence was verified by sequencing. 
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Figure 2.4.  RTHS construct of CtBP1.  
 
 
Figure 2.5.  Gel confirming the presence of CtBP1 in pTCHP16. First three lane: 
PCR product using CtBP1 primers (1320 bp). Last three lane: pTCHP16-CtBP1 
plasmids digested HpaI (7103 bp).  
 
To confirm the interaction between the fusion proteins, the CtBP1-pTCHP16 plasmid 
was transformed into the reporter strain SNS118 and an ONPG assay was conducted 
(section 6.1.3.9).
26 The standard activity (SA) for the above reaction is calculated using 
the following equation: 
SA = A420/t x V OD600, 
Where t is the incubation time in sec; V is the sample volume; OD600 is the optical 
density of the culture at 600 nm, which relates to the density of cell culture and A420 is 
the absorbance at 420 nm, which relates to the ONP produced.  
 
The ONPG assay showed there was interaction between the fusion proteins with a 
twofold repression of the reporter construct at IPTG levels of 50 µM, indicating the 
formation of a CtBP1 homodimer in the RTHS (Figure 2.6).  
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Figure 2.6.  ONPG assay of CtBP1-pTCHP16 in SNS118. An increase in IPTG led to 
a decrease in standard activity. Repression was observed at 50µM concentration of 
IPTG. 
 
It is important that the optimal IPTG levels are obtained for the screen, as excessively 
high levels would lead to too much protein in the cytosol, making screening and 
inhibitor identification difficult. Dimerisation of the target proteins results in the 
formation of a functional repressor that prevents the transcription of reporter genes 
downstream, leading to cell death on selective media. The reporter construct consists of 
three reporter genes: HIS3, which encodes a yeast auxotroph of imidazole glycerol 
phosphate dehydratase, needed for the synthesis of histidine. The second reporter is 
Kan
R, which codes for aminoglycosidase 3’-phosphotransferase for kanamycin 
resistance. These two reporters are chemically tuneable and conditionally selective for 
reporter genes. 3-amino-1,2,4-triazole (3-AT) is a competitive inhibitor of HIS3. 
Kanamycin and 3-AT are used to fine tune leaky expression of HIS3 and Kan
R reporter 
genes. The third reporter gene is Lac Z (β-galactosidase), which allows quantification of 
the protein-protein interactions through ONPG assays mentioned above. 
Then to identify the optimal levels of IPTG required for high-throughput screening, a 
series of minimal media selection plates were prepared. The target protein-protein 
interaction was visualized by drop spotting ten-fold dilutions of different putatives of 
CtBP1-pTCHP16 in SNS118 (Figure 2.6)  (with positive and negative controls) onto 
selective media containing a range of 3 –AT (2.5-5 µM) and kanamycin (25-50 µg/mL) 
in the absence and presence of IPTG (0-50 µM). A lower rate of growth cell was 
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observed on plates containing 3 –AT (5 µM) and kanamycin (50 µg/mL) even in the 
absence of IPTG, indicating that these conditions were too harsh. The experiment was 
repeated using 3-AT (2.5 µM) and Kan (25 µg/mL) and a range of IPTG (0, 15, 25, 
50 µM). The optimal levels required for expression of fusion proteins and blocking 
transcription of reporter genes downstream were 3-AT (2.5 µM) and Kan (25 µg/mL) 
and IPTG (25 µM) (Figure 2.7). The drop spotting data also confirmed the CtBP1 
homodimeric interaction in the RTHS. To eliminate the possibility that the growth 
inhibition is due to the toxicity of the expressed protein, the RTHS strains were drop 
spotted onto LB agar with 25 µM IPTG (Figure 2.8). All strains grew to the same extent 
on plates with and without IPTG; the observed growth inhibition on selective media can 
therefore be attributed to the targeted protein-protein interactions. 
 
Figure 2.7.  Drop spotting of CtBP1 RTHS construct, 0 µM IPTG (left) to 25 µM 
IPTG (right). 
 
 
Figure 2.8.  Drop spotting of CtBP1 RTHS construct on to rich media, 0 µM IPTG 
(left) to 25 µM IPTG (right). 
                                                                 Chapter 2:  Screening and Selection of Peptides   
51 
 
The cassette coding for the CtBP1-434 repressor fusion was integrated onto the 
chromosome of the E. coli reporter strain by phage specific recombination using the 
HK022 phage integrase as previously reported.
17a, 104 Chromosomal integration 
stabilises expression levels of the CtBP1-434 repressor protein, and eliminate false 
positives arising (during selection) from plasmid ejection.  The method employed to 
achieve this was the CRIM (conditional-replication, integration, and modular) 
integration system (Figure 2.9). The CRIM plasmid used (pAH68), contains unique 
sites within the MCS, which include SphI, PstI, SalI, XbaI, BamHI, SmaI, KpnI, SacI 
and EcoRI. The pAH68 plasmid also contains a phage site (attP), which can be 
integrated into the chromosome of the host bacterium at bacterial attachment sites 
(attB). Integration is carried out by phage integrase enzyme (Int protein). This enzyme 
is encoded by the helper plasmid (pAH69), under the control of temperature sensitive 
cI857 repressor.
104 
 
Figure 2.9.  Integration of CRIM pAH68 plasmid into phage attachment site 
attHK022. Positive integration identified by PCR product of primers P1, P2, P3 and 
P4.
104 
 
The CtBP1 construct was cut out of pTHCP16 using HpaI and NruI. SacI cuts the 
CtBP1 gene and therefore that could not be used. The cassette was ligated to pAH68 
plasmid, which was cut once with SmaI. The problem with this is that insert can ligate 
to the vector in both directions or the vector can easily re-ligate. The pAH68 plasmid 
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52 
 
5’ phosphate group from DNA, to prevent backbone re-ligation. The correct orientation 
of the insert was confirmed by PCR using the reverse primer from pAH68 plasmid (this 
binds 500bp outside the MCS of pAH68) and the forward primer for CtBP1 (giving a 
band of 1820 bp). PCR was also run using both the forward and reverse CtBP1 primers 
(giving a band at 1320 bp). The plasmid was digested once to check the length of the 
plasmid (4634 bp). Five different putatives of pAH68-CtBP1 were tested. Figure 2.10 a 
shows that the CtBP coding sequence is present in all five but only the first putative is 
in the right orientation and of the correct length.  
The pAH68-CtBP1 construct was then integrated on to the chromosome of SNS118 
using the HK022 integrase expressed from the pAH69 helper plasmid. Production of int 
protein was suppressed by initial recovery in SOC at 30 °C for 1 h, then allowed to 
begin by shifting the temperature to 42 °C for a further 30 min. Positive integrants were 
identified using pre-designed primer P1, P2, P3 and P4 (Figure 2.9). Positive integrants 
give two bands, one at 289 nt and one at 824 nt, corresponding to the PCR products of 
P1/P2 and P3/P4 PCR product (Figure 2.10 B). Unsuccessful integration results in a 
band at 740 nt from the PCR product of P2 and P3 from the unaltered pAH68 plasmid. 
Initially the yield of positive integrant was low. An alternative method for preparing 
electrocompetent cells was followed as described by Lu Zhou, Ke Zhang and Barry L. 
Warnner in Methods in molecular biology: Reviews and Protocols.
105 Cells were grown 
at 30 °C OD600 0.5 with 100 µg/mL amp present (to maintain helper plasmid) then kept 
for a further 20min at 42 °C. Rapid temperature change was obtained by using a water 
bath. This did not lead to an improvement in integrant yield. There could possibly have 
been a fault with the helper plasmid pAH69, which may have prevented it from either 
producing the cI857 repressor protein or the crucial Int protein. Therefore, a fresh 
source of pAH69 was obtained from The Coli Genetic Stock Centre at Yale University 
(USA). The new batch led to a dramatic increase in the amount of positive integrant 
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Figure 2.10.  Gels of CtBP1 constructs, (A) Check to test positive integration into 
pAH68, (digestion of product, PCR using CtBP1 F and R primers, and PCR using 
CtBP1 F and pAH68 reverse primer). (B) Colony PCR checking for positive 
integrants on the chromosome of SNS118. 
 
Putatives containing the CtBP1 construct on the chromosome of SNS118 were cultured; 
PCR was run to confirm the presence of the CtBP1 gene. These were then drop spotted 
on minimal media plates to investigate the formation of a functional repressor when the 
CtBP-434 fusion protein was expressed from the chromosome (Figure 2.11). The 
experiments were run using 3-AT (2.5 µM) and Kan (25 µg/mL) and a range of IPTG 
(5, 10, 12.5, 25, 30 and 50 µM). It was found that 25 µM of IPTG was sufficient to 
repress the reporter construct; therefore these conditions were used for SICLOPPS 
selection. 
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Figure 2.11.  Drop spotting of CtBP1/68-SNS118 putatives on minimal media plates 
with and without IPTG, respectively. P6 UEV SNS118 and CtBP1/16.1 in SNS118 
were used as positive controls. 
 
2.2.2.  CtBP2 RTHS 
The CtBP2 gene was cloned as fusion with the DNA-binding domain of of 
bacteriophage 434- repressor and placed under the control of an IPTG inducible 
promoter. The CtBP2 coding sequence was amplified via PCR using designed primers, 
which allow the introduction of restriction sites into the sequence. The CtBP2 cDNA 
sequence contains a SalI site and therefore this restriction enzyme could not be used. 
So, XhoI was used instead as its cohesive ends are compatible with SalI. The CtBP2 
gene was incorporated in to the pTCHP16 Plasmid (Gm2929 strain) using XhoI and 
NruI restriction sites (Figure 2.12). The isolated plasmid was digested with HpaI to 
confirm its length (~7121) and a PCR was carried out to check the insert was present 
(Band at 1338bp) (Figure 2.13). 
 
Figure 2.12.  RTHS construct of CtBP2. 
                                                                 Chapter 2:  Screening and Selection of Peptides   
55 
 
 
Figure 2.13.  Gel confirming the presence of CtBP2 in pTCHP16. First three lane: 
PCR product using CtBP2 primers (1338 bp). Last three lane: pTCHP16-CtBP2 
plasmids digested HpaI (7121 bp).  
 
To confirm the interaction between the fusion proteins, the CtBP2 fusion protein in our 
RTHS was transformed into SNS118 and an ONPG assay was carried (Figure 2.14). 
The ONPG assay showed there was some interaction between the fusion proteins with a 
one-fold repression of the reporter construct at IPTG levels of 50µM.  
 
Figure 2.14.  ONPG assay of CtBP2-pTHCP16 in SNS118. An increase in IPTG led to 
a decrease in standard activity. Repression was observed at 50µM concentration. 
 
To find the levels of IPTG required for complete repression of the reporter genes, 
minimal media plates were prepared for drop spotting (cells were diluted 10 fold). The 
resulting CtBP2 RTHS showed IPTG-dependent inhibition of cell growth on minimal 
media, indicating that CtBP homodimerisation leads to the formation of a functional 
repressor in the RTHS blocking production of the reporter gene (Figure 2.15). 
0 200 400 600 800 1000
0.0008
0.0010
0.0012
0.0014
0.0016
0.0018
0.0020
[IPTG] / uM
S
t
a
n
d
a
r
d
 
A
c
t
i
v
i
t
y
 
/
 
O
D
6
0
0
500 
750 
1000 
1500 
8000 
10000 
6000 
 
 
1338 bp 
7121 bp                                                                 Chapter 2:  Screening and Selection of Peptides   
56 
 
 
Figure 2.15.  Drop spotting of CtBP2 RTHS construct, 0 µM IPTG (left) to 25 µM 
IPTG (right). 
 
The cassette coding for the CtBP2-434 repressor fusion was integrated onto the 
chromosome of the E. coli reporter strain as previously reported,
17a, 104 to stabilize 
expression levels of the CtBP2-434 repressor protein, and eliminate any false positives 
arising (during selection) from plasmid ejection. 
The CtBP2-pTHCP16 plasmid was digested using HpaI and NruI, as there is a SacI 
digestion site within the CtBP2 gene. The cassette was ligated to pAH68 plasmid, 
which was cut once with SmaI. Once the CtBP2-pAH68 plasmid was constructed, the 
CtBP2 RTHS construct was integrated onto the chromosome of SNS118 (Figure 
2.16 A).  
 
Figure 2.16.  Gels confirming integration of the CtBP2 construct onto the 
chromosome of SNS118; (A) colony PCR run using P1, P2, P3 and P4 primers, (B) 
PCR run using CtBP2 primer to confirm the presence of the CtBP2 gene.   
 
Putatives containing the CtBP2 construct on the chromosome of SNS118 were cultured; 
PCR was run to confirm the presence of the CtBP2 gene (Figure 2.16 B). These were 
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chromosome Figure 2.17. The optimal level of IPTG for selection was determined to be 
25 µM.  
 
Figure 2.17.  Drop spotting of CtBP2-pAH68 putatives in SNS118. P6UEV SNS118 
and CtBP2/16.8 in SNS118 were used as positive controls. From left to right 
increasing amounts of IPTG from 0, 25 to 50 µM. 
 
2.2.3.  Construction of CtBP2mut 
CtBPs contain a central NAD(H) binding domain, and binding of NAD(H) to CtBPs 
promotes dimerisation. Point mutation in the NAD(H) binding motif leads to a dramatic 
decline in homdimerisation efficiency and transcriptional activity of CtBP1 and CtBP2 
isoforms. To confirm the observed formation of the functional repressor was due to 
CtBP dimerisation, we used the monomeric CtBP mutants as a negative controls. This 
specific point mutation (G189A) in the NAD(H) binding motif of hCtBP2 (GXGXXG) 
was chosen. The alanine substitution in CtBP2 NAD(H) binding domain makes CtBP2 
insensitive to NADH. The mutation was introduced via PCR mutagenesis (Figure 2.18). 
Two PCR reactions were carried out to amplify the 5’- and the 3’- portions of the DNA 
to be mutated (Figure 2.19 A). Two PCR products were mixed and used for another 
PCR using just the CtBP2 primers (Figure 2.19 B). The PCR product was then sub-
cloned into the pTCHP16. The construct was then cloned into the pAH68 plasmid 
(Figure 2.19 C) and integrated onto the chromosome of SNS118 (Figure 2.19 D).                                                                  Chapter 2:  Screening and Selection of Peptides   
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Figure 2.18.  Diagram illustrating the PCR mutagenesis methodology.  
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Figure 2.19.  (A) Gel of PCR product from the 1
st PCR, (B) gel of PCR product from 
the 2
nd PCR both illustrated above (Figure 2.18) (C) gel of colony PCR to check the 
insertion of CtBP2mut into pAH68. (D) gell of integration of CtBP2mut on to the 
chromosome. 
 
Figure 2.20 shows a set of minimal media plates with increasing amount of IPTG. 
P6UEV and CtBP2wt were used as controls and four different putative of CtBP2mut 
were drop spotted in dilutions of 10 from left to right. The addition of IPTG leads to 
dimerisation and the production of fusion proteins. That leads to the active repressor 
being formed which results in inhibition of transcription of the reporter genes 
downstream, which results in cell death.  On the plate with zero IPTG all the cells grew 
but as the amount of IPTG was increased the cells struggled to grow on the more diluted 
spots. These results show that there is dimerisation occurring in CtBP2mut albeit less 
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Figure 2.20.  Minimal media plates, cultures drop spotted in dilutions of 10 from left 
to right. P6 UEV and CtBP2wt were used as controls, followed by 4 putatives of 
CtBP2mut. Levels of IPTG added to the plate’s increases from left to right. 
 
2.2.4.  CtBP Heterodimeric RTHS 
Due to most of the restriction sites in the pTCHP14 MCS being present within the 
CtBP1 and CtBP2 gene, truncations containing the CtBP dimerisation domains 
(CtBP1dim and CtBP2dim) were used to construct the CtBP1/CtBP2 heterodimeric 
RTHS. For CtBP2, amino acids 82 to 330 were amplified via PCR. The CtBP2dim gene 
was incorporated into pTCHP14 Plasmid using SalI and SacI restriction sites.  For 
CtBP1, amino acids 76 to 324 were amplified via PCR. The CtBP1dim gene was 
incorporated into pTCHP14 Plasmid using SmaI and KpnI restriction sites (Figure 
2.21). The RTHS construct was then integrated into pAH68. Attempts were made to 
incorporate the construct onto chromosome of SNS118. Again, from the colony PCR 
there were no positive colonies.  Due to time constraints no further work was carried out 
on the CtBP heterodimeric system.  
 
Figure 2.21.  CtBP2 heterodimeric construct. 
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2.3.  SICLOPPS 
2.3.1.  Construction of Library 
To identify cyclic peptides that inhibit CtBP1 homodimeric interaction, SICLOPPS
31 
34 
library was constructed using degenerate oligonucleotides that code for the C- and N-
terminus of the Synechocytis sp PCC6803 DnaE split inteins joined by a predetermined 
number of random amino acids. A PCR-based technique was used in which the random 
oligonucleotides of the library are incorporated into the forward primer between the 
region that binds the 3’ end of IC and the 5’ end of IN. The reverse primer anneals to the 
chitin-CBD, amplifying the IN-CBD fusion gene (CBDr primer). The variable region 
was encoded from of NNS, where N represents any of the four DNA bases (A, C, G 
or T) and S represents C or G. The NNS sequence generates 32 codons (4X4X2) and 
encodes all 20 amino acids while eliminating both ochre (UAA) and opal (UGA) stop 
codons from the library. Amber stop codons (UAG) are represented in the library at a 
frequency of 1/32.
33 The intein chemistry requires the first amino acid to be a 
nucleophilic cysteine or serine. There is no limit on the number of amino acids in the 
target peptide.  
It had been previously reported that after the first PCR, half of the amplified DNA 
fragments contain mismatches in the random nucleotide region,
34, 106 and this may be 
due to the complexity of the library. A second PCR using a “zipper” primer 
corresponding to the 3’ end of IC was therefore used to ensure the annealing of all DNA 
sequences to their complimentary strand. Either Deepvent or Gotaq polymerases were 
used for PCR but the PCR efficiency was greater when using Gotaq and more DNA was 
obtained. The PCR product and pARCBD plasmid were digested with BglI and HindIII. 
Digested products were gel purified. The pARCBD was treated with shrimp alkaline 
phosphotase to prevent re-ligation of the backbone plasmid. A 1:1 plasmid/insert 
overnight ligation at 4 °C was set up, and a control was also run using pARCBD 
plasmid and water. It was important to have high transformation efficiency in order to 
have a high library size. Therefore, after ligation the enzyme was heat killed and then 
dialysed to remove salt and contaminant, which are known to decrease efficiency. For 
dialysis, a Millipore membrane was floated shiny side up on deionised water in a falcon 
tube, and the sample was carefully pipetted on to the centre of the membrane. The tube 
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NEB10β electrocompetent cells. The electroporation cuvettes were pre-chilled on ice 
before transformation, and it was also important to add recovery solution immediately 
after electroporation as a delay of 1 min was found to cause a 3-fold reduction in 
efficiency.   
Upon intercellular expression of the SICLOPPS intein for the transformed plasmid, the 
split inteins process to give a library of cyclic peptides. Combining the bacterial RTHS 
with SICLOPPS enables the rapid screening of a large library of compounds against a 
chosen protein-protein interaction.
17a, 
17b The selection process links survival of a 
bacterial cell on minimal media to the distruption of a chosen protein-protein 
interaction. Inhibition of dimerisation by a cyclic peptide distrupts the repressor, 
allowing the expression of the reporter genes, resulting in the survival of the host cell on 
selective media. 
Four SICLOPPS libraries were constructed for screening the CtBP RTHS, One 
encoding SGWXXXX (X = any amino acid) cyclic heptomers, another encoding 
SGWXXXXX cyclic octamers and the other two encoding SGWXXXXXX cyclic 
nonamers and C+5 cyclic hexamers as previously described.
31 The SGW sequence 
allows efficient circular ligation. The SGW cyclic peptide libraries were designed to 
contain an invariable motif of serine (required nucleophile for intein processing), 
glycine (avoids racemisation during chemical synthesis and tryptophan (functions and a 
chromophore for HPLC purification). The C+5 cyclic peptide libraries were designed to 
contain an invariable motif of cysteine (required nucleophile for intein processing).  
 
2.3.2.  Screening of peptides in the CtBP1 RTHS 
The SICLOPPs library was transformed into the CtBP1 RTHS strain and plated onto 
histidine-free minimal media plate supplemented with arabinose (inducer of 
SICLOPPS), IPTG (Inducer of selection strain), Kan and 3-amino-1,2,3-triazole (3-AT, 
a competitive inhibitor of HIS3 gene product). The plates were incubated until colonies 
were readily visible (Figure 2.22A). Individual colonies were picked and restreaked 
onto rich media plates containing Spectinomycin (resistance from the selection strain) 
and Chloramphenicol (resistance from the SICLOPPS plasmids) (Figure 2.22 B). To 
eliminate false positives, several filtering steps were developed that enabled rapid and                                                                 Chapter 2:  Screening and Selection of Peptides   
63 
 
convenient assessment of candidates. Aberrant selectants could arise because of the 
possibility of damage to the expression of SICLOPPS or the CtBP fusion and they were 
detected by (1) the failure of IPTG to inhibit growth; (2) the inability of arabinose to 
improve growth; and (3) the inability to confirm the expected phenotype upon 
retransformation of the plasmid.  
           
Figure 2.22.  (A)Typical selection plate, (with IPTG and Arabinose), (B) restreaking 
of colonies from selection plate. 
 
Surviving colonies were harvested overnight and then drop spotted onto selection 
minimal media plates with and without arabinose in order to screen against arabinose-
dependent growth advantage to eliminate false positives (Figure 2.23). Plasmids 
showing growth advantage on plates with arabinose were isolated and retransformed 
into the CtBP1 selection strain to confirm the expected phenotype. After isolation of the 
SICLOPPS plasmids containing potential inhibitors and retransforming into the CtBP1-
68-8.1 selection strain, 44 potential peptides showing growth advantage on arabinose 
plates were isolated (Figure 2.24).  
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Figure 2.23.  +/- arabinose Drop spotting of potential cyclic peptide inhibitor in the 
reporter strain CtBP1-68-8.1. 
 
 
Figure 2.24.  Retransformation of CtBP1 SGW+6 SICLOPPS plasmids into CtBP1 
selection strain. 
 
To assess the selectivity of the identified peptides, the corresponding SICLOPPS 
plasmids were retransformed into a RTHS monitoring the interaction of an unrelated 
protein, ATIC
17a (a homodimeric enzyme in the de novo purine biosynthesis pathway). 
This step identifies any false positive results due to binding to regions of the RTHS 
unrelated to CtBP1 (example shown in Figure 2.25).                                                                  Chapter 2:  Screening and Selection of Peptides   
65 
 
 
Figure 2.25.  Drop spotting of Potential Peptides inhibitors (1-3, 6-9, 11, 13-15, 19-21) 
for CtBP1 transformed in CtBP1 (left on both plates) and ATIC (right on both 
plates) on minimal media plates without (left) and with (right) arabinose. Peptides 
that made it through all the screens are highlighted. 
 
23 plasmids showed specificity for CTBP1. These plasmids were then transformed into the 
CtBP2-68-118-10 selection strain (Figure 2.26). CtBP1 and CtBP2 are very similar in 
sequences; they share 78% in amino acid identity and 83% similarity. So, it was interesting to 
find that some of these peptides were specific inhibitors of CtBP1.  
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Figure 2.26.  Drop spotting of Potential Peptides inhibitors for CtBP1 transformed in 
CtBP1 (left on both plates) and CtBP2 (right on both plates) on minimal media 
plates without (above) and with (below) arabinose. Examples of putative showing 
growth advantage in CtBP1 are highlighted in white, and those showing growth 
advantages in both CtBP1 and CtBP2 are highlighted in yellow.  
 
One of the benefits of genetically encoded combinatorial libraries is the ease of deciphering 
their chemical composition, compared to synthetically derived libraries. SICLOPPS plasmids 
were sent for DNA sequencing to determine the amino sequence of the variable region present 
on the selected SICLOPPS plasmid (Figure 2.27).  Peptide 6, 9, 19 and 31 were selective for 
both CtBP1, 10 other peptides that the showed activity in both the CtBP1 and CtBP2 screen 
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Figure 2.27.  Sequenced selected SICLOPPS peptides, (A) Drop spotting, (B) Table 
showing peptide sequence and scoring of activity (1* most active, 1 active 2 least 
active). Peptides 6, 9, 19 and 31 were selective for both CtBP1, the other peptides 
showed activity for both CtBP1 and 2. Sequencing for peptide 20 failed. 
 
2.3.3.  Screening of peptides in the CtBP2 RTHS 
The SGW+6 and C+5 libraries were transformed into the CtBP2-68 in SNS118 strain. 
The initial drop spotting showed that all the colonies picked from the screening plate 
had growth advantages on arabinose plates. The corresponding SICLOPPS plasmids 
were isolated and retransformed into the CtBP2 strain. When retransforming CtBP2 
SICLOPPS plasmid into the CtBP2 selection strain, the colonies did not grow as 
expected with colonies showing a growth advantage on both +/- arabinose plates. 
Different libraries and different selection conditions were tried but the same results 
were observed, which indicated a fault in the RTHS construct. Due to time constraints 
the CtBP2 selection was not carried further, and peptides from the CtBP1 screen were 
synthesised for testing in mammalian cells. 
                                                                  Chapter 2:  Screening and Selection of Peptides   
68 
 
2.4.  Peptide Synthesis 
The selected peptides were synthesized and purified to examine their effect on CtBP 
activity in vitro. Due to the low yields obtained when using SICLOPPS to produce 
cyclic peptide production in vivo, all peptides were synthesized via solid phase peptide 
synthesis (Figure 2.28). Peptides were made using Fmoc solid-phase chemical 
synthesis, starting with the carboxy-terminal amino acid attached to the Wang resin, and 
adding one amino acid at a time to the amino terminal end to build the peptide. One of 
the advantages of the Fmoc method is that it allows for milder deprotection conditions 
to be used. This method utilizes 20% piperidine as a base in DMF in order to remove 
the Fmoc group, which exposes the α-amino group for subsequent reaction with an 
incoming activated amino acid. Unlike the BOC method, which uses acid to deprotect 
the α-amino group, Fmoc SPPS uses a base for deprotection, and thus the exposed 
amine is neutral. Therefore, no neutralisation of the peptide is required after 
deprotection. Along with development of Fmoc SPPS, different resins have been 
developed in order to remove the peptide from the resin by TFA.  
There are many advantages to solid phase peptide synthesis:
 
•  The reactions can be driven to completion by the addition of excess reagents, 
and any excess reagents can be removed by washing the resin with suitable 
solvents. 
•  Reactions, which show low chemoselectivity can be directed by the attachment 
to an appropriate resin. 
•  Resins allow for the rapid diffusion of reagents and accommodate increasing 
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Figure 2.28.  Standard reaction scheme for solid phase peptide synthesis. 
 
Monitoring the reactions in the solid phase is not as straight forward as in the solution 
phase. It is not possible to use TLC, NMR and IR to monitor the reactions in the solid 
phase because the product is attached to the polymeric support. To utilize these 
characterization methods, a small sample of the product has to be cleaved from the 
resin. However, this was not a viable option with our work because the reactions were 
initially performed on a small scale. Instead, the Kaiser test was used (Figure 2.29). The 
Kaiser test is a qualitative test for the presence or absence of a free amino group, and it 
can be a useful indication for the completeness of a coupling step. The test is based on 
the reaction of ninhydrin with primary amines, which gives a characteristic dark blue 
colour on removal of the Fmoc group and a straw yellow colour in the presence of an 
Fmoc protected amino group. The test requires minimal amount of analyte and is 
completed within a few minutes. The Kaiser test was therefore used after every 
coupling and deprotection step to determine if the reaction was successful.  
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Figure 2.29.  Reaction scheme for the Ninhydrin test. 
  
After total synthesis of the peptides, they were cleaved from the resin and deprotected. 
The cysteine of cysteine containing peptides was subsequently protected with 
2,2’-Dithiodipyridine (Aldrithiol). Once peptides were synthesised, they were 
characterized by mass spectroscopy and analytical HPLC. The peak corresponding to 
the cyclic peptide was isolated from the HPLC and the mass ion obtained from the mass 
spectroscopy showed that the desired sequence was observed.  
Transport of proteins and peptides across the cell membrane is challenging, due to the 
impermeable nature of the cell membrane that restrict cellular drug uptake to small 
(<600 Da) and to hydrophobic molecules. Methods of cellular delivery include 
microinjection, electroporation, receptor-mediated endocytosis and scrape loading. 
There are certain drawbacks each of these methods such as cell toxicity, low transfer 
efficiency and being time consuming. To improve cyclic peptide delivery into targeted 
mammalian cells, a short peptide sequence derived from the 86-mer trans-activating 
transcriptional activator (Tat) protein encoded by the Human immunodeficiency virus 
type 1 (HIV-1) was attached to the cyclic peptides through a disulfide bond between 
two cysteines. The Tat sequence has previously been shown to aid the translocation of a 
variety of proteins across the plasma membrane of mammalian cells.
107 The region 
responsible for the cell penetrating properties has shown to be confined to a stretch of 9 
basic amino acids RKKRRQRRR. The cationic charges of the peptide and the anionic 
charges of the membrane component initiate the membrane adsorption of the peptide. 
The cationic charge plays a role in the uptake process and a single deletion or 
substitution of basic charges induced a reduction of the cell association of the 
peptide.
108 The non-random region of the cyclic peptide was changed from SGW to 
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CGW and a cysteine was added to the beginning of Tat to enable the joining of the 
cyclic peptide to Tat via a disulphide bond. 
Peptides 6 and 61 were chosen initially for synthesis, as peptide 6 was the most potent 
inhibitor of CtBP1 and peptide 61 was the most active inhibitor for both CtBP1 and 
CtBP2. 
2.4.1.  Peptide 61 
 
Scheme:1  (i) Fmoc-Ser(tBu)-OH, DMF 15 min, rt ; (ii) Pyridine, 2,6 
dichlorobenzyl chloride, 15 hr rt; (iii) Fmoc-Tyr(tBu)-OH, PyBop, DIPEA; 2 hr rt; 
(iv) Fmoc-Met-OH, PyBop, DIPEA; 2 hr rt; (v) Fmoc-Arg(Pmc)-OH, PyBop, 
DIPEA; 2 hr rt; (vi) Fmoc-Val-OH, PyBop, DIPEA; 2 hr rt; (vii) Fmoc-Val-OH, 
PyBop, DIPEA; 2 hr rt; (viii) Fmoc-Thr(tBu)-OH, PyBop, DIPEA; 2 hr rt; 
(ix) Fmoc-Trp(Boc)-OH, PyBop, DIPEA; 2 hr rt; (x) Fmoc-Gly-OH, PyBop, 
DIPEA; 2 hr rt; (xi) 94% TFA, 2.5% EDT, 2.5% water, 1% TIS 3 hr, rt; (xii) EDC, 
HOBt, DCM, 24 hr, rt.  
 
As Scheme:1 shows, the first step in the synthesis of peptide 61 is to load the Wang 
resin with serine residue. After washing, any remaining hydroxyl groups of the resin 
were benzoylated with 150 µl 2, 6-dichlorobenzoyl chloride and 150 µl pyridine in 4 ml 
DMF for 2 h. It has been reported that the use of 2, 6-dichlorobenzoyl chloride 
procedure did not lead to the formation of dipeptides due to premature cleavage of the 
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Fmoc-group under basic condition when using DCC/DMAP.
109 The Kaiser test was 
carried out to test for the coupling of an amino acid and the removal of the Fmoc group.  
On completion of the linear peptide the peptide was cleaved from the resin using TFA. 
During this process highly reactive cationic species are generated from the protecting 
groups and the linkers on the resin, and these can, unless trapped, react with and hence 
modify those residues containing nucleophilic functional groups: Trp, Met, Tyr and 
Cys. To prevent this, various nucleophilic reagents (known as scavengers) are added 
with TFA to quench these ions. In our case, TIS and water were added. The amino acids 
Met, Cys, Trp are extremely susceptible to alkylation by cations produced during the 
cleavage process. When these amino acids are present the most commonly used 
scavenger is EDT as it is a good scavenger for t-butyl cations. It also assists in the 
removal of the trityl protecting group and is particularly effective in preventing acid 
catalysed oxidation of Trp residues.   
Crude peptide mixtures were subjected to reverse-phase chromatography, on a Waters 
HPLC system by using water/acetonitrile gradient with 0.1% trifluoroacetic acid. A 
typical program was 95:5 (water:acetonitrile) for 10 min and then the flow was then 
changed to 50:50 and held for 15 minutes before reducing the flow was reduced to 95:5 
for 5 min. Mass analysis was performed via HM ESI+ mass spectrometry .  
After HPLC purification, the solvent was removed on the rotary evaporator and dried in 
the desiccator overnight to ensure the peptide was dry. It was also important to ensure 
that the glassware used in the reactions was dry, and that dry DMF was also used as the 
reaction solvent for cyclisation. This was necessary because the presence of water 
resulted in a low yield of cyclic peptide and ∼50% of the peptide remaining linear 
(Figure 2.30). 
 
Figure 2.30.  HPLC trace of the cylisation reaction. 
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The cyclisation also needed to be performed under high dilution, in order to prevent 
oligomerisation. Cyclisation was carried out by mixing the linear peptide with EDC, 
which is used as a carbonyl activating agent for coupling of primary amines to yield an 
amide bond. HOBt was also added to the reaction mixture, and this is one of the most 
widely used reagents in peptide synthesis due to the excellent reactivity and chiral 
stability of OBt esters of amino acids and peptides. The crude cyclised product was 
purified via HPLC (prep6040 (50:50 flow changed to 60:40 for 10 min)). Mass analysis 
was performed via HM ESI+ mass spectrometry  
 
2.4.2.  Pep6 
 
 
Scheme:2  (i) Fmoc-Ser(tBu)-OH, DMF 15 min, rt ; (ii) Pyridine, 
2,6 dichlorobenzyl chloride, 15 hr rt; iii) Fmoc-Ser(tBu)-OH, PyBop, DIPEA; 2 hr 
rt; (iv) Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 2 hr rt; (v) Fmoc-Val-OH, PyBop, 
DIPEA; 2 hr rt; (vi) Fmoc-Thr(tBu)-OH, PyBop, DIPEA; 2 hr rt; 
(vii) Fmoc-Asn(Trt)-OH, PyBop, DIPEA; 2 hr rt; (viii) Fmoc-Trp(Boc)-OH, PyBop, 
DIPEA; 2 hr rt; (ix) Fmoc-Gly-OH, PyBop, DIPEA; 2 hr rt; (x) 94% TFA, 2.5% 
EDT, 2.5% water, 1% TIS 3 hr, rt; (xi) EDC, HOBt, DCM, 24 hr, rt.  
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Scheme:2 shows the synthesis of peptide 6; the same procedure as for peptide 61 was 
followed. Peptide 6 is soluble in water due the presence of two hydrophilic serine amino 
acids, an arginine, a threonine and an asparagine amino acid.  
 
2.4.3.  Tat 
 
 
Scheme:3  (i) Fmoc-Gln(Trt)-OH, DMF 15 min, rt ; (ii) Pyridine, 2,6 
dichlorobenzyl chloride, 15 hr rt; iii)Fmoc-Pro-OH, PyBop, DIPEA; 2 hr rt; (iv) 
Fmoc-Pro-OH, PyBop, DIPEA; 2 hr rt; (v) Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 2 
hr rt; (vi) Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 2 hr rt; (vii) Fmoc-Arg(Pmc)-OH, 
PyBop, DIPEA; 2 hr rt; (viii) Fmoc-Gln(Trt)-OH, PyBop, DIPEA; 2 hr rt; (x) Fmoc-
Arg(Pmc)-OH, PyBop, DIPEA; 2 hr rt; (ix) Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 2 
hr rt; (x) Fmoc-Lys(Boc)-OH, PyBop, DIPEA; 2 hr rt; (xi) Fmoc-Lys(Boc)-OH, 
PyBop, DIPEA; 2 hr rt; (xii) Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 2 hr rt; (xiii) 
Fmoc-Gly-OH, PyBop, DIPEA 2 hr rt; (xiv) Fmoc-Cys(Trt)-OH, PyBop, DIPEA 2 
hr rt. (xv) 94% TFA, 2.5% EDT, 2.5% water, 1% TIS 3 hr, rt; (xvi) Aldrithiol, 
DMF, rt, 15hr; xvii) Tcep, DMF, 1 hr, rt. 
 
Scheme:3 shows the synthesis of Tat. The standard procedure for the synthesis of linear 
peptides was followed. Tat can be attached to cyclic peptides in order to aid the 
internalisation of the peptides into mammalian cells. One challenge facing peptide 
synthesis is the γ-lactam formation of arginine (Figure 2.31). The formation of the γ-
lactam occurs when the internal nitrogen of the guanidine attacks the activated ester, 
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irreversibly forming the lactam ring. This reaction is competitive with peptide-bond 
formation, and it greatly reduces the coupling efficiency of arginine. For efficient 
coupling of arginine the coupling reaction was carried out twice. 
 
Figure 2.31.  γ-Lactam Formation. 
 
After cleavage of the peptide from the resin the sulphur of the cysteine residue was 
protected using aldrithiol (2,2’-Dithiodipyridine) to prevent any side reactions. The 
linear peptide was purified prior to cyclisation.  
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2.4.4.  61 Tat-Tagged 
  
Scheme:4  (i) Fmoc-Tyr(tBu)-OH, DMF 15 min, rt ; (ii) Pyridine, 2,6 
dichlorobenzyl chloride, 15 hr rt; iii) Fmoc-Met-OH, PyBop, DIPEA; 2 hr rt; 
(iv)Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 2 hr rt; (v) Fmoc-Val-OH, PyBop, 
DIPEA; 2 hr rt; (vi) Fmoc-Val-OH, PyBop, DIPEA; 2 hr rt; 
(vii)  Fmoc--Thr(tBu)--OH, PyBop, DIPEA; 2 hr rt; (viii) Fmoc-Trp(Boc)-OH, 
PyBop, DIPEA; 2 hr rt; (ix) Fmoc-Gly-OH, PyBop, DIPEA 2 hr rt;(x) Fmoc-
Cys(Trt)-OH, PyBop, DIPEA 2 hr rt; (xi) 94% TFA, 2.5% EDT, 2.5% water, 
1% TIS 3 hr, rt; (xii) Aldrithiol, DMF, rt, 15hr  (xiii) EDC, HOBt, DCM, 24 hr, rt; 
(xiv)Tcep, DMF, 1 hr, rt;  xv)Tat-s-s-py, DMF, rt. 
 
Scheme:4 shows the synthesis of peptide 61 Tat-tagged. The same reaction scheme as 
peptide 61 (Scheme:1) was followed; the serine was replaced with a cysteine in order to 
carry out the Tat-tagged reaction. On cleavage from the resin the cysteine was protected 
using aldrithiol to avoid any side reactions. The linear protected peptide was purified 
via HPLC prior to cyclisation. The aldritiol protecting group was removed using 
tris(2-carboxyethyl)phosphine (TCEP). TCEP is often used as a reducing agent to break 
disulfide bonds (Figure 2.32). TCEP has advantages over other common reducing 
agents such as being odourless, a more powerful reducing agent, an irreversible 
reducing agent, more hydrophilic and more resistant to oxidation in air. Initially 
1,3-propanedithiol was used to reduce the disulphide bond via thiol exchange. A 
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disadvantage of this process is that the reaction takes 6 hr compared to 1 hr reaction 
time with TCEP. The deprotected peptide was then mixed with Tat and DMF for the 
final step of the Tat-tagging. 
 
Figure 2.32.  Reaction Scheme for TCEP disulphide bond reduction. 
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2.4.5.  Peptide 6 Tat-Tagged 
 
 
Scheme:5  (i) Fmoc-Ser(tBu)-OH, DMF 15 min, rt ; (ii) Pyridine, 2,6 
dichlorobenzyl chloride, 15 hr rt; iii) Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 30 min 
rt; (iv) Fmoc-Val-OH, PyBop, DIPEA; 30 min rt; (v) Fmoc-Thr(tBu)-OH, PyBop, 
DIPEA; 30 min rt; (vi) Fmoc-Asn(Trt)-OH, PyBop, DIPEA; 30 min rt; 
(vii) Fmoc-Trp(Boc)-OH, PyBop, DIPEA; 30 min rt; (viii) Fmoc-Gly-OH, PyBop, 
DIPEA 30 min rt; (ix) Fmoc-Cys(Trt)-OH, PyBop, DIPEA 30 min rt; (x) 94% TFA, 
2.5% EDT, 2.5% water, 1% TIS 3 hr, rt; (xi) Aldrithiol, DMF, rt, 15hr  (xii) EDC, 
HOBt, DCM, 24 hr, rt; (xiii)Tcep, DMF, 1 hr, rt; xiv)Tat-s-s-py, DMF, rt. 
 
Scheme:5 illustrates the synthesis of peptide 6 Tat-tagged. Again the serine was 
replaced with cysteine so that the peptide could be attached to Tat via a disulfide bond. 
The linear peptide was synthesised on the peptide synthesiser (CEM Liberty1 
microwave peptide synthesiser). The preloaded resin was added to the reaction vessel. 
All the amino acid coupling and deprotection reagents were made up in bottles and 
connected to the machine. The Liberty1 system features microwave peptide synthesis, 
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which offers several advantages over conventional synthesis conditions including 
shorter reactions resulting in fast cycle times and higher purity peptides than 
conventional synthesis. Coupling time was reduced from 2 hr to 30 min. The last amino 
acid was left protected. On completion, the linear peptide was removed and deprotected 
as normal. The peptide was then cleaved from the resin. The standard procedure for 
cleavage from the resin, cysteine protectection, cyclisation and Tat-tagging was 
followed.   
 
2.4.6.  Peptide 32 
 
Scheme:6  i) Fmoc-Tyr(tBu)-OH, DMF 15 min, rt ; (ii) Pyridine, 2,6 dichlorobenzyl 
chloride, 15 hr rt; (iii) Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 2 hr rt; 
(iv) Fmoc-Cys(Trt)-OH, PyBop, DIPEA 2 hr rt; (v) Fmoc-Val-OH, PyBop, DIPEA; 
2 hr rt; (vi) Fmoc-Asn(Trt)-OH, PyBop, DIPEA; 2 hr rt; (vii) Fmoc-Phe-OH, 
PyBop, DIPEA 2 hr rt; (viii) 94% TFA, 2.5% EDT, 2.5% water, 1% TIS 3 hr, rt; 
(ix) Aldrithiol, DMF, rt, 15hr; (x) EDC, HOBt, DCM, 24 hr, rt; (xi) Tcep, DMF, 
1 hr, rt. 
 
Scheme:6 was followed for the synthesis of peptide 32. Standard procedures were 
followed. 
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2.4.7.  Peptide 33 
 
Scheme:7  i) Fmoc-Tyr(tBu)-OH, DMF 15 min, rt ; (ii) Pyridine, 2,6 dichlorobenzyl 
chloride, 15 hr rt; (iii) Fmoc-Tyr(tBu)-OH, PyBop, DIPEA; 2 hr rt; 
(iv) Fmoc-Arg(Pmc)-OH, PyBop, DIPEA; 2 hr rt; (v) Fmoc-Asn(Trt)-OH, PyBop, 
DIPEA; 2 hr rt; (vi) Fmoc-Cys(Trt)-OH, PyBop, DIPEA 2 hr rt; (vii) Fmoc-Phe-
OH, PyBop, DIPEA 2 hr rt; (viii) 94% TFA, 2.5% EDT, 2.5% water, 1% TIS 
3 hr, rt; (ix) Aldrithiol, DMF, rt, 15hr;  (x) EDC, HOBt, DCM, 24 hr, rt; xi)Tcep, 
DMF, 1 hr, rt. 
 
Scheme:7 was followed for the synthesis of peptide 33. Standard procedures were 
followed. 
The RTHS has confirmed the homodimeric interaction of CtBP1 and CtBP2. The RTHS 
and SICLOPPS system have been combined to successfully uncover inhibitors of 
CtBP1 and CtBP2. The most active inhibitors were first synthesised to test in vitro 
(Chapter 3) and in vivo (Chapter 4) assays. 
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The selection of CtBP2 was not completed, it would be useful get inhibitors that just 
inhibit CtBP2. CtBP1-pTCHP14 and CtBP2-pTCHP14 plasmid have been constructed, 
these need to be integrated onto the chromosome. It will be interesting to see if these 
peptides inhibit the heterodimerisation of CtBPs in the RTHS/SICLOPPS screen. 
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3  In Vitro Analysis of Peptides 
 
  CtBP Protein Expression and Purification 
Cloning CtBP1 into pET28 vector bacterial expression vector 
    Cloning CtBP2 into pET28 vector bacterial expression vector 
  Purification 
    CtBP1 Purification 
    CtBP2 Purification   
  Development of ELISA 
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Chapter two goes into details of the discovery and synthesis of the peptide inhibitors of 
CtBP1 and CtBP2. The aim of this chapter was to build an in vitro assay of NADH-
dependant CtBP dimerisation in order to test the peptides on CtBP1/2 homodimer and 
heterodimers. We decided to set up an ELISA, using proteins tagged with two different 
tags (His-tag and GST-tag) to allow the capture and detection of the proteins. The GST 
reagents were already available in JPB lab therefore, we first started by making the 
His-tagged reagents. 
 
3.1  CtBP Protein Purification 
The expression and purification of recombinant proteins facilitates production and 
detailed characterisation of virtually any protein. Figure 3.1 illustrates an overview of 
the steps required for the expression and analysis of recombinant proteins. Recombinant 
DNA techniques permit the construction of fusion proteins in which specific affinity 
tags are added to the protein sequence of interest. The use of affinity tags simplifies the 
purification of the recombinant fusion proteins by employing affinity chromatography 
methods. In order to purify CtBP the full-length gene was cloned into the T7 expression 
vector pET28. The pET28 vectors carry an N-terminal His-Tag/thrombin/T7-Tag 
configuration plus an optional C-terminal His-Tag sequence. The His-Tag contains 6 
consecutive histidine residues, which allows strong binding of the protein to a 
chromatography column bearing Ni
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Figure 3.1.  Overview of the steps involved in expression and analysis of 
recombinant proteins. 
 
3.1.1  Cloning CtBP1 into pET28 vector bacterial expression vector 
The full-length CtBP1 coding sequence (1320 bp) was amplified by PCR. The PCR and 
isolated pET28 vector were digested with XhoI and NdeI (giving a N-terminal His-tag). 
The digested PCR product and plasmid were then ligated using NEB T4 ligase; this 
resulted in the insertion of the target gene into the pET28 plasmid (Figure 3.2). This 
plasmid was then transformed into BL21(DE3)pLysS competent cells (Promega). 
BL21(DE3)pLysS  also contains a plasmid, pLysS, which carries the gene encoding T7 
lysozymes. T7 lysozyme is a natural inhibitor of T7 RNA polymerase and reduces the 
background expression levels of target genes under the control of the T7 promoter. The 
level of protein produced upon induction by IPTG is not affected.  
 
3.1.2  Cloning CtBP2 into pET28 vector bacterial expression vector 
The full-length CtBP2 gene (1338 bp) was amplified by PCR. The PCR and isolated 
pET28 vector were digested with XhoI and NdeI (giving a N-terminal His-tag). The 
digested PCR product and plasmid were then ligated using NEB T4 ligase; this resulted 
in the insertion of the target gene into the pET28 plasmid (Figure 3.2). This plasmid 
was then transformed into BL21(DE3)pLysS competent cells (Promega).                                                                   Chapter 3:  In Vitro Analysis of Peptides 
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Figure 3.2.  pET28 Plasmid map and sequence. 
 
3.2 Purification 
CtBP1-pET28 and CtBP2-pET28 was transformed into both BL21(DE3)pLysS and 
BL21-CodonPlus*(DES)-RIPL competent cells (Stratagene) to compare the 
purification. BL21-CodonPlus*(DES)-RIPL (RIPL) competent cells contain extra 
copies of rare E.coli argU, ileY, leuW, proL tRNA genes which correct for codon bias 
and dramatically improve expression of sequence from other organisms.  The induction 
of recombinant protein expression is effected by the addition of the lac-inducer IPTG. It 
is important to identify the optimal conditions when expressing the protein in order to 
get the maximum amount of soluble protein. Induction in bacteria can be performed 
using one of two basic methods. One method is fast induction and that does not work 
for all proteins and can give suboptimal yield. The second method is by slow induction 
and can enhance the solubility of some proteins. Growing cells at lower temperature is 
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better, mainly because at slower growth rates proteins that may otherwise not fold well 
during expression will fold more efficiently, thus increasing the yield and minimising 
inclusion bodies (which is what happens when the protein is expressed and precipitates 
out). Incubation time is important and induction should be carried out at OD 0.6-0.7. At 
this OD most cells would have reached exponential growth, with the vast majority of 
cells alive and healthy, which makes them ideal for protein expression. At an OD that is 
too high (over 1 or higher) the culture will start to collect dead cells, which do not 
express protein. An OD that’s too low (<0.4) has a negative impact, as most of the 
culture is media so there are not enough cells to make protein. Shorter induction times 
and lower temperatures are considered best for maintaining recombinant solubility. 
500 ml cultures of CtBP1-pET28 and CtBP2-pET28 were grown at 37 °C, induction 
was carried out once an OD of 0.6 was reached using 0.2 mM IPTG. The flask was 
transferred to an incubator for 1 h 30 min at rt. The culture was centrifuged and the 
pellet was collected and frozen till used. The cell pellet was re-suspended in 10 ml of 
lysis buffer per gram of cells, which is made up of reagents used to break up the cells 
and release the protein. The lysis buffer contains: 0.2% Triton X 100 which helps to 
solubilise the protein; lysozyme which cuts the wall of the bacteria; DNAse I which cuts 
the DNA into small pieces and protease inhibitor which stops proteases from breaking 
up the protein. The cells were frozen, thawed and sonicated to further help break the 
bacteria. The cells were then centrifuged to separate the soluble material (supernatant) 
from the insoluble material (pellet). Samples were collected before and after induction, 
and before and after centrifugation in order to load on to the gel for analysis. 
The supernatant was loaded on to the FPLC (fast protein liquid Chromatography), 
HisTrap crude affinity columns (GE healthcare). HisTrap crude affinity columns were 
used during the purification of His-tagged CtBP1 and CtBP2. These columns are ready-
to-use columns and are pre-packed with pre-charged Ni Sepharose 6 Fast flow. This 
pre-packed column is intended for purification of histidine-tagged recombinant proteins.  
For the ELISA it is important that the CtBP1 and CtBP2 proteins are purified in a 
predominantly monomeric form. In order to achieve this the Cell lysate was incubated 
with pyruvate (0.25 mM) made up in binding buffer (TrisHCl (20 mM) and NaCl 
(350 mM) pH 7.4) for 30 min once loaded onto the column.  Pyruvate has been found to 
be a substrate for CtBP dehydrogenase activity although pyruvate is a relatively poor                                                                  Chapter 3:  In Vitro Analysis of Peptides 
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substrate, its addition caused a release of the bound NAD(H).
110 NAD(H) binds to the 
nucleotide binding domain of CtBPs and promotes dimerisation.
41 
The GST-CtBP1FL and GST-CTBP2FL constructs were available in the Blaydes lab.
111 
500 ml cultures of GST-CtBP1FL and GST-CTBP2FL were grown at 37 °C. Induction 
was carried out once an OD of 0.6 was reached using 0.25 mM IPTG. The flask 
containing the mix was transferred to an incubator for 2 h at rt. Cell lysis was carried 
out using the same procedure as the CtBP-His proteins. The supernatant was loaded on 
to the FLPC, GSTrap affinity columns were used during the purification of GST-tagged 
CtBP1 and CtBP2. The GSTrap affinity columns are pre-packed, ready-to-use columns 
containing Glutathione Sepharose 4 Fast Flow. The columns are designed for a one step 
purification of GST fusion proteins. 
 
3.2.1  His-CtBP1 purification 
Initially the protein was lysed with lysis buffer (Table 6.18), the supernatant was filtered 
and loaded onto the column. Washes at lower concentration of imidazole (made up in 
binding buffer, Table 6.19) were carried out to try to remove any contaminants (10 mM 
(4%) and 20 mM (8%)) before a10 ml gradient from 20 mM to 250 mM was applied to 
remove bound protein. The yield and purity of protein was low (Figure 3.3) (fractions 
43-49) compared to Figure 3.5 (fractions 26-40)). Proteins were expressed in both 
BL21(DE3)pLysS and BL21-CodonPlus*(DES)-RIPL (RIPL) competent cells. After 
purification it was found that more protein and less contaminants were obtained when 
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Figure 3.3.  Purification of His-CtBP1 on HisTrap To = Sample before 
induction (lane 1), Tend  = sample after induction (lane 2), Total = total cell 
lysate (lane 3), Insol = insoluble protein (lane 4), Sol = soluble protein (lane 5), 
sample before loading (lane 6), FT (4) = fraction collected from the flow 
through (lane 7), lanes 8-14, 16-25 are the fractions collected. 
 
Therefore, it was decided to express the protein in the RIPL strain. Batch binding was 
carried out instead of column binding. The protein was captured on Ni
++ superflow 
beads before applying to a column on the FPLC. A switch was made from column 
binding to batch binding in order to try and obtain a higher yield of protein. Batch 
purification allow for more efficient binding of the protein, it could be seen from Figure 
3.3 the flow through fraction (lane 7) contains unbound protein. Also, a more of a 
shallow imidazole gradient was used to try and remove some of the contaminant 
observed previously. 2 ml of 50% beads were prepared by taking 1.5 ml of 75% beads 
and washing with 15 ml PBS. The 50% beads were added to the supernatant and 
incubated overnight at 4 °C on a rotator. The mixture was centrifuged at 1300 rpm (the 
supernatant was kept as unbound). The beads were washed twice with 50 ml of binding 
buffer (20 mM Tris-HCl pH 7.4, 350 mM NaCl, (wash 1 and wash 2)). The beads were 
then incubated with binding buffer and 0.25 mM Sodium Pyruvate for 30 min, keeping 
the conditions the same as the purification on the column (wash 3). The beads were 
incubated at 4 °C on the rotor with binding buffer and 20 mM imidazole for 20 min 
(wash 4). The beads were transferred onto a column and mounted onto the FPLC. 
40 mM imidazole (16%), 50 mM (20%) and 60 mM (24%) was used to see if 
contaminants seen previously could be removed. An 18 ml gradient from 60 mM to 
T
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250 mM was run to remove bound protein. As can be seen in Figure 3.5 the protein 
obtained was more pure. 
Fractions 30 to 33 (4ml) and fractions 28, 29 and 34 to 41 (Figure 3.5) were pooled 
together and dialysed against 2 L of PBS with 15% glycerol using 12 kDa MWCO 
(molecular weight cut-off) dialysis tubing overnight at 4 °C. The buffer was replaced 
with 2 L of fresh PBS and dialysis was continued for a further 2 hr. After dialysis the 
material was collected and the protein concentration was determined using Bio-Rad. 
The concentration of His-CtBP1 was 0.3 µg/µl. Gel analysis was also carried to confirm 
the protein concentration. The protein was aliquoted into 5 µl single use aliquots, then 
snap frozen and stored at -80 °C. 
 
Figure 3.4.  Purification of His-CtBP1 on 1 ml Ni-NTA superflow column. 
 
 
 
 
40 mM 
50 mM 
60 mM 
60 mM-250 mM 
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Figure 3.5.  His-CtBP1 Purification fractions Gel (A) 1.To (sample before 
induction), 2.Tend (sample after induction), 3.Total, 4.Insoluble, 5.Soluble, 
6.Unbound, 7.Wash1 with binding buffer, 8.Wash2 with binding buffer, 
9.Wash3 with binding buffer + 0.25 mM sodium pyruvate, 10.Wash4 with 
binding buffer + 20 mM imidazole, 11.Fraction #4, 12.Fraction #8, 13.Fraction 
#12, 14.Fraction #19, 15.Marker. His-CtBP1 Purification fraction Gel (B) 
1.Fraction #24, 2.Fraction #26, 3.Fraction #28, 4.Fraction #29, 5.Fraction #30, 
6.Fraction #31, 7.Fraction #32, 8.Fraction #33, 9.Fraction #35, 10.Fraction #36, 
11.Fraction #37, 12.Fraction #40, 13.Marker, 14.Fraction #45, 15.Beads after 
elution. 
 
3.2.2  GST-CtBP1 Purification 
Before purification of GST-CtBP1 was carried out a gel was run after induction to 
determine whether the protein was expressed, Figure 3.6 shows that after induction the 
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Figure 3.6.  Induction of GST-CtBP1 and GST-CtBP2 (T0 – Before induction, 
T2 – After induction). 
 
After the Bacteria were lysed, the solution was prepared for purification on 1 ml 
GSTrap column. Once the sample was applied to the column, the column was washed 
with PBS (back to baseline). Then 15 ml of 0.55 mM sodium pyruvate in binding buffer 
was applied to fill line A and the column, the FPLC was paused for 20 min. Then the 
same solution was applied for another 10 min before changing back to PBS. The total 
contact time with sodium pyruvate was 30 min.  
There were still impurities in the GST-CtBP1, therefore requiring further purification. 
Fractions 27 to 30 were pooled together and diluted with 50 ml of buffer A (20 mM tris 
HCl pH 8 and 10 mM NaCl) to be further purified via ion exchange, using anion 
exchanger Q HP 1 ml column form GE (Figure 3.7). Ion exchange separates molecules 
or groups that have different charges. To optimise binding of all charged molecules, the 
mobile phase is generally a low to medium conductivity solution (i.e. low to medium 
salt concentration). Adsorption of the molecules to the solid support is driven by the 
ionic interaction between oppositely charged ionic groups in the sample molecule and 
functional ligands of the support. By increasing salt concentration (linear salt 
concentration) molecules with the weakest ionic interaction start to elute first, stronger 
interactions elute later. These interactions can be controlled by varying conditions such 
as ionic strength and pH. The pH of the mobile phase buffer must be between pI 
(isoelectric point) or pKa of the charged molecule and pKa of the charged group on the 
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solid support.
112 A pI 6.32 was calculated online (expasy.org, it requires you to enter the 
protein sequence). The pH needs to be greater than 1 unit above the pI ie greater then or 
equal to 7.5. Therefore a strong anion exchanger (Q) was used to bind the protein of 
interest and a start buffer with pH 8 was used. 
 
 
Figure 3.7.  Purification of GST-CtBP1 FL on 1 ml GSTrap. (A) FPLC trace, 
(B) Gel of fractions collected during purification, Total cell lysate (lane 1), 
insoluble protein (lane 2), cell lysate before loading onto the column (lane 3), 
Faction from the flow through (lane 4), fraction collected during elution (lane 
5-11), marker (lane 12) 
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Figure 3.8.  Purification of GST-CtBP1 on Q HP column. (A) FPLC trace, 
(B) Gel of fractions collected during purification. 
 
After purification, fractions 40 to 44 were collected (Figure 3.8) and dialysed in 12-
14 kDa MWCO dialysis tubing against 1 litre of PBS and 15% glycerol at 4 °C 
overnight. After dialysis the material was collected and the protein concentration was 
determined using Bio-Rad. The concentration of GST-CtBP1 was 0.25 µg/µl. Gel 
analysis was also carried to confirm the protein concentration (0.2 µg/µl) (Figure 3.13). 
The protein was aliquoted into 5 µl single use aliquots, then snap frozen and stored at 
-80 °C. 
 
3.2.3  His-CtBP2 purification 
As for His-CtBP1 due to low yield and purity the purification was repeated this time 
capturing the protein on Ni
++ superflow beads before applying to a column on the 
FPLC. Also, a more shallow imidazole gradient was used to try to remove some of the 
contaminant. The same procedure as His-CtBP1 was followed. As can be seen in Figure 
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3.10 purer protein was obtained. Fractions 30 to 41 (18 ml) were pooled together and 
dialysed against 2 L of PBS with 15% glycerol using 12 kDa MWCO dialysis tubing 
overnight at 4 °C. The buffer was replaced with 2 L of fresh PBS and dialysis was 
continued for a further 2 hr. After dialysis the material was collected and the protein 
concentration was determined using Bio-Rad. The concentration of His-CtBP1 was 
0.4 µg/µl. Gel analysis was also carried to confirm the protein concentration. The 
protein was aliquoted into 5 µl single use aliquots, then snap frozen and stored at 
-80 °C. 
 
Figure 3.9.  Purification of His-CtBP2 on 1 ml Ni-NTA superflow column. 
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Figure 3.10.  His-CtBP2 Purification fractions Gel (A) 1.To, 2.Tend, 3.Total, 
4.Insoluble, 5.Soluble, 6.Unbound, 7.Wash1 with binding buffer, 8.Wash2 with 
binding buffer, 9.Wash3 with binding buffer + 0.25 mM sodium pyruvate, 
10.Wash4 with binding buffer + 20 mM imidazole, 11.Fraction #5, 12.Fraction 
#7, 13.Fraction #10, 14.Fraction #16, 15.Marker. His-CtBP2 Purification 
fractions Gel (B) 1.Fraction #22, 2.Fraction #28, 3.Fraction #29, 4.Fraction 
#30,5.Fraction #32, 6.Fraction #33, 7.Fraction #35,8.Fraction #36, 9.Fraction 
#38, 10.Fraction #40, 11.Fraction #41, 12.Fraction #42, 13.Fraction #44, 
14.Marker, 15.beads after elution. 
 
3.2.4  GST-CtBP2 Purification 
The same procedure as for GST-CtBP1 was carried out and the GST-CtBP2 was more 
pure in comparison. Even though GST-CtBP2 was pure enough ion exchange was still 
carried to ensure both proteins were treated the same. A pI of 6.53 was calculated online 
and therefore an anion exchanger was used. Fractions 35 to 40 (Figure 3.11) were 
pooled together and diluted in 50 ml of buffer A (20 mM tris HCl pH8 and 10 mM 
NaCl) and applied to the column.                                                                   Chapter 3:  In Vitro Analysis of Peptides 
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Figure 3.11.  Purification of GST-CtBP2FL on 1 ml GSTrap, (A) FPLC trace, 
(B) gel of fractions collected. 
 
 
Figure 3.12.  Purification of GST-CtBP2FL on Q HP column, (A) FPLC trace, 
(B) gel of fractions collected 
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After purification, fractions 42 to 49 were collected (Figure 3.12) and dialysed in 
12-14 kDa MWCO dialysis tubing against 1 litre of PBS and 15% glycerol at 4 °C 
overnight. After dialysis, the material was collected and the protein concentration was 
determined using Bio-Rad. The concentration of GST-CtBP2 was 0.055 µg/µl. Gel 
analysis was also carried out to confirm protein concentration (0.05 µg/µl) (Figure 
3.13). The protein was aliquoted into 5 µl single use aliquots, then snap frozen and 
stored at -80 °C. 
 
 
Figure 3.13.  GST-CtBP vs. BSA to determine protein concentration. 
 
3.3 Enzyme-linked immunosorbent assay (ELISA) 
ELISAs were used for the quantification analysis of the effect of the cyclic peptide on 
the homo- and hetrodimerisation of CtBPs. The screen involves the immobilisation of 
either GST-CtBP1 or GST-CtBP2 (depending on the screen) onto the glutathione plates, 
followed by the addition of His-CtBP protein and peptide. Mouse anti His primary 
antibody was used to recognise the His on the second CtBP protein, followed by sheep 
anti-mouse HRP (horseradish peroxidase) secondary antibody illustrated in Figure 3.14. 
This allows recognition of the primary antibody and quantification of the protein 
interaction. The activity of the inhibitor can be monitored by a concentration-dependent 
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reduction in the horseradish peroxidase signal, because of the disruption of the complex. 
SuperSignal ELISA femto Maximum Sensitivity Substrate was used; this is a highly 
sensitive, chemiluminescent, HRP substrate for ELISA detection and quantification. 
The SuperSignal substrate generates detectable light within one minute of addition to 
trace amount of soluble HRP, saving incubation time. The SuperSignal ELISA femto 
Maximum Sensitivity Substrate is made up of luminol/enhancer and a stable peroxide 
buffer. 
 
Figure 3.14.  Diagram illustrating the ELISA setup. 
 
Horseradish peroxidase (HRP) is a 40kDa protein that catalyses the oxidation of 
substrates by hydrogen peroxide, resulting in a coloured or fluorescent product or the 
release of light as a by-product. HRP functions optimally at a near to neutral pH. The 
high turnover rate, stability, low cost and wide availability of substrates, makes HRP 
enzymes the choice for most applications.  
Chemiluminescence has a large linear response for detection and quantification over a 
wide range of protein concentrations. Chemiluminescence yields the greatest sensitivity 
of any available detection method. In a chemiluminescence ELISA, the substrate is the 
limiting reagent in the reaction; as it is exhausted, light production decreases and 
eventually ceases. It is important to optimise the conditions and use appropriate 
antibody dilutions in order to produce a stable output of light, producing consistent and                                                                  Chapter 3:  In Vitro Analysis of Peptides 
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sensitive results. Luminol is one of the most widely used chemiluminescent reagents 
and its oxidation by peroxide results in creation of an excited state product, 
3-aminophthalate. This product decays to a lower energy state by releasing photons of 
light (Figure 3.15). 
 
Figure 3.15.  Luminol is oxidised in the presence of horseradish peroxidase 
and hydrogen peroxide to form an excited state (3-aminophthalate). The 
3-aminophthalate emits light at 425nm as it decays to the ground state. 
 
The blocking and washing step are important during an ELISA. The binding capacity of 
micro plate wells is typically higher than the amount of protein coated in each well. The 
remaining surface area must be blocked to prevent antibodies or other proteins from 
adsorbing to the plate during subsequent steps. A blocking buffer is a solution of 
irrelevant protein, mixture of proteins, or other compound that may be able to adsorb to 
all remaining binding surfaces on the plate. The ideal blocking buffer will bind to all 
potential sites of nonspecific interaction, eliminating background, without preventing 
protein binding. This will improve sensitivity of an assay by reducing background 
signal and improving the signal-to-noise ratio. During the development of the ELISA, 
BSA (Bovine serum Albumin) made up in TBS (Tris Buffered Saline) with 0.05% 
tween was used as a blocking buffer. Sets of control experiments were set up to 
determine the optimum conditions for the ELISA. Both protease free (Bovine serum 
Albumin protease free powder, Cat 700-101P, Gemini Bio Products) BSA and globulin 
free BSA (Albumin from bovine, A7638, Sigma) were tried, it was found that the 
protease free BSA gave a lower background signal. Wells blocked with globulin free 
BSA gave higher readings when wells were treated with just His-CtBP1 and His-
CtBP2.  (Figure 3.16). A control experiment was also run using 1% BSA and 3% BSA. 
The 3% BSA blocking buffer showed an improved signal-to-noise ratio.                                                                  Chapter 3:  In Vitro Analysis of Peptides 
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Figure 3.16.  Graph showing a comparison between protease free BSA and 
Globulin free BSA in different ELISA conditions.  
 
To investigate the amount of GST-CtBP1 protein required for the experiment, serial 
dilutions of the protein were plated. The protein was prepared in wash buffer 
(TBS/0.05% Tween-20). It was important to incorporate washes between each step to 
wash away any unbound protein or antibody. Initially two quick washes and one 5 min 
wash was carried out. This was increased to three 5 min washes and that showed 
improvements in unspecific binding. The R41 anti-GSTCtBP1
111 antibody was used to 
detect the protein, followed by a goat anti-rabbit HRP labelled antibody was used for 
quantification. As the concentration of protein increased, the signal increased and 
maximum signal was obtained at 100 ng. 100 ng of GST and GST-CtBP1 was used 
(Figure 3.17). A titration of GST-CtBP2 was then carried out using the same conditions 
and antibodies as for the GST-CtBP1 titration assay. 200 ng of GST and GST-CtBP2 
was used.  
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Figure 3.17.  Graph showing change in luminescence reading as GST-CtBP1 
concentration increases. 
 
The His-CtBP2 protein was titrated into plates treated with GST-CtBP2 in order to 
investigate the amount of His-CtBP2 required for the CtBP2 homodimeric and CtBP 
heterodimeric assay. The plates were first treated with GST-CtBP2 and GST alone to 
see how much background binding was occurring (i.e. His-CtBP2 just binding to the 
GST protein). Plates were washed and blocked before the addition of His-CtBP2 and 
the protein was added with and without the addition of NADH (1 mM) (NADH should 
promote dimerisation of the CtBPs). A 1/2000 dilution of mouse anti-his antibody was 
added to detect the bound His-CtBP2 protein and a 1/2000 dilution of sheep anti mouse 
HRP labelled secondary antibody that was used for quantification and detection of 
primary antibody. After the addition of SuperSignal the absorbance was measured at 
425nm on the plate reader. The optimal amount chosen was 600 ng as it gave a better 
signal to noise ratio and gave a greater difference between the +/- NADH (Figure 3.18). 
The same experiment was carried out for His-CtBP1, the optimum amount chosen was 
600 ng. 
 
Figure 3.18.  Graphs showing titration of His-CtBP2, (A) Titration into wells 
with GST-CtBP2 and GST, (B) Titration with and without NADH. 
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0.5 mM was taken as the optimal NADH value, this value was chosen based on work 
carried out by mirnexami et al.
111 It was found that when the antibody is not sufficiently 
diluted, the amount of enzyme present is too high and the substrate is used up quickly 
and a stable output of light will not be reached. A 1/2000 dilution was initially used for 
both antibodies, but this was not the optimum dilution and it resulted in the signal 
burning out and gave a 0 reading on the plate reader. It can be clearly seen from Figure 
3.19 that the GST-CtBP1 has turned a darker colour then the GST alone indicating that 
there is more dimerised protein present.  
 
Figure 3.19.  An experimental plate showing the effect of signal burn out. Left 
hand side shows GST-CtBP1 coated wells; right hand side shows GST coated 
wells. 
 
An antibody titration was carried out in the CtBP1 homodomeric ELISA in order to 
discover the optimum dilution. 600 ng of His-CtBP1, 100 ng of GST-CtBP1 and 
0.5 mM of NADH was used. The same assay was run substituting GST-CtBP1 with 
GST alone (taken as background signal). Initially two experiments were carried out: in 
the first experiment the primary antibody was kept at a dilution of 1/2000; in the 
second, the primary antibody was kept at a dilution of 1/5000. The secondary antibody 
was titrated at a dilution 1/1000 to 1/6000 (A and B Figure 3.20). A higher signal to 
noise ratio was obtained when the primary antibody was diluted 1/5000. The experiment 
was then repeated using higher dilutions of secondary antibody against 1/5000 and 
1/10000 dilutions of primary antibody in order to further optimise the conditions (C and 
D Figure 3.20). The maximum signal to noise ratio was obtained when a 1/5000 dilution 
for the primary antibody and a 1/10000 dilution for the secondary antibody were used. 
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Figure 3.20.  Titration of secondary antibody, (A) 1/2000 dilution of primary 
antibody, (B) 1/5000 dilution of primary antibody, (C) 1/5000 dilution of 
primary antibody, (D) 1/10000 dilution of primary antibody. 
 
In summary the optimised conditions for the ELISA was to use 100 ng GST-CtBP1, 
200 ng GST-CtBP2, 600 ng of both His-CtBP1 and His-CtBP2, 3% BSA/TBS 0.05% 
tween for blocking, a 1/5000 dilution for the primary antibody, a 1/10000 dilution for 
the secondary antibody and finally three washes at 5 min each after each step. GST was 
used as a control at the same concentration as the GST-CtBP protein. In initial 
experiments 0.5 mM NADH was mixed with the His-CtBP protein before adding it to 
the wells. This was then changed to first adding the His-CtBP protein and allowing it to 
react for 30 min then adding the 0.5 mM NADH and allowing it to react for a further 
1 hr. The reason behind this was that if His-CtBP and NADH are mixed beforehand the 
proteins might dimerise before adding to the assay therefore preventing dimerisation of 
His-CtBP with GST-CtBP. The experimental procedure for the CtBP heterodimeric 
system and the CtBP1 and CtBP2 homodimeric system is described in sections 6.3.3.3, 
6.3.3.1 and 6.3.3.2 respectively. 
Once the ELISA had been optimised Peptide 6 and 61 were tested in all the assays 
(CtBP1 homodimeric, CtBP2 Homodimeric and CtBP heterodimeric). The peptide was 
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added to the His-CtBPs at different concentrations and allowed to react for 30 min at rt 
before the addition of NADH in binding buffer and the reaction was continued for a 
further 1 hr at rt. Each individual experiment was carried out in duplicate wells. All 
experiments with GST-CtBP were run in parallel with experiments with GST. The GST 
readings were subtracted from the GST-CtBP readings as background. Three repeats of 
each experiment were done and the results were normalised (Figure 3.21-Figure 3.28 
are all normalised plots). The following steps were carried out for normalisation: 
•  The average of each duplicate well was taken and the GST background was 
subtracted for each concentration (average-background) this was done for all 
three repeats. 
•  The sum (∑) of all the average-background was taken. 
•  The highest sum (∑1) from the three repeats was taken and divided by the sum 
of individual experiment (∑1/∑2). This was done for all three triplicates. 
•  This value was multiplied by the average-background value to give the 
normalized value at each concentration. 
Normalisation was carried out due to the variation of the readings between experiments 
this could be because of the slight time variation between adding the SuperSignal and 
taking the reading on the plate reader. We hypothesise that both peptide 6 and 61 would 
have an inhibitory effect on the CtBP1 homodimeric assay and the CtBP heterodimeric 
assay but only Peptide 61 would have an effect on the CtBP2 homodimeric assay. This 
is because SICLOPPS screen shows that Peptide 61 prevents dimerisation of CtBP1 and 
CtBP2 whereas Peptide 6 only inhibited the dimerisation of CtBP1 (Figure 2.27).                                                                   Chapter 3:  In Vitro Analysis of Peptides 
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Figure 3.21.  Peptide 61 titrations into CtBP heterodimeric assay (GST-CtBP2 
and His-CtBP1), three repeats and average plot.  
 
 
Figure 3.22.  Peptide 61 titrations into the CtBP heterodimeric assay (GST-
CtBP1 and His-CtBP2), three repeats and average plot. 
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Figure 3.23.  Peptide 6 titrations into the CtBP heterodimeric assay (GST-
CtBP1 and His-CtBP2), three repeats and average plot. 
 
 
Figure 3.24.  Peptide 6 titrations into the CtBP heterodimeric assay (GST-
CtBP2 and His-CtBP1), three repeats and average plot. 
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Figure 3.25.  Peptide 6 titration into the CtBP2 Homodimeric assay. Three 
repeats and average plot. 
 
 
Figure 3.26.  Peptide 61 titration into the CtBP2 Homodimeric assay. Three 
repeats and average plot. 
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Figure 3.27.  Peptide 6 titration into the CtBP1 Homodimeric assay. Three 
repeats and average plot. 
 
 
Figure 3.28.  Peptide 61 titration into the CtBP1 Homodimeric assay. Three 
repeats and average plot. 
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Marked inhibition of the CtBP protein-protein interactions occurred in the presence of 
both peptide 6 and 61 in the µM range. Analysis of EC50 (half maximal effective 
concentration) values was carried out using the Prism software. EC50 refers to the 
concentration of a drug required to induce a response halfway between the baseline and 
maximum responses.  
Variations in the results were observed for the two heterodimeric assays and the order in 
which the CtBP1 and CtBP2 protein was added appeared to have an effect. Peptide 61 
gave a lower EC50
 when CtBP1 was coated on to the plate compared to when CtBP2 
was coated (14.32 µM (Figure 3.22) compared to 42.224 µM (Figure 3.21)) Peptide 6 
gave a lower EC50 when CtBP2 was coated first, 0.395 µM (Figure 3.24) in comparison 
with when CtBP1 was coated, 5.3 µM (Figure 3.23). Peptide 61 also had a lower EC50 
for the CtBP2 homodimeric assay compared to the CtBP1 homodimeric assay 
(13.32 µM (Figure 3.26) compared 58.75 µM (Figure 3.28)). Peptide 6 gave a lower 
EC50 for both heterodimeric assays and the CtBP1 homodimeric assay. These effects 
may be due to the way the peptides bind to the protein, or the protein interaction being 
weaker therefore requiring less peptide. Table 3.1 Shows EC50 values for both peptide 
6 and 61 in the different ELISA assays. Both estimate values and prism values are 
given, as the prism curve fitting is not reliable. 
  
EC50 (μM) 
(Estimate)  EC50 (μM) (prism) 
Pep61 CtBP2 Homo  10000  13238 
Pep61 CtBP1 Homo  25000  58748 
Pep6 CtBP1 Homo  9000  27743 
Pep61 CtBP heter (GST-CtBP2: His-CtBP1)  1000  42.2 
Pep61 CtBP Heter (GST-CtBP1: His-CtBP2  500  14.3 
Pep6 CtBP heter (GST-CtBP2: His-CtBP1)  500  0.3954 
Pep 6 CtBP heter (GST-CtBP1: His-CtBP2)  100  5.3 
     
Table 3.1  Table showing EC50 results for each peptide in the different ELISA 
assays. Both estimate and prism values are given. 
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The CtBP2 homodimeric assay with peptide 6 did not work very well (Figure 3.25). The 
first assay worked as would be expected for peptide 6 where a signal was obtained from 
the dimerising proteins but there was not an effective decrease in signal as peptide was 
added. The subsequent two experiments did not work, as there is no signal over the 
background. This could be due to the proteins going off or issues with blocking 
therefore higher background signal was obtained. 
Overall the ELISA allowed us to show CtBP dimerisation in vitro and the importance of 
NADH in improving dimerisation. Both peptide 6 and 61 have shown inhibitory effects. 
Further experimental work is required to determine whether the peptides work as 
competitive or non-competitive inhibitors. The assay can be used to test other 
compounds identified in the SICLOPPS screen, or any modified compounds of peptide 
6 and 61 that may be made in the future to improve the inhibitor activity of the peptides. 
The CtBP2 homodimeric assay requires further development, as the results obtained 
from this assay are inconsistent. It would be of interest for future work to have crystal 
structures of the CtBPs with the peptide to see how the peptides binds to the protein and 
carry out subsequent experiments to determine binding efficiency of the peptides.Chapter 4: In Vivo Effects of CtBP Dimerisation Inhibition 
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4.  In vivo effects of CtBP Dimerisation Inhibition 
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Given the multiple roles and forms of CtBPs in cells, conventional methods (such as 
gene knockout or siRNA knockdown) are not ideally suited for deciphering their 
mechanisms as they eliminate the target protein from the whole system rather than a 
single function. Cyclic peptides that specifically inhibit homodimerisation of CtBP1 and 
those that inhibit the dimerisation of CtBP1 and CtBP2 were uncovered by SICLOPPS 
screening via the bacterial reverse two-hybrid system, for inhibitors of CtBP1 
homodimerisation. The uncovered cyclic peptides specifically inhibit the protein-protein 
interaction of CtBPs without affecting their cellular levels. This phenotype can therefore 
be directly assigned to the protein-protein interaction of CtBP, rather than their presence 
or absence from the cell. The peptides were tested in a number of assays to try and 
further understand how CtBPs function. 
 
4.1  Time Lapse 
4.1.1  Microinjection  
It has previously been shown that one of the most distinctive phenotypes caused by the 
combined inhibition of CtBP1 and CtBP2 protein synthesis is loss of mitotic fidelity. 
This effect on mitosis is an important determinant of the loss of cancer cell viability by 
CtBP depletion.
58 It has been shown that the maintenance of mitotic fidelity by CtBPs 
requires that they are active in the nucleus and that they are able to bind DNA-binding 
transcriptional repressors and/or chromatin modifying enzymes. It is yet unknown if it 
is required for CtBP to dimerise in order to maintain mitotic fidelity and therefore we 
have tried to address this question using cyclic peptide inhibitors of CtBP dimerisation.  
Peptide 6 and 61 were microinjected into synchronized MCF-7 breast cancer cells in 
early S phase. The fidelity of subsequent mitosis was determined by time-lapse video 
microscopy. 
To permit the reliable analysis of the effect of peptides on the first mitosis post-
microinjection, the cells were injected at a defined time after release from serum-
starvation-induced G1 arrest. Optimization of conditions for cell synchronization and 
release was carried out by CN Birts et al.
86 Following subsequent re-stimulation with 
serum, it took approximately 30 hr for the first cells to enter mitosis.  Chapter 4: In Vivo Effects of CtBP Dimerisation Inhibition 
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Microinjection was carried out 20 hr after serum re-stimulation. Cells were injected in 
the cytoplasm with peptide. Dextran-FITC was co-injected to allow cells to be followed 
for a further 48 hr by fluorescent live cell imaging. Dextran-FITC was also injected on 
its own as a control. Mitotic events were scored as aberrant if there was a failed 
abscission, extended rounding during mitosis or the death of one or both daughter cells 
directly after mitosis. Peptide 61 was first tested at 25 µM and 50 µM; at 25 µM the 
peptide did not cause aberrant mitosis, but at 50 µM up to 50% of mitotic cells were 
aberrant (Figure 4.1). The experiment was repeated but this time injecting cells with 
50 µM of peptide 6 and 61 in order to confirm previous results of peptide 61 and to test 
the effects of peptide 6. Figure 4.2 shows that this approach had minimal non-specific 
toxicity to the cells. Injection with peptide did not increase cell death or reduce the 
ability of cells to enter first mitosis. Compared to control-injected cells peptide 61, 
which inhibits the homodimeriation of both CtBP1 and CtBP2, caused a significant 
(P<0.001) increase in the percentage of mitosis that were aberrant from 1.6% to 31.3% 
(Figure 4.2). This suggests that a proportion of the cells undergo cell division without 
segregating their DNA, leading to an increase in cells with 4N DNA.  
 
Figure 4.1.   Peptide 61 (25 µM and 50 µM) treated cells were monitored by live cell 
imaging over a period of 48 hr post-serum re-stimulation. The percentage of cells in 
which the first event was either mitosis or death was recorded. The cells that 
underwent mitosis were subjected to further analysis, as indicated. 
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Figure 4.2.  Peptide 61 and peptide 6 treated cells were monitored by live cell 
imaging over a period of 48 hr post-serum re-stimulation. The percentage of cells in 
which the first event was either mitosis or death was recorded. The cells that 
underwent mitosis were subjected to further analysis, as indicated. 
 
The length of time spent by each microinjected cell in mitosis was also quantified 
(Figure 4.3); FITC injected cells spent an average of 1.3 hr in mitosis and peptide 
injected cells spent an average of 3 hr in mitosis. Bergman et al observed a similar 
observation where CtBP siRNA resulted in a striking increase in the average time spent 
in mitosis. The delay is a consequence of cells spending a longer period of time in 
prometaphase, which can indicate prolonged activation of the spindle assembly 
checkpoint.
58 
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Figure 4.3.  Time taken for peptide 61 and peptide 6 treated cells to complete mitosis. 
The bars through clusters of time points represent the mean times taken to complete 
mitosis. 
 
Previous work using siRNA has shown that both CtBP1 and CtBP2 have to be blocked 
in order to see this effect on mitosis.
58 Peptide 6, which is specific to CtBP1, did not 
have any effect on the mitotic fidelity of the MCF-7 cells (Figure 4.2), suggesting that 
CtBP2 homodimers may be sufficient to maintain the fidelity of mitosis. Cells were 
transfected with CtBP2 siRNA using INTERFERin siRNA transfection reagent in order 
to knockout CtBP2. Following CtBP2 siRNA transfection cells were treated with 
peptide 6. Small interfering RNA (siRNA) are involved in RNA interference (RNAi) 
pathway, where they interferes with the expression of specific genes by hybridizing to 
its corresponding RNA sequence in target mRNA. This then activates degradation of 
mRNA. Once the target mRNA is degraded, the mRNA cannot be translated into 
protein. The siRNA pathway is illustrated (Figure 4.4).  
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Figure 4.4.  Diagram illustrating the siRNA pathway. 
 
As can be seen in Figure 4.5 peptide 6 with CtBP2 siRNA showed a significant 
(p<0.0001) increase in the frequency of aberrant mitosis to 43.8% compared to 3.3% in 
the control injections. CtBP2 siRNA itself did not result in aberrant mitosis, unless 
combined with CtBP1 siRNA. A control experiment was carried out using a scrambled 
control siRNA that does not have an effect on CtBPs to confirm that the increase in 
aberrant mitosis was not due to the addition of siRNA. The time spent in mitosis for 
each microinjected cell was quantified. FITC injected cells spent an average of 1.3 hr in 
mitosis and peptide injected cells spent an average of 3.5 hr in mitosis (Figure 4.6). 
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Figure 4.5.  Peptide 6 with control siRNA (left hand side) and peptide 6 with CtBP2 
siRNA (right hand side) treated cells were tracked by live cell imaging over a period 
of 48 hr post-serum re-stimulation. The cells that underwent aberrant mitosis were 
monitored, as indicated. 
 
 
Figure 4.6.  Time taken for peptide 6 and CtBP2 siRNA treated cells to complete 
mitosis. The bars through clusters of time points represent the mean times taken to 
complete mitosis. 
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4.1.2  Tat-tagged peptides 
In order to establish whether the effects of the peptides were independent of any 
potential influence of their mechanism of delivery into the cell, peptide 6 and 61 were 
coupled to the cell penetrating HIV-Tat peptide as previously described for other 
SICLOPP-derived cyclic peptides.
26 MCF-7 cells were treated with peptide 61Tat-
tagged at 25 µM and 50 µM similar effects were observed but to lesser extent compared 
to the microinjection, 31% compared to 11% and 13% (Figure 4.7). Therefore the 
experiment was repeated testing peptide 6, peptide 61 and Tat at 50 µM and 100 µM 
(Figure 4.8). Tat was used as a control on its own as Tat should not have an effect. In 
cells treated with 50 µM and 100 µM of peptide 61 there were 27% and 22% aberrant 
mitosis respectively in comparison with 4% and 5% for peptide 6 and Tat respectively. 
 
Figure 4.7.  Tat-tagged peptide 61 (25 µM and 50 µM) treated cells were monitored 
by live cell imaging over a period of 48 hr post-serum re-stimulation. The 
percentage of cells in which the first event was either mitosis or death was recorded. 
The cells that underwent mitosis were subjected to further analysis, as indicated. 
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Figure 4.8.  Tat-tagged peptide 61 (50 µM and 100 µM) treated MCF-7 cells were 
monitored by live cell imaging over a period of 48 hr post-serum re-stimulation. The 
percentage of cells in which the first event was either mitosis or death was recorded. 
The cells that underwent mitosis were subjected to further analysis, as indicated. 
 
The time spent in mitosis for each Tat-tagged treated cell was quantified (Figure 4.9). 
Non-treated and Tat treated cells spent an average of 1.3 hr in mitosis and peptide 61 
treated cells spent an average of 3.5 hr in mitosis. 
 
Figure 4.9.  Time taken for Tat, Tat-tagged peptide 6 and peptide 61 MCF-7 treated 
cells to complete mitosis. The bars through clusters of time points represent the 
mean times taken to complete mitosis. 
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MDA-MB231 cells were treated with peptide 6, peptide 61 and Tat at 50µM and 
100 µM. As with MCF-7 peptide 6 did not have an effect where as peptide 61 caused 
aberrant mitosis but the effect was not as great as with MCF-7 cells (27% compared to 
12%, Figure 4.10). There was an increase in time spent in mitosis from 1.5 hr in Tat 
treated cell to 4 hr following peptide 61 treatment (Figure 4.11). MDA-MB 231 cells 
are p53 mutated cells and therefore we would have expected to see more death in 
peptide treated cells that have undergone chromosome segregation defects, as 
previously seen by siRNA treated cells.
58 MDA-MB231 cells are more mobile then 
MCF-7 cells, making it more difficult to analyse and follow during live cell imaging. 
Therefore, for further live cell imaging experiments only MCF-7 cells were used. 
 
Figure 4.10.  Tat, Tat-tagged peptide 61and peptide 6 (50 µM and 100 µM) and 
DMSO treated and non-treated MDA-MB231 cells were monitored by live cell 
imaging over a period of 48 hr post-serum re-stimulation. The percentage of cells in 
which the first event was either mitosis or death was recorded. The cells that 
underwent mitosis were subjected to further analysis, as indicated. 
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Figure 4.11.  Time taken for Tat, Tat-tagged peptide 6 and peptide 61 MCF-7 treated 
cells to complete mitosis. The bars through clusters of time points represent the 
mean times taken to complete mitosis. 
 
After live cell imaging, cells were counted in the first and last image to work out the 
percentage increase in cells (Figure 4.12).  Treatment with peptide 61 in both MCF-7 
cells and MDA-MB231 cells led to a smaller increase in cell number compared to Tat 
and peptide 6 treated cells. The above analysis (Figure 4.10) has shown that this 
decrease in cell number is not due to cell death. Therefore, the decrease in the 
percentage increase of cells could be due to the fact that more cells went through 
aberrant mitosis (one binucleate cell instead of two individual cells) and cells were 
spending longer in mitosis and/or undergoing cell cycle arrest after the first mitosis. 
 
Figure 4.12.  MCF-7 and MDA-MB231 treated Cells counted in the first image and 
last image during live cell imaging to calculate the percentage increase in cell 
number. 
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As with the microinjection experiments Tat-tagged peptide 6 did not have an effect on 
aberrant mitosis. Therefore, the experiment was repeated this time by treating the cell 
with CtBP2 siRNA prior to treatment with Tat-tagged peptide 6 (Figure 4.13). This 
resulted in a significant increase in aberrant mitosis (P<0.0001), 6% and 1% for Tat 
50 µM and 100 µM to 16% and 30% for CtBP2 siRNA with peptide 6 50 µM and 
100 µM, respectively. Figure 4.14 shows images captured during live cell imaging, the 
red circle follows an example of a cell that goes through aberrant mitosis. The cell looks 
as if it has split to two cells but then comes back together giving a single binucleate cell, 
due to failed abscission. The time spent in mitosis for each Tat-tagged treated cell was 
quantified. Non-treated and Tat treated cells spent an average of 1.5 hr in mitosis; cells 
treated with peptide 6 and CtBP2 siRNA spent an average of 3.5 hr in mitosis (Figure 
4.15). 
 
Figure 4.13.  Tat, Tat-tagged peptide 6 with CtBP2 siRNA treated cells were tracked 
by live cell imaging over a period of 48 hr post-serum re-stimulation. The cells that 
underwent aberrant mitosis were monitored.  
 
 
Figure 4.14.  MCF-7 cells treated with CtBP2 siRNA and peptide 6 Tat-tagged 
induces aberrant mitosis. 
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Figure 4.15.  Time taken for Tat, Tat-tagged peptide 6 with CtBP2 siRNA treated cells 
to complete mitosis was monitored. The bars through clusters of time points 
represent the mean times taken to complete mitosis. 
 
X-ray crystallography and mutational studies have determined that CtBP homo- and 
heterodimerisation is dependent upon critical residues in the central dehydrogenase-
homology domain of the protein. Therefore, isolated dehydrogenase domain CtBPDD 
could be used as an alternative tool to disrupt CtBP1 and CtBP2 homo- and heter-
dimerisation in cells. A double point mutant (R147A, R169L the CtBP2 dehydrogenase 
domain) would disrupt this CtBP-binding activity of this domain, without affecting its 
gross structure, and this serves as a well-defined negative control, CtBPDDM. When 
injected into synchronized MCF-7 cell by Dr Charles Birts, CtBPDD but not 
CtBP2DDM resulted in a significant (p<0001) increase in the proportion of mitotic 
events that failed to progress normally
86 (Figure 4.16). This data supports the results for 
the peptide treated cells that illustrate that CtBP dimerisation is important in 
maintaining mitotic fidelity. 
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Figure 4.16.  GST, CtBPDD and CtBPDDM treated cells were tracked by live cell 
imaging over a period of 48 hr post-serum re-stimulation. The cells that underwent 
aberrant mitosis were monitored, as indicated. 
 
4.1.3  Immunofluorescence analysis 
4.1.3.1  Mitotic Index and Cells with Micronuclei 
Mitotic Index is defined as the ratio between the number of cells in mitosis and the total 
number of cells. Mitotic Index is calculated by counting the number of cells containing 
visible chromosomes divided by the total number of cells in the field of view. In order 
to analyse the phenotype of CtBP-depleted cells, detailed morphological analysis of 
DAPI-stained cell nuclei was carried out (Figure 4.17). DAPI is a fluorescent stain that 
binds strongly to A-T rich regions in DNA. Along with the mitotic index, cells with 
micronuclei were also counted. Micronuclei can arise from whole chromosomes, which 
lag at mitosis due to, for example, damaged kinetochore or faulty spindle apparatus, or 
from acentric chromosome fragments created by DNA breaks. There was a significant 
increase in the occurrence of micronuclei, from 6% of the Tat treated cells to 16.5% 
following peptide 61 treatment. Compared to the untreated cells peptide 61 resulted in a 
significant reduction in the mitotic index similar to that observed with CtBP siRNA. 
Peptide 6 and Tat on its own illustrated a less of an effect (Figure 4.18).  This was 
supported with a siRNA control experiment (Figure 4.19), where cells were treated with 
CtBP siRNA, both CtBP1 and CtBP2 siRNA, and CtBP1 and CtBP2 siRNA 
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individually. Individually CtBP1 and CtBP2 had little effect, similar to that observed 
with peptide 6, which only block CtBP1. Cells treated with CtBP siRNA and CtBP1 and 
CtBP2 siRNA together showed significant increase in cells with micronuclei, similar to 
that observed with peptide 61, which blocks CtBP1 and CtBP2. 
 
Figure 4.17.  DAPI-stained MCF-7 nuclei of control treated cells and peptide 61 
treated cells. Micronuclei indicated with white arrows (in collaboration with Dr 
Charles Birts).  
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Figure 4.18.  Quantification of micronuclei in MCF-7 cells 3 day post-transfection 
with CtBP siRNA, TAT, peptide 6 and 61 at 50 and 100 µM (Dr Charles Birts).  
 
 
Figure 4.19.  Quantification of micronuclei in MCF-7 cells 3 day post-transfection 
with control, CtBP, CtBP1 + CtBP2, CtBP1 and CtBP2 siRNA (Dr Charles Birts). 
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24 hr.
58 CtBP siRNA similarly reduced CtBP abundance. We have demonstrated that 
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none
CtBP siRNA
TAT 50 µ M
TAT 100 µ M
pep-6 50µ M
pep- 6 100  µ M
pep-61 50 µ M
pep-61 100 µ M
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035
mitotic index
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5 % cells with micronuclei
m
i
t
o
t
i
c
 
i
n
d
e
x
%
 
c
e
l
l
s
 
w
i
t
h
 
m
i
c
r
o
n
u
c
l
e
i
0.00
5.00
10.00
15.00
20.00
25.00
none control CtBP CtBP1
+
CtBP2
CtBP1 CtBP2
siRNA
%
 
o
f
 
c
e
l
l
s
 
w
i
t
h
 
m
i
c
r
o
n
u
c
l
e
iChapter 4: In Vivo Effects of CtBP Dimerisation Inhibition 
127 
 
carried out by Dr Charles Birts). Therefore any phenotypes observed can therefore be 
directly assigned to the protein-protein interaction of CtBP, rather than their presence or 
absence from the cell.  
 
Figure 4.20.  Immunoblot confirming effects of siRNAs and peptide on the abundance 
of their targets in MCF-7 cells. The abundance of the p53 protein was also 
examined. 
 
4.1.4  MTS assays.  
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] is a Tetrazolium-based assay. The MTS assay was carried out to 
complement the experiments from cell counting in the live cell imaging. Metabolism in 
viable cells produces “reducing equivalents” such as NADH or NADPH. These 
reducing compounds pass their electrons to an intermediate electron transfer reagent 
that can reduce the tetrazolium product, MTS, into an aqueous, soluble formazan. The 
CellTiter 96
(R) Aqueous products are MTS assays for determining the number of viable 
cells in culture and therefore the combined effects of inhibition of cell division and 
induction of cell death over the treatment period can be monitored.  
Cells were initially treated with Tat-tagged peptide 6 and 61 (at a concentration of 0, 
0.5, 1, 5, 10, 25, 50, 100 µM). 48hr post treatment the MTS was run (Figure 4.21). 
DMEM was added on its own as a background control and the peptides were run in 
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a decrease in the presence of viable cells. In MDA-MB231 cells 50 µM of peptide 6 and 
10 µM of peptide 61 were sufficient for maximum decrease in signal. In MCF-7 cells 
50µM of peptide 6 and 25 µM of peptide 61 were sufficient for maximum decrease in 
signal. Survival was plotted as a percentage of untreated cells. In MCF-7 cells the signal 
decreased to 69% and 53% for peptide 6 and 61 respectively from 0-100 µM. In 
MDA-MB231 cells the signal decreased to 54% and 64% for peptide 6 and 61 
respectively from 0-100 µM. 
 
Figure 4.21.  Graph showing results from the MTS assay; the graphs above show how 
the fluorescent signal decreases as the peptide concentration increases in MDA-
MB231 and MCF-7 cells respectively; the graphs below shows the percentage of 
signal at each concentration compared to untreated cells. 
 
The experiment was repeated but this time Tat was also used as a control to ensure Tat 
was not having an effect on the cells (Figure 4.22). MCF-7 and MDA-MB231 cells 
were treated with peptide 6, 61 and Tat at concentrations of 0.1, 1, 3, 10, 30 and 100 
µM. In MDA-MB231 cells 10 µM of peptide 6 and 30 µM of peptide 61 were sufficient 
for maximum decrease in signal. In MCF-7 cells 30 µM of peptide 6 and 10 µM of 
peptide 61 were sufficient for maximum decrease in signal.  In MCF-7 cells the signal 
decreased to 45%, 51%, 82% for peptide 6, 61 and Tat respectively from 0-100 µM. In 
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MDA-MB231 cells the signal decreased to 31%, 69% and 83% for peptide 6, 61 and 
Tat respectively from 0-100 µM. Tat did not lead to a significant decrease in signal 
compared to peptide 6 and 61. 
 
Figure 4.22.  Graph showing results from the MTS assay; the graphs above show how 
the fluorescent signal decreases and peptide concentration increases in MDA-
MB231 and MCF-7 cells respectively; the graphs below shows the percentage of 
signal at each concentration compared to untreated cells. 
 
4.1.5  Colony Forming Assay 
The results from the MTS assay were not conclusive, therefore colony-forming assays 
were carried out as this assay is a more sensitive measure of the ability of the peptides 
to inhibit cellular proliferative capacity than MTS. Also a more visual view of the effect 
of the peptides on the ability of single breast cancer cells to establish colonies can be 
obtained. Tat alone was used as a control. Peptide 61 resulted in a decrease in the 
number of colonies present in MCF-7 and MDA-MB-231 10 d post-transfection, 
whereas peptide 6 resulted in a decrease in colony number in MDA-MB-231 cells. This 
is in agreement with the live cell imaging analysis (Figure 4.13).  
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Figure 4.23.  Colony-forming assay for both MCF-7 and MDA-MB231 cells 10 days 
post-transfection with peptide 6, peptide 61 and TAT. 
 
 
Figure 4.24.  Giemsa staining of MCF-7 and MDA-MB231 cell colonies 10 days post-
transfection with Tat, peptide 6 and 61. 
 
4.1.6  Flow Cytometry 
Different cells can be identified by measuring the fluorescence they emit when they 
pass a laser beam in a flow cytometer. In a fluorescence-activated cell sorter (FACS), 
which is an instrument based on flow cytometry, the cells can be identified and 
separated from each other. To investigate whether breast cancer cells arrest in a specific 
point of the cell cycle after treatment with peptides, flow cytometry analysis of DNA 
content was carried out. Cells from the time-lapse experiment were trypsinised and 
collected in centrifuge tubes and centrifuged. After subsequent washes with PBS and 
70% ethanol the pellet was stored at 4 °C until propidium iodide (PI) staining was 
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carried out. PI intercalates into double-stranded nucleic acids. It is excluded by viable 
cells but can penetrate cell membranes of dying or dead cells and is used as a DNA stain 
for flow cytometry. The staining and flow cytometry was carried out by Dr Charles 
Birts. The analysis did not show a significant effect of the peptides. This may have been 
due the fact that there were not enough cells for analysis as the samples were small. Due 
to time constraints the experiment has not yet been repeated. 
 
Figure 4.25.  Analysis of cellular content by flow cytometry. 
 
4.1.7  P53 activity 
The tumor protein 53 (p53), is a tumor suppressor protein that in humans is encoded by 
the TP53 gene.
113 p53 is crucial in multicellular organisms, where it regulates the cell 
cycle and thus functions as a tumor suppressor that is involved in preventing cancer. 
The regulation of p53 function is tightly controlled through several mechanisms 
including p53 transcription and translation, protein stability and post-translational 
modifications. P53 is mostly located in the cytoplasm. When DNA damage occurs, p53 
gets imported into the nucleus via its NLS and undergoes tetramization, binds and 
activates DNA damage-response genes.
114  
It has previously been shown by Bergman et al that inhibition of CtBP expression in 
MCF-7 cells caused an increase in p53 protein abundance, and up regulation of its 
transcriptional target, p21
WAF1 (cyclin-dependent kinase inhibitor 1). The p21
WAF1 
protein binds to and inhibits the activity of cyclin-CDK2 or –CDK4 complexes, and 
thus functions as a regulator of cell cycle progression at G1.
58 To investigate whether the 
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peptides led to an increase in p53 protein abundance, MCF-7 cells were treated with 
peptide 6 and 61. 2 d post-transfection immunofluorescence staining was carried out. A 
p53 primary antibody was used followed by a Rabbit-α-mouse FITC (1:50) secondary 
antibody (FITC stains areas containing p53 green). Cells were counterstained with 
DAPI during secondary antibody incubation (stains the nucleus blue). Sufficient 
Blocking and washing was required to prevent unspecific binding of the antibodies. For 
blocking, 10% FCS in PBS was used; for washing 5 min washing with PBS was carried 
out; for the final wash two 5 min washes with PBS and one 5 min wash with water was 
carried out.  Nutlin (Figure 4.26 C) was used as a positive control as it inhibits the 
interaction between MDM2 and p53, thus stabilizing p53. 
 
Figure 4.26.  Structure of (A) DAPI, (B) FITC and (C) Nutlin. 
 
Treatment with peptide 6 and 61 did not lead to a significant increase in p53 up 
regulation in comparison with nutlin (Figure 4.27).  It can be seen that the majority of 
p53 protein is located in the cytoplasm. These results are supported by the immunoblot 
in Figure 4.20, which show that treatment with peptide 6 and 61 did not cause an 
increase in p53 abundance whereas cells treated with both CtBP1 and CtBP2 siRNA 
showed an increase. This may be due to the fact that CtBP siRNA leads to a reduction 
of cellular CtBP levels whereas the peptides break up dimerisation but do not affect 
cellular levels. Further investigation is required.  
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Figure 4.27.  Immunofluorescence staining for p53 in MCF-7 cells treated with 
peptide 6, peptide 61 and nutlin. 
 
4.1.8  Cell Migration Assay 
Effect of Peptide 6 on MCF-7 single cell migration towards collagen  
The study of cell invasion and migration is of great importance to enable a better 
understanding of underlying biological and molecular mechanisms. Cell invasion is the 
intrusion and destruction of adjacent tissues particularly with respect to cancer cells. 
Cell migration is the movement of cells from one area to another generally in response 
to chemical signals and is important in diverse physiological and pathological processes 
including embryonic development, cell differentiation, wound healing, immune 
response, inflammation and cancer metastasis. 
Transwell migration assay used for studying the motility of different cells including 
metastatic cancer cells. The assay relies on a permeable layer of support, usually a 
microporous membrane that is tissue culture treated, which is positioned between two 
compartments that mimic two different microenvironments for cell growth. Cells on one 
side of the compartment can migrate through the micropores on the membrane in 
response to a chemoattractant. Migrated cells can then be quantified by methods as Chapter 4: In Vivo Effects of CtBP Dimerisation Inhibition 
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simple as fix/stain and count. A typical set up for the migration assay in a single well of 
a 24 well plate is illustrated in Figure 4.28. 
All migration assays were carried out by Marta Chrzan. Cells were incubated with 
peptide 6 and Tat in the presence of collagen IV for 30 min at 4 °C prior to plating in 
Transwells (40,000 cell/well). Cells were also treated with BSA and collagen IV only as 
controls. Integrin-mediated migration was induced with collagen IV (10µg/ml). BSA 
was used to measure non-specific migration. The migration assay illustrated that 
peptide6 and peptide61 lowered the number of migrated cells to almost half of that for 
the control Tat on its own (Figure 4.29, Figure 4.30).  
 
Figure 4.28.  A typical set up for the migration assay in a single well of a 24 well 
plate. 
 
 
Figure 4.29.  Cell migration assay results of MCF cells treated with peptide 6 and Tat.   Chapter 4: In Vivo Effects of CtBP Dimerisation Inhibition 
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Figure 4.30.  Cell migration assay  results of MCF-7 cells treated with Tat, peptide 6 
and 61; the left hand side illustrates cell count for cells that have migrated across the 
membrane; the right hand side shows migration as a percentage of Tat. 
 
There are certain drawbacks of the transwells assay. For example, the migrated cells 
must be stained with chemical dyes or labelled with fluorescent molecules. In most 
cases the membrane is removed from the insert then counted manually using a 
microscope or evaluated using a spectrometer. That can be labour intensive and lead to 
limited throughput. Also, labelling may alter gene expression profiles and lead to 
intra-assay variability because of differences in labelling efficiency. Cell counting can 
also be inconsistent and irreproducible. 
Roche xCELLigence provides kinetic information about cell migration by dynamically 
recording the entire cell migration and invasion process in real time without labelling 
cells. Information about cell growth, morphological changes and cell death can be 
obtained. This assay considerably improves invasion and migration assay quality. As 
cells migrate from the upper chamber to the lower chamber in response to 
chemoattractant, they contract and adhere to the electronic sensors on the underside of 
the membrane resulting in an increase in impedance. The impedance increase correlates 
to increasing number of migrated cells on the underside of the membrane, and cell-
index values reflecting impedance changes are automatically and continuously recorded Chapter 4: In Vivo Effects of CtBP Dimerisation Inhibition 
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by the RTCA DP instrument. Therefore cell migration activity can be monitored via cell 
index profile.  
The xCELLigence data (Figure 4.31) confirms the finding that for peptide 6, cells 
initially migrate across the membrane but then the amount of migration levels off at 
around 2 hr. Whereas, the control Tat is constantly migrating across the membrane. 
Peptide 61 constantly migrating across the membrane too but at a slower rate compared 
to the Tat and that could account for the lower cell count. Towards the end of the assay, 
the levels seem to drop for all three assays this could be due the fact that the cells have 
been with out serum for too long and the cells are therefore are dying.  
 
Figure 4.31.  Graph illustrating the migration profile of MCF-7 cells treated with Tat, 
peptide 6 and 61. 
 
The RTHS and SICLOPPS have been combined to uncover cyclic peptide inhibitors of 
CtBP1 and CtBP2 dimerisation (Chapter 2). This is important to study the effect of 
disrupting dimerisation of CtBPs in cancer cells. Peptide 6 and 61 showed similar 
effects to CtBP siRNA without causing a decrease in cellular levels of CtBP. In the 
SICLOPPS screen peptide 6 showed inhibition of CtBP1 whereas Peptide 61 showed 
inhibition of both CtBP1 and CtBP2. This was supported by the in vivo studies in this 
chapter. When studying the mitotic fidelity of cells peptide 61 showed an increase in 
aberrant mitosis and time spent in mitosis, whereas peptide 6 only showed this effect in 
the presence of CtBP2 siRNA. Thus confirming the importance both CtBP1 and CtBP2 
dimerisation in maintaining mitotic fidelity.Chapter 5: Conclusion 
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5.  Conclusion 
     
There has been an increasing amount of evidence linking CtBPs to tumorigenesis and 
tumor progression. CtBPs are transcriptional corepressors that promote cell survival, 
migration and invasion.
76b, 68, 69 The ability of CtBP1 and CtBP2 to homodimerise and 
heterodimerise has previously been reported. The CtBP nucleotide binding domain 
plays an important role in dimerisation. NADH is able to bind in the nucleotide binding 
domain with high affinity and is important for CtBP dimerisation and CtBP regulated 
transcriptional co-repressor activity.
115, 42, 116 Many models have been postulated 
implicating the importance of CtBP dimers as bridge linking transcription factors and 
effectors.
69, 48 
CtBP inhibition is a therapeutic target in cancer therapy due to the potentially druggable 
dehydrogenase domain. Straza et al have reported a dehydrogenase 4-methylthio-2-
oxobutyric acid (MTOB) CtBP inhibitor. MTOB induced p53-independent apoptosis in 
a variety of human cancer cells and it led to a loss of cell viability. High levels of CtBPs 
were detected in colon cancer. Therefore, colon cancer exhibits heightened sensitivity to 
anti-CtBP therapy. MTOB induced apoptosis and reduced tumor burden in human colon 
cancer cells.
117 
In this study RTHS and SICLOPPS have been combined to uncover cyclic peptide 
inhibitors of CtBP1 and CtBP2 dimerisation. It is important to study the effect of 
disrupting dimerisation of CtBPs in cancer cells. Peptide 6 and 61 showed similar 
effects to CtBP siRNA without causing a decrease in cellular levels of CtBP. In the 
SICLOPPS screen peptide 6 showed inhibition of CtBP1 whereas peptide 61 showed 
inhibition of both CtBP1 and CtBP2. When studying the mitotic fidelity of cells, 
peptide 61 showed an increase in aberrant mitosis and time spent in mitosis, whereas 
peptide 6 only showed this effect in the presence of CtBP2 siRNA. This confirms the 
importance of both CtBP1 and CtBP2 in maintaining mitotic fidelity. 
It has previously been shown that RNAi mediated knockdown of CTBP1 and CtBP2 
leads to a decrease in cell invasion and migration.
118, 119 Treatment of MCF-7 cells with 
peptide 6 and 61 led to a decrease in migration. That indicates the importance of CtBP 
dimerisation in cell migration and the ability of CtBPs to recruit DNA binding Chapter 5: Conclusion 
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transcription factors. To further understand the effects of peptide 6 and 61 in the 
recruitment of transcription factors, it would be of interest, as part of future work, to 
send the peptide treated cells for microarray analysis to investigate the changes in gene 
expression. 
Our mechanism of combining the RTHS and SICLOPPS allows us to obtain small 
molecule tools that are useful for improving our understanding of disease mechanism 
and developing new therapies. Peptide 6 and 61 inhibit CtBP dimerisation and they 
could be candidate drugs for cancer, or they could help identify new drug targets. The 
peptides have shown to have an influence on MCF-7 breast cancer cells without having 
a toxic effect on the cells. There are issues with regard to delivery of the peptides across 
the cell membrane. So, a more efficient way of delivering the peptides into the cells is 
required other then microinjection and Tat-tagging, in order to make them more suitable 
as a therapeutic drugs. Cyclic peptides have a greater potential as therapeutic agents 
compared to the linear peptide due to increased chemical and enzymatic stability and 
receptor selectivity which arises from the restricted conformational flexibility.
120 
The initial step in drug research to improve a potential therapeutic drug is 
simplification. Not all the amino acids in the peptide are required to achieve biological 
effects. Therefore it is important to establish which amino acids are of importance for 
the peptides activity. Alanine scanning is a technique used to identify specific amino 
acid residues that are responsible for the protein function, stability and conformation. 
Alanine is used because of its small inert methyl functional group. Alanine is used to 
substitute each non-alanine residue one at a time. Alanine scanning of peptide 6 and 61 
can be carried out to determine which residues are essential for the function of the 
peptides. Another method for generating compounds with drug-like permeability and 
oral bioavailability is N-methylation. N-methylation has shown to improve 
pharmacological properties such as lipophilicity, proteolytic stability, bioavailability 
and conformational rigidity.
120-121 These peptides can then be tested in the ELISA to see 
how the residue substitution and N-methylation affects the activity of the peptide. 
Active peptides can then be further tested in animal permeability studies.   
We need to better understand how the peptides function and bind to CtBPs. Therefore, 
further work would involve the crystallisation of CtBPs and peptides. To date, all 
crystallisation that has been carried out on CtBPs has excluded the C-terminal due to the Chapter 5: Conclusion 
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high mobility or disorder of the C-terminal region in the full-length protein that may 
maintain an unstructured conformation, preventing the formation of productive crystal 
contacts. For the ELISA the full length CtBP was used, and therefore the CtBP-pET28 
vectors can be modified to exclude the C-terminal. Compared to the ELISA more 
protein is required and an extra gel filtration step is also required. 
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6  Experimental 
Polymerase chain reaction (PCR) was carried out using Eppendorf mastercycler 
personal and BioRad MyCycler Thermal cycler. DNA purification was carried out using 
QIAquick PCR Purification Kit (QIAGEN, Germany) and Promega Wizard plus Mini 
Prep DNA Purification System (Promega UK Ltd, UK). DNA concentration was 
measured using Nano Drop ND-1000 spectrophotometer (NanoDrop Technologies, 
USA). Agarose gels were run using Bio Rad Power Pack basic and imaged on BioRad 
Universal Hood II imager using QuantityOne software by BioRad (Bio-Rad 
Laboratories Ltd, UK) imaging system. Transformation by electroporation was carried 
out on the Bio Rad pulse controller and gene pulsar. Optical density of cell cultures was 
measured using the Thermo Electron Corporation BioMate 3. PDraw was used to 
choose restriction enzymes, work out annealing temperature, and design primers. 
Sequencing was carried out by MWG (Germany). Molecular biology reagents were 
purchased from New England Biolabs or Promega. 
 
Bacterial strains SNS126, SNS118 and DH5α and plasmids pTHCP14, pTHCP16, 
pAH68 and pAH69 were provided by Professor Benkovic at Pennsylvania State 
University (USA). Bacterial strains GM2929 and BL21 were provided by Dr Roach 
from The University of Southampton (UK). The plasmid strains containing the cDNA 
of CtBP1 and CtBP2 were provided by Dr Jeremy Blaydes from the Faculty of 
Medicine University of Southampton. The pET28 vector was provided by Patric Duriez 
from the Faculty of Medicine University of Southampton. 
 
6.1  Screening and selection of peptide 
6.1.1  Reagents 
All solutions were sterilised by either autoclaving for 20 min at 115 °C on liquid media 
cycle or filtration through a 0.22 µm filter (Millipore, U.S.A) as required. 
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Tris Base    242 g, 2 M 
Glacial acetic acid  57.1 mL, 1 M 
EDTA pH 8    100 mL, 0.5 M 
Water      Adjust to 1 L 
 
Adjust to pH 8.0 using dilute NaOH. 
1x solution is made by adding 20 mL (50x) to 1 L of sterilised deionised water 
 
6.1.1.2  Phosphate Buffered Saline (PBS) 
Sodium Chloride          125 mM 
Sodium Phoshate          16 mM 
Sodium Hydrogen Phosphate       10 mM 
pH 7.3 
 
6.1.1.3  2X O-Nitrophenyl-Beta-D-Galactopyranoside (ONPG) assay Buffer. 
                Final Concentration 
Na2HPO412H2O            120 mM 
NaH2PO42H2O            80 mM 
MgCl26H2O              2 mM 
2-mercaptoethanol            100 mM 
ONPG (sigma)            1.33 mg/mL 
6.1.1.1  Tris-acetate-EDTA (TAE) Buffer 50x Chapter 6: Experimental 
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6.1.1.4  Z buffer 
  Quantity  Final concentrations 
Sodium phosphate monobasic  0.851 g  60 mM 
Sodium phosphate dibasic  0.522 g  40 mM 
Potassium Chloride  74 mg  10 mM 
Magnesium Sulphate  0.245 g  10 mM 
Β-mercaptoethanol  280 µL  40 mM 
Sterile distilled water  Make up 100 mL   
Table 6.1.  Composition of Z buffer. 
 
6.1.1.5  Luria-bertani (LB) broth 
LB-Broth powder (Fisher Scientific, UK)      6.25 g/250 mL 
	 ﾠ
6.1.1.6  LB agar plates 
LB-Agar powder (Fisher Scientific, UK)      10 g/250 mL 
	 ﾠ
LB agar powder (10 g) (Fisher Scientific) was dissolved in water (250 mL) and 
autoclaved for 20 min at 115 °C on the liquid media cycle. The media was allowed to 
solidify. When required the media was microwaved until liquid, then allowed to cool to 
around 50 ºC. Once cooled the required antibiotics were added. The media was then 
mixed gently to prevent bubbles from forming and then poured into sterile petri dishes. 
Plates were left to solidify, and then stored in the fridge. When required, the plates were 
dried in the incubator for 30 min at 37 °C. Antibiotic concentrations used for plasmids 
were as follows: Ampicillin (100 µg/mL), Chloramphenicol (25 µg/mL), Kanamycin 
(50 µg/mL) and Spectinomycin (50 µg/mL). For resistance coming from the 
chromosome the quantity of antibiotics used was halved. 
	 ﾠ
6.1.1.7  Minimal media plates 
Agar powder (3.75 g) (Fisher Scientific) was dissolved in Water (200 mL) and 
autoclaved for 20 min at 115 °C on the liquid media cycle. Minimal media (50 mL) 
(6.1.1.8) was added. The bottle of agar was stored in the oven at 60 °C to stop it from 
solidifying. 10 different plates were prepared; mixtures for each plate were prepared in Chapter 6: Experimental 
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falcon tubes. 1 and 2 were control plates: 1 containing Kan (0 µg/mL), 3AT (0 mM) and 
IPTG (0 µL), the other containing Kan (0 µg/mL), 3AT (0 mM) and IPTG (200 µL), 
Tubes 3 to 10 all contained 3AT (250 µL, 5 µM), and Kan (125 µL, 50 µg/mL) and the 
levels of IPTG added to each was varied (0-100 µM). Glycerol (50%, 10mL), MgSO4 
(250 µL) and Spectinomycin (625 µL) was added to the agar and mixed. The agar 
mixture (25 mL) was then added to individual falcon tube and poured into the plates. 
The plates were allowed to dry in the incubator for 2 hr at 37 °C before use. Cells were 
drop spotted onto the plates with a 10-fold dilution. 
	 ﾠ
	 ﾠ	 ﾠ
	 ﾠ
	 ﾠ
(NH4)2SO4                5 g 
KH2PO4                22.5 g 
K2HPO4                52.5 g 
Sodium citrate.H2O              2.5 g 
Sterile distilled water             1 L 
 
6.1.1.9  SOC medium 
LB Growth media              50 mL 
MgCl2                  1 M, 500 mL 
MgSO4                2M, 500 mL 
 
6.1.2  DNA manipulation 
PCR were carried out using Eppendorf master cycle gradient. DNA purification was 
carried out using Qiagen QIAquick columns and QIAprep spin column. DNA 
concentration was measured using the Nano Drop ND-1000 V312 spectrophotometer. 
Agarose gels were run using the Bio Rad Power Pack 3000 and imaged with gene 
genius bio imaging system. Transformation by electroporation was carried out on the 
Bio Rad pulse controller and gene pulser. Optical density of cell cultures was measured 
using the Thermo Electron Corporation BioMate 3. PDraw was used to choose 
restriction enzymes, work out annealing temperature, and design primers. 
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6.1.2.1  Bacterial Cultures 
The required sample was scraped using a pipette tip from the frozen stock in the -80 °C 
freezer, or from the LB agar plate and mixed in LB media (10 mL). The culture was 
then grown in the incubator o/n at 37 °C with shaking unless otherwise stated.  
 
6.1.2.2  Polymerase chain reaction (PCR) 
PCR reactions were carried out using deep vent polymerase (New England Biolabs) and 
Gotaq (Promega). 
  Volume (µL)  Stock concentration  Total quantity 
GoTaq Buffer  10   5 x  1 x 
dNTPs  5  2 mM  10 nmol 
Forward Primer  1  10 µM  0.01 nmol 
Reverse Primer  1  10 µM  0.01 nmol 
Template  1  50-150 ng/ µL  50-150 ng 
GoTaq polymerase  0.25  5 u/ µL  1.25 U 
Sterile distilled 
water 
31.75     
Total  50     
Table 6.2.  Composition of GoTaq (Promega) reaction mixture. 
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  Volume (µL)  Stock concentration  Total quantity 
Thermopol Buffer  5  10 x  1 x 
dNTPs  5  2 mM  10 nmol 
Forward Primer  1  10 µM  0.01 nmol 
Reverse Primer  1  10 µM  0.01 nmol 
Template  1  50-150 ng/ µL  50-150 ng 
Deepvent polymerase  1  2 u/ µL  2 U 
Sterile distilled water  36     
Total  50     
Table 6.3.  Composition of deep vent (New England Biolab) reaction mixture. 
 
Typical reaction cycle 
    Initial denaturation    94 °C for 2 min 
    Denaturation      94 °C for 30 sec 
    Annealing      45 °C-65 °C for 30 sec 
    Extension      72 °C for 1 min 
    Final Extension    72 °C for 2 min 
Annealing temperature is dependent on primer sequence. Extension time is dependent 
on the length of the gene. 
Following amplification, the product was confirmed by restriction endonuclease 
digestion and agarose gel electrophoresis. The amplified product was then purified 
using QIAGEN QIAquick purification system. All primers (Table 6.4) were synthesised 
by Eurofins MWG Operon. 
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Primer  Sequence (5’-3’) 
CtBP1F  GTTGTT GTCGAC ATGGGCAGCTCGCAC 
CtBP1R  GTTGTT TCGCGA CTA GTCAACAACACTATT 
CtBP2F  GTTGTT CTCGAG ATGGCC CTTGTG GATA 
CtBP2R  GTTGTT TCGCGA CTATTG CTCGTT GGGGT 
NADHF  CTCATTGGCTTTGCGCGCACGGGGCAG 
NADHR  CTGCCCCGTGCGCGCAAAGCCAATGAG 
CtBP2dimF(SalI)       GTTGTTGTCGACATGAGTACAGGCTGCTGTACAG 
CtBP2dimR(SacI)  GTTGTTGAGCTCCTATGGCTGGCAACTAGAAGGCAC 
CtBP1dimF(SmaI)  GTTGTTCCCGGGATGGTTGACATTGATTATTGAC 
CtBP1dimR(KpnI)  GTTGTTGGTACCCTAAAGTGCGAGCTGCCCATGAATTC 
CtBP1FNdeI  GGG AAT TCC ATA TGA TGG GCA GCT CGC ACT TGC TC 
Ctbp1XhoI  GTT GTT CTC GAG CTA CAA CTG GTC ACT GGC GTG GTC 
CtBP2F(NdeI)  GGG AAT TCC ATA TGA TGG CCC TTG TGG ATA AGC A 
CtBP2R(XhoI)  GTT GTT CTC GAG CTA TTG CTC GTT GGG GTG CTC TCG 
P1  GGAATCAATGCCTGAGTG 
P2  ACTTAACGGCTGACATGG 
P3  ACGAGTATCGAGATGGCA 
P4  GGCATCAACAGCACATTC 
C+5  GGAATTCGCC AATGGGGCGA TCGCCCACAA TTGCNNSNNS 
NNSNNSNNST GCTTAAGTTT TGGC 
CBD F  GTTGTTAAGCTTTCATTCAAGCTGCCACAAGG 
Zipper F  GGAATTCGCCAATGGGGCGATCGCC 
SGW+6  GGAATTCGCCAATGGGGCGATCGCCCACAATAGCGGCTGGN
NSNNSNNSNNSNNSNNSTGCTTAAGTTTTGGC 
SGW+5  GGAATTCGCCAATGGGGCGATCGCCCACAATAGCGGCTGGN
NSNNSNNSNNSNNSTGCTTAAGTTTTGGC 
SGW+4  GGAATTCGCCAATGGGGCGATCGCCCACAATAGCGGCTGGN
NSNNSNNSNNSTGCTTAAGTTTTGGC 
Table 6.4.   Primer sequences. 
 
6.1.2.3  DNA Purification: 
The DNA sample was mixed with PBI (5 xs the concentration of DNA) in an 
eppendorf. The mixture was then added to QIAGEN QIAquick spin column and Chapter 6: Experimental 
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centrifuged in the microcentrifuge for 1 min at 1300 rpm. The flow through was 
discarded and the column was reinserted into the collection tube. PE (750 µl) was added 
to the column and centrifuged for 1 min. Again the flow through was discarded and the 
column was centrifuged for a further min. The collection tube was then discarded. The 
column was inserted into an eppendorf and eluted with autoclaved water (50 µl). 
Purified DNA was then stored at -20 ºC.  
 
6.1.2.4  Promega plasmid Prep: 
O/n culture of required cells was set up (6.1.2.1). Cells were centrifuged for 10 min at 
4 ºC and 13000 rpm. The flow through was discarded. The cells were thoroughly re-
suspended with cell re-suspension solution (250 µl) and added to an eppendrof. Cell 
lysis solution (250 µl) was added to the tube and inverted 4 times to mix and incubated 
at rt for 2 min. An alkaline protease solution (10 µl) was then added and inverted 4 
times to mix and incubated at rt for 5 min. Neutralisation solution (350 µl) was added 
and inverted 4 times to mix. The mixture was then centrifuged for 10 min at 13000 rpm. 
The pellet was discarded and the solution was added to a QIAGEN QIAquick Spin 
columns. The mixture was then centrifuged for 1 min at 13000 rpm and the flow 
through was discarded. Wash solution (750 µl) was added and centrifuged for a further 
min, and the flow through discarded. Wash solution (250 µl) was added and centrifuged 
for 1 min; the flow through was discarded and centrifuged for a further 2 min. The spin 
column was transferred to an eppendorf and eluted with water (50 µl). The column was 
discarded and the DNA was stored at -20 ºC.    
 
6.1.2.5  Digestion: 
A variety of restriction enzymes (from Promega and New England Bio-labs) were 
employed. Digestions were set up in PCR tubes, the total volume made up to 50 µl. 
Single digestion or double digestion (cleaving DNA substrate with 2 restriction 
enzymes simultaneously) were set up, depending on the compatibility of the two 
enzymes. Chapter 6: Experimental 
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  Volume (µL)  Stock concentration  Total quantity 
Plasmid  44  50-300 ng/ µL  2.2-13 ng 
Buffer  5  10 x  1 x 
Restriction enzyme  1  10 U/ µL  10 U 
Total  50     
Table 6.5.  Restriction Enzyme digestion mixture. 
 
  Volume (µL)  Stock concentration  Total quantity 
Plasmid  39  50-300 ng/ µL  2.2-13 ng 
Buffer  5  10 x  1 x 
BSA  5  1 mg/mL   
Restriction enzyme  1  10 U/ µL  10 U 
Total  50     
Table 6.6.  Digestion requiring Bovine Serum albumin (BSA). 
 
6.1.2.6  Ligation: 
Ligation of the plasmid backbone and gene insert was set up in PCR tube according to 
Table 6.7, using DNA quantities calculated following Promega protocol as below. The 
mixture was vortexed before adding the ligase and gently pipetted after. The reaction 
was carried out for 4 hr at rt or for 16 hr at 4 ºC. The ligase enzyme was killed before 
transforming into chemically or electrocompetent cells by heating at 70 ºC for 10 min 
then cooling to 4 ºC 
Ng of vector x Kb size insert = ng of insert 
Kb size insert Chapter 6: Experimental 
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  Volume (µL)  Stock concentration  Total quantity 
Buffer   1  10 x  1x 
Linear plasmid  4-7.5  5-50 ng/ µL  35-200 ng 
Insert  0.5-4  5-50 ng/ µL  2.5-100 ng 
T4 Ligase  1  3 U µL  3 U 
Total  10     
Table 6.7.  Composition of ligation mixture. 
 
6.1.2.7  Agarose Gel Electrophoresis 
Agarose gel electrophoresis was employed to size fractionate DNA for analysis or 
eluting from the gel. 1% agarose gel was prepared by dissolving agarose powder (2 g) 
in 1x TAE buffer (200 mL) by heating in the microwave. Ethidium Bromide was 
included in the gel matrix at 0.05 µg/mL to enable fluorescent visualisation of DNA 
fragments under ultraviolet light (UV). Agarose gels were submerged in TAE buffer in 
a horizontal electrophoresis apparatus. Samples (5 µL analysis and 50 µL gel 
purification) were mixed with loading dye (1 µL per 5 µL sample) and loaded into the 
sample wells. A DNA ladder was used to determine the size of the DNA fragment. 
Electrophoresis was conducted at 90 mA for 30 min at rt. After electrophoresis, gels 
were placed on a UV light box for visualisation of the DNA separation pattern. 
 
6.1.2.8  Gel purification: 
The MinElute Gel Extraction kit was used for purification. Digested plasmid (50 µl) 
was mixed with the loading dye (10 µl), and then loaded onto the gel. The gel was then 
ran and imaged (UV light kept on for minimum amount of time to avoid DNA damage). 
The gene band of interest was cut from the agarose gel with a clean sharp scalpel. The 
gel slice was weighed in an eppendorf tube. Three volumes of buffer QC to 1 volume of 
gel (eg. 300 µl of buffer QC to each 100 mg of gel, maximum amount of gel per spin is 
400 mg) were added to the tube. The gel was melted at 65 ºC (~15 min); the tube was 
vortexed every 2-3 min to help the gel dissolve. Isopropanol (1 gel volume) was added Chapter 6: Experimental 
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and inverted several times to mix. The mix was then purified by adding PE (750 µl) and 
centrifuging for 1 min at 13000 rpm and eluted with distilled water. 
 
6.1.2.9  Preparation of chemically competent cells for transformation: 
E.coli strains were grown o/n at 37 ºC in LB (10 mL) without antibiotics. The culture 
(50 µl) was then transferred to fresh LB Media (50 mL), with no antibiotics. The 
cultures were incubated at 37 ºC until the OD600 had reached 0.4-0.6. The culture was 
then centrifuged (10 min, 4 ºC, 13000 rpm). The supernatants decanted off and the cells 
were re-suspended in ice cold TBF I Buffer (10 mL) (Table 6.8) then centrifuged 
(10 min, 4 ºC, 13000 rpm). The supernatant was discarded and the cells were re-
suspended in ice-cold TBF II buffer (1 mL) (Table 6.9). Cells (100 µl) were aliquoted 
into PCR tubes (this was done on dry ice). The PCR tubes were put into a falcon tube 
and stored in the -80 ºC freezer until they were required. 
  Quantity  Final Concentration 
Potassium acetate  0.588 g  30 mM 
Rubidium Chloride  2.42 g  100 mM 
Calcium Chloride  0.294 g  10 mM 
Manganese chloride  2 g  50 mM 
Glycerol  30 mL  15% v/v 
Sterile deionised water  Adjust to 200 mL   
Adjust to pH 5.8 with 1% acetic acid. 
Table 6.8.  Composition of TBFI buffer. 
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  Quantity   Final Concentration 
MOPS  0.21 g  10 mM 
Rubidium Chloride  0.121 g  10 mM 
Calcium Chloride  1.10 g  75 mM  
Glycerol  15 mL  15% v/v 
Sterile deionised water  Adjust to 100 mL   
Adjust to pH 6.5 with dilute NaOH 
Table 6.9.  Composition of TBFII buffer. 
 
6.1.2.10 Preparation of electrocompetent cells 
Cells were cultured o/n in LB media (5 mL) without antibiotic. 5mL of the culture was 
then transferred to fresh LB media (500 mL), with no antibiotic, until the OD600 had 
reached 0.4-0.6. The culture was centrifuged (3100 rpm, 15 min, 4 °C). Supernatant 
decanted off and cells were washed by re-suspension in 500 mL of ice-cold glycerol 
solution (10% w/v) followed by centrifugation (3100 rpm, 10 min, 4 °C). Washes were 
repeated a further two times with 250 mL, then 20 mL. The cells were then re-
suspended in 1 mL of glycerol solution (10% w/v) and aliquoted into 100 µL portions 
and immediately frozen using dry ice and stored at -80 °C until needed.  
   
6.1.2.11 Transformation: 
1.  Using	 ﾠchemically	 ﾠcompetent	 ﾠcells	 ﾠ
100 µL of competent cells were thawed on ice. 5 µL of Plasmid DNA was added and 
the mixture incubated on ice for 30 min. The samples were then heat shocked at 42 ºC 
for 45 sec and transferred to ice to cool for 1-2 min. 895 µL SOC media was added to a 
tube and the cells were then added. The solution was then shaken at 37 ºC for 1 hr. 
100 µL of recovery solution was transferred onto 90 mm LB agar plates supplemented 
with the appropriate selection antibiotic. Plates were then incubated at 37 ºC o/n. 
Colonies of transformed bacteria were selected on the following day. 
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2.  Using	 ﾠelectro-ﾭ‐competent	 ﾠcells	 ﾠ
The aliquot of electro competent cells (kept in -80 ºC freezer) were allowed to thraw on 
ice for 10 min. 5 µL of plasmid was added to the cells and the plasmid mixture was then 
transferred to the electroporative cuvette and an electric charge was passed through the 
sample and immediately after SOC medium (895 µL) was added. The mixture was then 
transferred to a culture tube and shaken at 37 ºC for one hr. 100 µL of recovery solution 
was transferred onto 90 mm LB agar plates supplemented with the appropriate selection 
antibiotic. Plates were then incubated at 37 ºC o/n. Colonies of transformed bacteria 
were selected the following day. 
 
6.1.2.12 Colony PCR: 
Batches of PCR mix were prepared containing the required template and primers. 10 µL 
of PCR mix was added to colony PCR tube. Individual colonies were picked with 
pipette tip and swirled into PCR mix. The PCR reaction was run and the gel was run to 
check whether the colonies contained the correct insert. 
  Volume (µL)  Stock concentration  Total quantity 
GoTaq green Buffer  20  5 x  1 x 
dNTPs  1  2 mM  10 nmol 
Forward Primer  2  10 µM  0.01 nmol 
Reverse Primer  2  10 µM  0.01 nmol 
GoTaq polymerase  0.5  5 u/ µL  2 U 
Sterile distilled water  65.5     
Total  100     
Table 6.10.  Composition of colony PCR. 
 
6.1.3  Construction of RTHS 
6.1.3.1  Construction of CtBP1 RTHS CtBP1-16 
The pTHCP16 plasmid was transformed into GM2929. Chapter 6: Experimental 
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The cDNA of Ctbp1 (1320 bp) was amplified by PCR by using Deep Vent (New 
England Biolabs) with Forward primer: CtBP1F 5’-
GTTGTTGTCGACATGGGCAGCTCGCAC-3’ and reverse primer: CtBP1 R 5’-
GTTGTTTCGCGACTAGTCAACAACACTATT-3’ with annealing temperature of 
54 ºC and extension time of 1.35 min. The PCR product and isolated GM2929 
pTHCP16 plasmid were digested with SalI using buffer 1 and BSA followed by NruI 
using buffer 3. The digested plasmid and insert were ligated o/n at 4 ºC and then 
transformed into chemically competent DH5α cells and grown o/n on LB Agar plates 
containing ampicillin (100 µg/mL). Positive colonies were identified by colony PCR 
and the plasmid was isolated. 
 
6.1.3.2  Construction of pAH68-CtBP1/pTHCP16 
The CtBP1-pTCHP16 plasmid was digested with HpaI using buffer 4 followed by NruI 
using buffer 3. The construct was isolated and purified by gel purification from the 
agarose gel using QIAGEN purification kit. The pAH68 plasmid was digested with 
SmaI using buffer 4 at 25 ºC. The vector was then treated with Shrimp alkaline 
phosphotase (Promega) for 1 hr at 37 ºC; the enzyme was then heat inactivated by 
incubating at 65 ºC for 30 min. The isolated RTHS construct and linearised pAH68 
were ligated o/n at 4 ºC. The ligase enzyme was heat inactivated before transformation 
by heating at 70 ºC for 10 min. The ligated mixture was then transformed into 
chemically competent DH5α pir cells and plated onto agar plate containing ampicillin 
(100 µg/mL) and incubated o/n at 37 ºC. Colony PCR was carried out to identify 
positive colonies. 
 
6.1.3.3  Construction of CtBP1/SNS118 
The pAH68-CtBP1-pTHCP16 plasmid (5 µL) was added to the SNS118 + pAH69 cells 
(100 µL) and the plasmid mixture was then transferred to the electroporative cuvette 
and an electric charge was passed through the sample and immediately after SOC 
medium (895 µL) was added. The mixture was then transferred to a culture tube and 
shaken at 30 ºC for 1 hr. The temperature of the incubator was increased to 42 ºC. 
While the shaker was increasing in temperature the recovery solution was shaken in the 
water bath at 42 ºC for a few min. The total incubation time at 42 ºC was 30 min. The Chapter 6: Experimental 
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recovery solution (5 µL, made up to 100 µL with distilled water) was then plated onto 
agar plates containing ampicillin and spectinomycin, and then incubated at 37 ºC o/n. 
Colony PCR using predesigned primers P1, P2, P3 and P4 (Table 6.4) was carried out to 
see whether the incorporation was successful. 
 
6.1.3.4  Construction of CtBP2 RTHS CtBP2-16 
The cDNA of Ctbp2 was amplified by PCR by using Deep Vent (New England Biolabs) 
with Forward primer: CtBP2 F 5’- GTTGTTCTCGAGATGGCCCTTGTGGATA-3’ 
and reverse primer: CtBP2 R 5’-GTTGTTTCGCGACTATTGCTCGTTGGGGT-3’ 
with annealing temperature of 55 ºC and extension time of 1.35 min. The PCR product 
and isolated GM2929 pTHCP16 plasmid were digested with XhoI using buffer 2 and 
BSA followed by NruI using buffer 3. The digested plasmid and insert were ligated o/n 
at 4 ºC and then transformed into chemically competent DH5α cells and grown o/n on 
LB Agar plates containing ampicillin (100 µg/mL). Positive colonies were identified by 
colony PCR and the plasmid was isolated. 
 
6.1.3.5  Construction of pAH68-CtBP2/pTHCP16 
The CtBP2/pTHCP16 plasmid was digested with HpaI using buffer 4 followed by NruI 
using buffer 3. The construct was isolated and purified by gel purification on agarose 
gel using QIAGEN purification kit. The pAH68 plasmid was digested with SmaI using 
buffer 4 at 25 ºC. The vector was then treated with Shrimp alkaline phosphotase 
(Promega) for 1 hr at 37 ºC; the enzyme was then heat inactivated by incubating at 
65 ºC for 30 min. The isolated RTHS construct and linearised pAH68 were ligated o/n 
at 4 ºC. The ligase enzyme was heat inactivated by heating at 70 ºC for 10 min. The 
ligated mixture was then transformed into chemically competent DH5α pir cells and 
plated onto agar plate containing ampicillin (100 µg/mL) and incubated o/n at 37 ºC. 
Colony PCR was carried out to identify positive colonies. 
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6.1.3.6  Construction of CtBP2/SNS118 
The same procedure as 6.1.3.3 was followed. 
 
6.1.3.7  Mutation of NADH domain of CTBP2 
6.1.3.7.1  Mega primer method 
Firstly two sets of PCR were run; one using the CtBP2 forward primer: CtBP2 F 5’-
GTTGTT CTCGAG ATGGCC CTTGTG GATA-3’ and the reverse mutation primer 
NADHF 5’-CTGCCCCGTGCGCGCAAAGCCAATGAG-3’, with an annealing 
temperature of 55 ºC and an extension time of 45 sec. The second PCR was run using 
the CtBP2 reverse primer: CtBP2 R 5’-GTTGTT TCGCGA CTATTG CTCGTT 
GGGGT-3’ and the forward mutation primer NADHF 5’-
CTCATTGGCTTTGCGCGCACGGGGCAG-3’, with an annealing temperature of 
56 ºC and an extension time of 50 sec. The PCR products were then combined and a 
PCR was run using the CtBP2 forward and reverse primer. The PCR was then cloned 
into the pTCHP16 plasmid following the same procedure as 6.1.3.4. The construct was 
then cloned onto the chromosome of SNS118 following the procedures in 6.1.3.5 and 
6.1.3.6. 
 
6.1.3.8  Construction of CtBP1dim-CtBP2dim/pTHCP14 
CtBP2dim 82-330 truncation was amplified by PCR using Deep Vent (New England 
Biolabs) with the forward primer: CtBP2dimF(SalI) 5'-
GTTGTTGTCGACATGAGTACAGGCTGCTGTACAG-3' and the reverse primer: 
CtBP2dimR (SacI) 5'-GTTGTTGAGCTCCTATGGCTGGCAACTAGAAGGCAC-3' 
with an annealing temperature of 56°C and extension time of 50 sec. The PCR product 
and isolated plasmid was digested using SalI-HF and SacI-HF (buffer 4 and BSA). The 
digested vector and insert were ligated o/n at 4°C then transformed into chemically 
competent DH5α and grown o/n on agar plate containing ampicillin (100 µg/mL). 
Positive colonies were identified by colony PCR and the CtBP2dim/pTHCP14 was 
plasmid isolated. 
CtBP1dim 76-324 truncation was then amplified by PCR using Deep Vent (New 
England Biolabs) with forward primer: CtBP1dimF (SmaI) 5'-Chapter 6: Experimental 
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GTTGTTCCCGGGATGGTTGACATTGATTATTGAC-3' and reverse primer: 
CtBP1dimR (KpnI) 5'-GTTGTTGGTACCCTAAAGTGCGAGCTGCCCATGAATTC-
3' with an annealing temperature of 54°C and extension time 50 sec. The PCR product 
and isolated CtBP2dim/pTHCP14 plasmid was digested using SmaI (buffer 4 and BSA 
at 25 °C) followed by KpnI (buffer 1 and BSA). The digested vector and insert were 
ligated o/n at 4°C then transformed into chemically competent DH5α and grown o/n on 
agar plate containing ampicillin (100 µg/mL). Positive colonies were identified by 
colony PCR and the CtBP1dim-CtBP2dim/pTHCP14 plasmid was isolated. 
 
6.1.3.9  ONPG (Ortho-Nitrophenyl-β-galactosidase) Assays: 
The CtBP-pTHCP16 was transformed into SNS118 cells. Positive colonies were grown 
in o/n cultures containing 10 mL LB, 50 µl amp and 25 µl spec. The o/n culture was sub 
cultured into 8 tubes, by adding 5 mL LB and 50 µl of o/n culture to each, (each tube 
was numbered to avoid mix up). The cultures were then incubated at 37 ºC for a further 
2 hrs in the shaker. The OD600 was measured (should be around 0.5-0.7). IPTG 
(100 mmol) was then added to each tube: in 1 50 µL; in 2 25 µL; in 3 12.5 µL; in 4 
50 µL; in 5 25µL; in 6 12.5 µL; in 7 5µL and no IPTG was added in to the 8
th tube.  
The cultures were then incubated for a further 1hr at 37 ºC. The OD600 was measured 
for all the samples. Sample assays were then run (4 samples at a time). Into an 
eppindorf 0.15 mL of culture, 0.55 mL of Z-buffer was added. A control was also set up 
containing 0.15 mL of water and 0.2 mL of Z-buffer. 1 drop of CHCl3 and 1 drop 1% 
SDS was added. The mixture was then vortexed for 10 sec. The sample was incubated 
at 37 ºC for 1 min, then 0.2 mL ONPG was added and the sample was incubated at 
37 ºC. The timer was started at time of incubation. When the colour change was 
observed (from clear to yellow) the reaction was stopped by the addition of 0.5 mL of 
Na2CO3. The timer was stopped; the incubation time of each sample was noted. The 
sample was then centrifuged for 1 min; the OD400 was measured for each sample. The 
results were then plotted using excel.  
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6.1.4  Constructing SICLOPPS library 
6.1.4.1  C+5  
The C-terminal intein from pARCBD was amplified using GoTaq (promega), using 
C+5 forward primers- 5’-GGAATTCGCC AATGGGGCGA TCGCCCACAA 
TTGCNNSNNS NNSNNSNNST GCTTAAGTTT TGGC-3’ with the CBD reverse 
primer- 5’-GTTGTTAAGCTTTCATTCAAGCTGCCACAAGG-3’ with annealing 
temperature of 55 ºC and extension time of 1 min 15 sec. The PCR product was purified 
with the QIAGEN kit and then used as the template for subsequent PCR reaction using 
the ZIPPER forward primer- 5’-GGAATTCGCCAATGGGGCGATCGCC-3’ and the 
same CBD reverse primer as above with an annealing temperature of 55 ºC and 
extension time of 1 min 15 sec. The PCR product and isolated blank pARCBD plasmid 
were digested using BglI (buffer 3) followed by HindIII (buffer 2). Digested vector was 
treated with shrimp alkaline phosphatase at 37 ºC for 1 hr, the enzyme was then 
inactivated by incubating at 65 ºC for 30 min. Digested vector and insert were ligated 
o/n at 4 ºC then dialyzed for 2hr. Ligation (3 µL) product was transformed into 
electrocompetent NEB10β and grown o/n on agar plates containing chloramphenical 
(50 µg/mL). Dilutions of the recovery solution were plated to work out the library size 
(10
3, 10
5, 10
7), and the remaining recovery solution was grown in 20 mL LB and 
Chloramphenicol. The library plasmid was then purified. 
 
6.1.4.2  SWG+6 
The same protocol as for the C+5 library was followed but the C+5 forward primer was 
replaced with the SWG+6 forward primer- 
5’GGAATTCGCCAATGGGGCGATCGCCCACAATAGCGGCTGGNNSNNSNNSN
NSNNSNNSTGCTTAAGTTTTGGC-3’. 
 
6.1.4.3  SWG+5 
The same protocol as for the C+5 library was followed but the C+5 forward primer was 
replaced with the SWG+5 forward primer-
5’GGAATTCGCCAATGGGGCGATCGCCCACAATAGCGGCTGGNNSNNSNNSN
NSNNSTGCTTAAGTTTTGGC-3’. Chapter 6: Experimental 
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6.1.4.4  SGW+4 
The same protocol as for the C+5 library was followed but the C+5 forward primer was 
replaced with the SWG+4 forward primer-
5’GGAATTCGCCAATGGGGCGATCGCCCACAATAGCGGCTGGNNSNNSNNSN
NSTGCTTAAGTTTTGGC-3’. 
 
6.1.4.5  Genetic selection 
SICLOPPS libraries were transformed into CtBP1-68-8.1 in SNS118 cells. The 
recovery was centrifuged (10 min); the cells were then re-suspended in a mixture of 
minimal media A, 50% glycerol and water. Dilutions were then plated onto minimal 
media supplemented with L- (+)-arabinose, 3-AT (625 µl, 2.5 mM), kanamycin (625 µl, 
25 mM) and IPTG (500 µl). Plates were then incubated in the incubator for 3 to 4 days 
at 37 ºC. Surviving colonies were restreaked onto rich media containing spectinomycin 
and chloramphenicol. Surviving colonies from these plates were then drop spotted onto 
the same minimal media plates with and without arabinose. Plasmids from those strains 
whose growth depended on the presence of arabinose were isolated and retransformed 
into the original selection strain. Transformants were drop spotted onto minimal media 
plates with and without arabinose to check activity. The most active plasmids were then 
transformed into other selection strains (ATIC and P6-UEV). 
 
6.1.5  Construction of Expression Vectors 
6.1.5.1  Construction of CtBP1-pET28 
The full length Ctbp1 coding sequence (1320 bp) was amplified by PCR by using Deep 
Vent (New England Biolabs) with forward primer: CtBP1FNdeI 5’-
GGGAATTCCATATGATGGGCAGCTCGCACTTGCTC -3’ and reverse primer: 
CtBP1XhoI 5’- GTTGTTCTCGAGCTACAACTGGTCACTGGCGTGGTC -3’ with an 
annealing temperature of 57 ºC and extension time of 1.35 min. The PCR product and 
isolated pET28 vector was digested with XhoI and NdeI using buffer 4 and BSA. The Chapter 6: Experimental 
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reaction mixture was incubated at 65 ºC for 20 min to inactivate the enzyme. The 
digested plasmid and insert were ligated o/n at 4 ºC then transformed into chemically 
competent Bl21 cells and grown o/n on LB Agar plates containing kanamycin 
(100 µg/mL). Positive colonies were identified by colony PCR and positive plasmids 
were isolated. 
 
6.1.5.2  Construction of CtBP2-pET28 
The full length Ctbp2 coding sequence was amplified by PCR by using Deep Vent 
(New England Biolabs) with forward primer: CtBP2F (NdeI) 5’-
GGGAATTCCATATGATGGCCCTTGTGGATAAGCA-3’ and reverse primer: 
CtBP2R (XhoI) 5’-GTTGTTCTCGAGCTATTGCTCGTTGGGGTGCTCTCG-3’ with 
annealing temperature of 56 ºC and extension time of 1.35 min. The PCR product and 
isolated pET28 vector was digested with XhoI and NdeI using buffer 4 and BSA. The 
reaction mixture was incubated at 65 ºC for 20 min to inactivate the enzyme. The 
digested plasmid and insert were ligated o/n at 4 ºC then transformed into chemically 
competent Bl21 cells and grown o/n on LB Agar plates containing kanamycin 
(100 µg/mL). Positive colonies were identified by colony PCR and positive plasmids 
were isolated. 
 
6.1.6  Peptide synthesis  
Peptides were synthesised by “solid phase” chemical synthesis, starting with the 
carboxyl-terminal amino acid attached to the solid phase, and adding one amino acid at 
a time to the amino terminal end to build the peptide. 
 
6.1.6.1  Loading Wang Resin. 
The Wang resin (500 mg, 0.55 mmol, 1eq) and Fmoc protected amino acid (2eq) were 
dissolved in DMF (3 mL) and gently stirred at rt for 15 min. Pyridine (1.47 µL, 
1.82 mmol, 3.3 eq) and 2, 6-dichlorobenzoyl chloride (158 µL, 1.1 mmol, 2 eq) were 
added to the reaction mixture and stirred at rt for 15 hr. The reaction was filtered and 
washed with DMF (3x 15 mL), DCM (3 x 15 mL) and diethyl ether (3x 15 mL). The 
reaction was dried under vacuo. Chapter 6: Experimental 
171 
 
 
6.1.6.2  Measuring Loading  
Loaded resin (6.1 mg) was dissolved in 20% piperidine/DMF (10mL) and left for 
15 min. The mixture was diluted with 20% piperidine/DMF giving a final volume of 
50 mL. The absorbance at 302 nm was measured and the loading was calculated using 
the following equation, 
Loading = ((A x V)/(ε x w)) x 1000 
A = Absorbance at 302 nm 
V = Volume 
W = Mass of resin 
ε = Molar extinction co-efficient of adduct at 302 = 7800 m
-1. 
 
6.1.6.3  Capping 
Benzoyl Chloride (150 µL), pyridine (150 µL) and DCM (4 mL) was added to the 
loaded resin and reacted in the bubbler at rt for 2 hr. 
  
6.1.6.4  Coupling 
The Fmoc protected amino acid (3eq) was dissolved in DCM/DMF (4:1, 1.5 mL). 
PyBop (3eq, 0.702 mmol, 365 mg) was added followed by DIPEA. The mixture was 
added to the resin and agitated (2 hrs) and then washed with DMF (3x 15 mL), DCM 
(3 x 15 mL) and diethyl ether (3x 15 mL). Addition of protected amino acid was 
verified via quantitative Ninhydrin test (straw yellow colour). 
 
6.1.6.5  Deprotection 
20% piperidine/DMF (10 mL) was added to the Fmoc protected peptidyl resin in the 
reaction vessel. The suspended resin was then agitated for 30 min then washed with 
DMF (3x 15 mL), DCM (3x 15 mL) and diethyl ether (3x 15 mL). Removal of the 
Fmoc group was confirmed by quantitative Ninhydrin test (purple colour). Chapter 6: Experimental 
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6.1.6.6  Ninhydrin Test. 
Solution A: 0.5 g ninhydrin in 10 mL EtOH 
Solution B: 0.4 mL of 0.001 M KCN aq in 20 mL pyridine. 
A small amount of resin was added to a reaction vial. Solution A (100 µL) and solution 
B (25 µL) was added to the vessel, the mixture was heated to 150  °C until a colour 
change was observerd. 
 
6.1.6.7  Cleavage from resin 
On completion the resin was placed in a flask and a mixture of 94.0% TFA: 2.5% water: 
2.5% EDT: 1%TIS (10-25 mL/g resin) was added. EDT was only added in the presence 
of Cys and Met (all equipment in contact with EDT was soaked in bleach due to strong 
odour). The reaction was stirred for 3 h at rt. The resin was removed via filtration and 
washed with TFA. The filtrates were combined and concentrated in vacuo and re-
dissolved in the minimum amount of TFA. The mixture was ether precipitated via the 
addition of cold ether (8-10 fold volume), the reaction was carried out in a falcon tube. 
The solution underwent centrifugation and the residual solution was decanted off 
leaving the peptide pellet.  
 
6.1.6.8  Addition of the Aldrithiol group 
The peptide was dissolved in DMF. Aldrithiol (10 equivalents) was added to the 
solution and the reaction and stirred o/n (reaction went a lime green colour). The 
mixture was concentrated in vacuo and ether precipitated twice to remove excess 
aldrithiol. 
6.1.6.9  Cyclisation reaction 
Linear peptide (1eq) was reacted with EDC (3eq) and HOBt (6eq) DMF. The reaction 
mixture was stirred for 24 h. The reaction mixture was concentrated in vacuo and ether 
precipitated.   
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6.1.6.10 Reduction of disulfide bonds with 1,3-propanedithiol 
The peptide was dissolved in degassed MeOH (1-3 mg/mL). 1,3-propanedithiol (5-fold 
excess relative to thiol) was added and the reaction was stirred under nitrogen for 6 hrs. 
The mixture was concentrated in vacuo and ether precipitated. The peptide was then 
purified via HPLC. 
 
6.1.6.11 Reduction of disulphide bond with TCEP 
The cyclic peptide (1eq) was dissolved in DMF (10 mL) and a solution of TCEP (1eq) 
in water (0.5 mL) was added. The mixture was stirred for 1 hr under Ar. The reaction 
was monitored by HPLC and controlled by MS. The solvent was removed and the 
products were precipitated with cold ether. 
 
6.1.6.12 Tat-Tagging 
The peptide from crude extract 6.1.6.11 was then coupled with Tat (2eq). The Tat-
tagged product was purified via HPLC (RP-HPLC separation using Atlantis® T3 Prep 
OBD™ column, 19 mm x100 mm, 5 µm C18, 17 mL/min). Crude peptide mixtures were 
subjected to reverse-phase chromatography, on a Waters HPLC system by using 
water/acetonitrile gradient with 0.1% trifluoroacetic acid. A typical program was 95:5 
(water:acetonitrile) for 1 min and then the flow was then changed to 50:50 over 10 min 
and held for 15 minutes before reducing the flow was reduced to 95:5 for 5 min.  
 
6.1.6.13 Synthesis of Tat 
 
The reagents in Table 6.11 were used to synthesise the linear peptide. The coupling 
(6.1.6.4) and deprotection (6.1.6.5) steps were followed as mentioned above. 
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Reagent  Equivalents  Concentration  Mass (mg) 
Fmoc-Gln(Trt)-O-wang resin  1  0.47   700 
Fmoc-Pro-OH  3  1.32  663.96 
Fmoc-Pro-OH  3  1.32  663.96 
Fmoc-Arg(Pmc)-OH (x2)  3  0.99  654 
Fmoc-Arg(Pmc)-OH (x2)  3  0.99  654 
Fmoc-Arg(Pmc)-OH (x2)  3  0.99  654 
Fmoc-Gly(Trt)-OH  3  0.99  603.9 
Fmoc-Arg(Pmc)-OH (x2)  3  0.99  654 
Fmoc-Arg(Pmc)-OH (x2)  3  0.99  654 
Fmoc-Lys(Boc)  3  0.99  463.9 
Fmoc-Lys(Boc)  3  0.99  463.9 
Fmoc-Arg(Pmc)-OH (x2)  3  0.99  654 
Fmoc-Gly-OH  3  0.99  290 
Fmoc-Cys(Trt)-OH  3  0.99  579 
PyBop  3  0.99  514.8 
DIPEA  6  1.98  345 µl 
Table 6.11.  Reagents for the synthesis of Tat. 
 
Note:  Arginine requires double coupling. Proline gives a slight red colour in the Kaiser 
test. 
On completion the Tat/resin (1.867 g) was placed in flask and a mixture of 94.0% TFA 
(43.9 µL): 2.5% water (1.2 µL): 2.5% TIS (1.2 µL): 1% EDT (0.467 µL) was added.  
The reaction was stirred for 3 hr at rt. The resin was removed via filtration and washed 
with TFA. The filtrates were combined and concentrated in vacuo and re-dissolved in 
minimum amount of TFA and ether precipitated via the addition of an 8-10 fold volume 
of cold ether (carried out in falcon tube). The solution underwent centrifugation and 
residual solution was decanted off leaving the peptide pellet.  
Tat peptide (1eq, 0.62 mmol, 1.125 g) was dissolved in DMF (100 mL). Aldrithiol 
(10 eq, 6.2mmol, 1.366 µg) was added to the reaction and stirred o/n (reaction went a 
lime green colour). The mixture was concentrated in vacuo and ether precipitated twice Chapter 6: Experimental 
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to remove excess aldrithiol. The product was then purified via 95:5 (water:acetonitrile) 
for 1 min and then the flow was then changed to 50:50 over 10 min and held for 15 
minutes before reducing the flow was reduced to 95:5 for 5 min, (retention time 
11 min). The mass was confirmed via high mass electron ionisation (HM ESI+) mass 
spectrometry:(M+H)
+ 1822.2, (M+2H)
+ 911.4, (M+3H)
+ 607.9, (M+4H)
+ 456. 
 
Figure 6.1.  HPLC trace and mass spec trace of Tat peptide. 
 
 
 
 
t
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6.1.6.14 Peptide 61 
6.1.6.14.1 Synthesis of GWTVVRMYS (Peptide 61) 
 
The Wang resin (500 mg, 0.55 mmol, 1eq) and Fmoc-Ser(tBu)-OH (421.74 mg, 
1.1 mmol, 2eq) were dissolved in DMF (3 mL) and gently stirred at rt for 15 min. 
Pyridine (1.47 µL, 1.82 mmol, 3.3 eq) and Benzoyl Chloride (158 µL, 1.1 mmol, 2 eq) 
was added to the reaction mixture and stirred at rt for 15 hr. The reaction was filtered 
and washed with DMF (3x 15 mL), DCM (3 x 15 mL) and diethyl ether (3x 15 mL). 
The reaction was dried under vacuo. Loading was 0.94 mmol g
-1. The amino acid was 
capped by adding Benzoyl Chloride (150 µL), pyridine (150 µL) and DCM (4 mL) to 
the loaded resin and reacting in the bubbler for 2 hr at rt. 
The reagents in Table 6.12 were used to synthesise the linear peptide, the coupling 
(6.1.6.4), deprotection (6.1.6.5) steps were followed as mentioned above. 
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Reagent  Equivalents  Concentration  Mass (g) 
Fmoc-Ser(tBu)-O-Wang resin  1  0.166  0.24 
Fmoc-Tyr(tBu)-OH  3  0.498  246.8 
Fmoc-Met-OH  3  0.498  185 
Fmoc-Arg(Pmc)-OH  3  0.498  329.2 
Fmoc-Val-OH  3  0.498  169.3 
Fmoc-Val-OH  3  0.498  169.3 
Fmoc-Thr(tBu)-OH  3  0.498  198 
Fmoc-Trp(Boc)-OH  3  0.498  262 
Fmoc-Gly-OH  3  0.498  146 
PyBop  3  0.498  259 
DIPEA  6  1  96 µL 
Table 6.12.  Reagents for the synthesis of linear peptide 61 (GWTVVRMYS). 
 
On completion, peptide 61/resin (600 mg) was placed in a flask and a mixture of 94.0% 
TFA (7.18 mL): 2.5% water (0.29 µL): 2.5% EDT (0.29 µL): 1% TIS (0.6 µL) was 
added. The reaction was stirred for 3 h at rt. The resin was removed via filtration and 
washed with TFA. The filtrates were combined and concentrated in vacuo and re-
dissolved in minimum amount of TFA and ether precipitated via the addition of an 8-10 
fold volume of cold ether (carried out in falcon tube). The solution underwent 
centrifugation and residual solution was decanted off leaving the peptide pellet. The 
crude product was purified via HPLC 95:5 (water:acetonitrile) for 1 min and then the 
flow was then changed to 40:60 over 10 min and held for 15 minutes before reducing 
the flow was reduced to 95:5 for 5 min, (retention time 8.6 min). The presence of the 
product was confirmed via HM ESI+ mass spectrometry: (M+H)
+1099.1.  
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Figure 6.2.   HPLC trace and mass spec trace of linear peptide 61. 
 
6.1.6.14.2 Cyclisation of GWTVVRMYS 
 
Linear peptide (1eq, 0.128 mmol 0.141g) was reacted with EDC (3eq, 0.39 mmol, 
76 mg) and HOBt (6eq, 0.768 mmol, 103 mg) DMF (150 mL). The reaction mixture 
was stirred for 24 h. The reaction mixture was concentrated in vacuo and ether 
precipitated. The crude product was purified via HPLC 95:5 (water:acetonitrile) for 1 
min and then the flow was then changed to 50:50 over 10 min and held for 15 minutes 
before reducing the flow was reduced to 95:5 for 5 min, (retention time 9.19 min). The 
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presence of the product was confirmed using HM ESI+ mass spectrometry:(M+H)
+ 
1081. The purified product (36.7 mg) was freeze dried and stored at -80 °C 
 
Figure 6.3.  HPLC trace and mass spec trace of cyclic peptide 61. 
 
6.1.6.15 Peptide 61 Tat-Tagged 
6.1.6.15.1 Synthesis of CGWTVVRMY 
 
The Wang resin (1200 mg, 1.32 mmol, 1eq) and Fmoc-Tyr(tBu)-OH (1308 mg, 
2.64 mmol, 2eq) were dissolved in DMF (12 mL) and gently stirred at rt for 15 min. 
Pyridine (352 µL, 4.36 mmol, 3.3 eq) and Benzoyl Chloride (306 µL, 2.64 mmol, 2 eq) 
was added to the reaction mixture and stirred at rt for 15 hr. The reaction was filtered 
and washed with DMF (3x 15 mL), DCM (3 x 15 mL) and diethyl ether (3x 15 mL). 
The reaction was dried under vacuo. Loading was 0.56 mmol g
-1. Benzoyl Chloride 
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(150 µL), pyridine (150 µL) and DCM (4 mL) was added to the loaded resin and reacted 
in the bubbler at rt for 2 hr to cap the amino acid. 
The reagents in Table 6.13 were used to synthesise the linear peptide, the coupling 
(6.1.6.4), deprotection (6.1.6.5) steps were followed as mentioned above. 
Reagent  Equivalents  Concentration  Mass (g) 
Fmoc-Gly-O-Wang resin  1  0.79  1 
Fmoc-Cys(Trt)-OH  3  2.37  1.386 
Fmoc-Tyr(tBu)-OH  3  2.37  1.117 
Fmoc-Met-OH  3  2.37  0.880 
Fmoc-Arg(Pmc)-OH  3  2.37  1.567 
Fmoc-Val-OH  3  2.37  0.791 
Fmoc-Val-OH  3  2.37  0.791 
Fmoc-Thr(tBu)-OH  3  2.37  0.941 
Fmoc-Trp(Boc)-OH  3  2.37  1.248 
PyBop  3  2.37  1.232 
DIPEA  6  4.74  825 µL 
Table 6.13.  Reagents for the synthesis of linear peptide 61cys (CGWTVVRMY). 
 
On completion, peptide 61Cys/resin (2.5718 g) was placed in a flask and a mixture of 
94.0% TFA (60 mL): 2.5% water (1.6 µL): 2.5% EDT (1.6 µL): 1% TIS (0.6 µL) was 
added.  The reaction was stirred for 3 h at rt. The resin was removed via filtration and 
washed with TFA. The filtrates were combined and concentrated in vacuo and re-
dissolved in minimum amount of TFA and ether precipitated via the addition of an 8-10 
fold volume of cold ether (carried out in falcon tube). The solution underwent 
centrifugation and residual solution was decanted off leaving the peptide pellet.  
Peptide 61Cys (1eq, 0.9 mmol, 1.114 g) was dissolved in DMF. Aldrithiol (10 eq, 
9 mmol, 1.98 g) was added to the reaction and stirred o/n (reaction went a lime green 
colour). The mixture was concentrated in vacuo and ether precipitated twice to remove 
excess aldrithiol. The crude product was purified via HPLC 95:5 (water:acetonitrile) for 
1 min and then the flow was then changed to 60:40 over 10 min and held for 15 minutes 
before reducing the flow was reduced to 95:5 for 5 min, (retention time 7.76 min). The Chapter 6: Experimental 
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presence of the product was confirmed via HM ESI+ mass spectrometry: (M+H)
+ 
1224.1.  The peptide was dried o/n in the desiccator.  
 
Figure 6.4.  HPLC trace and mass spec trace of linear peptide 61cys. 
 
6.1.6.15.2 Synthesis of Cyclic CGWTVVRMY 
 
Linear peptide (1eq, 0.173 mmol 0.212g) was reacted with EDC (3eq, 0.52 mmol, 
63 mg) and HOBt (6eq, 1.56 mmol, 210 mg) DMF (200 mL). The reaction mixture was 
stirred for 24 h. The reaction mixture was concentrated in vacuo and ether precipitated. 
The crude product was purified via HPLC 95:5 (water:acetonitrile) for 1 min and then 
the flow was then changed to 60:40 over 10 min and held for 15 minutes before 
H
N NH
NH
NH N
HHN
HN
HN
HN O
O
O O
O
O
O
O O
S
HO
S HN
HN
NH2
HO HN
H
S
N
t
R 7.76 Chapter 6: Experimental 
182 
 
reducing the flow was reduced to 95:5 for 5 min, (retention time 7.9 min). The presence 
of the product was confirmed via HM ESI+ mass spectrometry: (M+H)
+ 1206, (M+2H)
+ 
603.9. 
 
Figure 6.5.  HPLC trace and mass spec trace of cyclic peptide 61cys. 
 
6.1.6.15.3 Tat-tagging of cyclic- CGWTVVRMY 
 
Tcep (1eq, 0.075 mmol, 21.5 mg), DMF (9 mL) and H2O (0.05mL) were added to the 
cyclic peptide 61cys (1eq, 0.075 mmol 91 mg) and the mixture was stirred for 1 hr. The 
peptide was added to Tat-S-S-Py (2eq, 114.8 mg) and DMF (2 mL) and reacted for 3 hr. 
The crude product was purified via HPLC 95:5 (water:acetonitrile) for 1 min and then 
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the flow was then changed to 50:50 over 10 min and held for 15 minutes before 
reducing the flow was reduced to 95:5 for 5 min, (retention time 9.4 min). The presence 
of the product was confirmed via HM ESI+ mass spectrometry: (M+2H)
+ 1459, 
(M+3H)
+ 973.5, (M+4H)
+ 730.3, (M+5H)
+ 584  
 
Figure 6.6.  HPLC trace and mass spec trace of Tat-Tagged peptide 61cys. 
 
6.1.6.16 Peptide 6  
6.1.6.16.1 Synthesis of GWNTVRSS (Peptide 6) 
 
 
The Wang resin (500 mg, 0.55 mmol, 1eq) and Fmoc-Ser(tBu)-OH (421.74 mg, 
1.1 mmol, 2eq) were dissolved in DMF (3 mL) and gently stirred at rt for 15 min. 
Pyridine (1.47 µL, 1.82 mmol, 3.3 eq) and Benzoyl Chloride (158 µL, 1.1 mmol, 2 eq) 
was added to the reaction mixture and stirred at rt for 15 hr. The reaction was filtered 
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and washed with DMF (3x 15 mL), DCM (3 x 15 mL) and diethyl ether (3x 15 mL). 
The reaction was dried under vacuo. Loading was 0.94 mmol g
-1. The amino acid was 
capped by adding Benzoyl Chloride (150 µL), pyridine (150 µL) and DCM (4 mL) to 
the loaded resin and reacting in the bubbler at rt for 2 hr. 
The reagents in Table 6.14 were used to synthesise the linear peptide, and the coupling 
(6.1.6.4) and deprotection (6.1.6.5) steps were followed as mentioned above. 
Table 6.14.  Reagents for the synthesis of linear peptide 6 (GWNTVRSS). 
 
On completion, peptide 6/resin (1.449 g) was placed in a flask and a mixture of 95% 
TFA (34.4 mL): 2.5% water (0.9 µL): 2.5% TIS (0.9 µL) was added.  The reaction was 
stirred for 3 h at rt. The resin was removed via filtration and washed with TFA. The 
filtrates were combined and concentrated in vacuo and re-dissolved in minimum amount 
of TFA and ether precipitated via the addition of an 8-10 fold volume of cold ether 
(carried out in falcon tube). The solution underwent centrifugation and residual solution 
was decanted off leaving the peptide pellet. The crude product was purified via HPLC 
95:5 (water:acetonitrile) for 1 min and then the flow was then changed to 60:40 over 10 
min and held for 15 minutes before reducing the flow was reduced to 95:5 for 5 min, 
(retention time 6.1 min). The presence of the product was confirmed via HM ESI+ mass 
spectrometry: (M+H)
+ 906.9, (M+2H)
+ 454.1 
 
Reagent  Equivalents  Concentration  Mass (g) 
Fmoc-Ser(tBu)-O-Wang resin  1  0.69  1 
Fmoc-Ser(tBu)-OH  3  2.07  0.794 
Fmoc-Arg(Pmc)-OH  3  2.07  1.368 
Fmoc-Val-OH  3  2.07  0.703 
Fmoc-Thr(tBu)-OH  3  2.07  0.823 
Fmoc-Asn(Trt)-OH  3  2.07  0.821 
Fmoc-Trp(Boc)-OH  3  2.07  1.09 
Fmoc-Gly-OH  3  2.07  0.607 
PyBop  3  2.07  1.076 
DIPEA  6  6.21  1081 µL Chapter 6: Experimental 
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Figure 6.7.  HPLC trace and mass spec trace of linear peptide 6. 
 
6.1.6.16.2 Synthesis of Cyclic- GWNTVRSS 
 
 
Linear peptide (1eq, 0.132 mmol 0.120 g) was reacted with EDC (3eq, 0.79 mmol, 
75 mg) and HOBt (6eq, 0.79 mmol, 107.4 mg) and DMF (150 mL). The reaction 
mixture was stirred for 24 h. The reaction mixture was concentrated in vacuo and ether 
precipitated. The crude product was purified via HPLC 95:5 (water:acetonitrile) for 1 
min and then the flow was then changed to 50:50 over 10 min and held for 15 minutes 
before reducing the flow was reduced to 95:5 for 5 min, (retention time 7.9 min). The 
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presence of the product was confirmed via HM ESI+ mass spectrometry (M+H)
+888.8.  
The cyclic peptide 6 (79 mg) was freeze dried and stored in the -80 °C freezer.  
 
Figure 6.8.  HPLC trace and mass spec trace of cyclic peptide 6. 
 
6.1.6.17 Peptide 6 Tat-Tagged 
6.1.6.17.1 Synthesis of GWNTVRCS  
 
 
The linear peptide was synthesised on the peptide synthesiser. The reagents in Table 
6.15 were loaded onto the machine. Amino acids were dissolved in DMF before 
loading, and the Fmoc-Ser(tBu)-O-Wang resin (loading of 0.69 mmol g
-1) was added 
directly to the reaction vessel. The reaction was run on a 0.25 mM scale. Coupling of 
Fmoc-Arg(Pmc)-OH was carried out twice. Each coupling step was followed by a 
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deprotection step as normal; however the final amino acid was left protected and was 
deprotected manually before cleavage from the resin. 
Table 6.15.  Reagents for the synthesis of linear peptide 6cys (CGWNTVRS). 
 
The resin was cleaved by adding 94% TFA (36 mL), 2.5% H2O (0.96 µL), 2.5% EDT 
(0.96 µL) and 1% TIS (0.4 µL) was added to the peptide (1.93 g). The reaction was 
stirred for 3 h at rt. The resin was removed via filtration and washed with TFA. The 
filtrates were combined and concentrated in vacuo and re-dissolved in a minimum 
amount of TFA and ether precipitated via the addition of an 8-10 fold volume of cold 
ether (carried out in falcon tube). The solution underwent centrifugation and the residual 
solution was decanted off leaving the peptide pellet.  
Peptide 6 Cys (1eq, 0.83 mmol, 1 g) was dissolved in DMF. Aldrithiol (10 eq, 
8.3 mmol, 1.829 g) was added to the reaction and stirred o/n (reaction went a lime green 
colour). The mixture was concentrated in vacuo and ether precipitated twice to remove 
excess aldrithiol. The crude product was purified via HPLC 95:5 (water:acetonitrile) for 
1 min and then the flow was then changed to 60:40 over 10 min and held for 15 minutes 
before reducing the flow was reduced to 95:5 for 5 min, (retention time 6.9 min). The 
presence of the product was confirmed via HM ESI+ mass spectrometry (M+H)
+ 
1031.9, (M+2H)
+ 516.7. The peptide was dried o/n in the desiccator.  
Reagent  Mass (g)  Reagent volume (mL) 
Fmoc-Ser(tBu)-O-Wang resin  0.362  - 
Fmoc-Cys(Trt)-OH  0.59  5 
Fmoc-Arg(Pmc)-OH  1.43  11 
Fmoc-Val-OH  0.41  6 
Fmoc-Thr(tBu)-OH  0.48  6 
Fmoc-Asn(Trt)-OH  0.72  6 
Fmoc-Trp(Boc)-OH  0.63  6 
Fmoc-Gly-OH  0.30  5 
PyBop  4.68  18 
DIPEA/NMP  -  3.1/5.9 
DMF  -  1012 Chapter 6: Experimental 
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Figure 6.9.  HPLC trace and mass spec trace of linear peptide 6cys. 
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6.1.6.17.2 Synthesis of Cyclic-CGWNTVRS 
 
 
Linear peptide (1eq, 0.193 mmol 0.200 g) was reacted with EDC (3eq, 0.579 mmol, 
114.2 mg) and HOBt (6eq, 1.737 mmol, 234.7 mg) and DMF (200 mL). The reaction 
mixture was stirred for 24 h. The reaction mixture was concentrated in vacuo and ether 
precipitated. The crude product was purified via HPLC 95:5 (water:acetonitrile) for 1 
min and then the flow was then changed to 50:50 over 10 min and held for 15 minutes 
before reducing the flow was reduced to 95:5 for 5 min, (retention time 7.7 min). The 
presence of the product was confirmed via HM ESI+ mass spectrometry: (M+H)
+ 
1013.9, (M+2H)
+ 507.7. 
NH
NH
N
H
HN
HN
HN
H
N
H
N
O
O
O
O
O
O
O
O
N
OH
HO
S
O
H2N
H
N HN
NH2
S
NChapter 6: Experimental 
190 
 
 
Figure 6.10.  HPLC trace and mass spec trace of cyclic peptide 6cys. 
 
6.1.6.17.3 Tat-tagging of cyclic-CGWNTVRS 
 
Tcep (1eq, 0.02 mmol, 5.7 mg), DMF (2 mL) and H2O (0.05mL) was added to cyclic 
peptide 6cys (1eq, 0.02 mmol 20 mg) and the mixture was stirred for 1 hr. The peptide 
was added to Tat-S-S-Py (2eq, 0.04 mmol, 77.3 mg) and DMF (2 mL) and the mixture 
was stirred for 3 hr. The crude product was purified via HPLC 95:5 (water:acetonitrile) 
for 1 min and then the flow was then changed to 60:40 over 10 min and held for 15 
minutes before reducing the flow was reduced to 95:5 for 5 min, (retention time 7.1). 
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The presence of the product was confirmed via HM ESI+ mass spectrometry: (M+2H)
+ 
1362.9, (M+3H)
+ 909.3, (M+4H)
+ 682.6, (M+5H)
+ 545.9. 
 
Figure 6.11.  HPLC trace and mass spec trace of Tat-tagged peptide 6cys. 
 
6.1.6.18 Peptide 33 
6.1.6.18.1 Synthesis of CNRYYF (Peptide 33) 
 
 
The reagents in Table 6.16 were used to synthesise the linear peptide and the coupling 
(6.1.6.4) and deprotection (6.1.6.5) steps were followed as mentioned above. 
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Reagent  Equivalents  Concentration  Mass (g) 
Fmoc-Tyr(tBu)-O-Wang resin  1  0.56  1 
Fmoc-Arg(Pmc)-OH (x2)  3  2.1  1.338 
Fmoc-Asn(Trt)-OH  3  1.68  0.831 
Fmoc-Cys(Trt)-OH  3  1.68  1228.5 
Fmoc-Phe(tBu)-OH  3  1.68  0.813 
Fmoc-Try(tBu)-OH  3  1.68  1.041 
PyBop  3  1.68  1.092 
DIPEA  6  3.36  403 µL 
Table 6.16.  Reagents for synthesis of linear peptide 33 (CNRYYF). 
 
On completion, peptide 33/resin (1.929 g) was placed in a flask and a mixture of 95.0% 
TFA (45.82 mL): 2.5% water (1.21 µL): 2.5% TIS (1.21 µL) was added.  The reaction 
was stirred for 3 h at rt. The resin was removed via filtration and washed with TFA. The 
filtrates were combined and concentrated in vacuo and re-dissolved in a minimum 
amount of TFA and ether precipitated via the addition of an 8-10 fold volume of cold 
ether (carried out in falcon tube). The solution underwent centrifugation and the residual 
solution was decanted off leaving the peptide pellet.  
Peptide 33 (1eq, 0.639 mmol, 0.622 mg) was dissolved in DMF. Aldrithiol (10 eq, 
6.39mmol, 1.4 g) was added to the reaction and stirred o/n (reaction went a lime green 
colour). The mixture was concentrated in vacuo and ether precipitated twice to remove 
excess aldrithiol. The crude product was purified via HPLC 95:5 (water:acetonitrile) for 
1 min and then the flow was then changed to 50:50 over 10 min and held for 15 minutes 
before reducing the flow was reduced to 95:5 for 5 min, (retention time 7.7 min). The 
presence of the product was confirmed via HM ESI+ mass spectrometry:(M+H)
+ 974.6. 
The peptide was dried o/n in the desiccators. Chapter 6: Experimental 
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Figure 6.12.  HPLC trace and mass spec trace of linear peptide 33. 
 
6.1.6.18.2 Synthesis of Cyclic-CNRYYF 
 
 
Linear peptide (1eq, 0.23 mmol 0.244g) was reacted with EDC (3eq, 0.69 mmol, 
136.4 mg) and HOBt (6eq, 2.07 mmol, 279.7 mg) DMF (250 mL). The reaction mixture 
NH
N
H
HN
HN NH
H
N
O
O
O
O
O
O
NH
NH H2N
OH
OH
S
O H2N
S
N
!"#$"%&%'()&$"*'((( ((( ((
!"#$"%&%'()&$"*'(
!
!
+&,-(.&'&/'0"%()&123'1(
!
"#$ %
&'(')'*+'!"#$ %,-,.-
/+0*1$ 2
&3$ .42,!56*78'9
/80)8!&3$ .4%%!56*78'9
:*;!&3$ %4-%!56*78'9
<=5>=*'*8!?6;8@$ %4A.!56*78'9
B)'0 ,AC.%D%-!0)E68)0)F!7*689
G'6H@8$ %,2ADCA!7*689
I09'!J'0K$ CA,4L
J7)68F ,24M-!N
#45 6%'&%10'7(
8*9:(;%0'1
)&3,'0<&(
6%'&%10'7
+&,-(=0>'?(
@0%2'&1
8*&,(
8*9:(;%0'1
%M - D 4 M , A A . D % . 4 , M N %4,, %L,LLLM
MM - , 4 M C , - L M 4 . A N %4DL D%LAAD
DD % % 4 M M M A D L , 4 C L N %42D ALLLD%
,D D M 4 A % M A % % M 4 A - N %4,, ,DAA..
2D - . 4 M - C A , % 4 C L N %4DL MC2-,D
L, . L 4 D % D . L , M 4 - 2 N %42D ,.CA,L
A, % L 4 , % . M L C M 4 M , N %4DL D2-L-L
-, D M 4 , C A . - M 4 % M N .4CD MA.2.C
C, D M 4 2 % % C , D M 4 L % N %4,, ,C.2-2
%. ,D24D 2ADL %4M2N %4L% %-C.2C
%% ,,D4M %,L22 D4M.N .4AL ,2CA-C
%M ,,D42 %,-%, D4MDN %4%. DL-D,L
%D ,2%4M L,-% %4,MN %4DL M%%%M-
%, ,2M4M MM.2, ,4-MN %4,, ADLLA,
%2 ,-A4C %MADA M4A-N %4MA LCD-%L
%L 2M%4D %MAC. M4ACN %4MA ,M2C-D
%A 2DA4M -AD. %4C%N %4,, D.MA2M
Page 1 of 2 RemoteAnalyzer Component Report
20/07/2011 http://152.78.196.118/RemoteAnalyzer/resultscomponentprint.aspx?id=869796BE24...
t
R 7.7 
!"#$%&'(" )*++,-. /$0(-&
1-(#$%& 2,+$3 %.%4'% 0$0&'5$6 /$0(-&$5 7.86$-3 &,9,66(4' 4,7 :,",4.6&;
/$0(-& <$&=(53 !"#$%&'(" )*++,-./$0(-& >,&$ 1-'"&$53
?@AB@ CDEDFECD?? /$0(-& <$&=(5 !>3 ?@AB@
?C3?D3DG H*-(0$EI("5(" 1,J$3 ? (K ?
) L < 1 I H ! 2 M N / < L O ! N 2
,",4.6& L%P*'-$5 Q.3 66ER@GCEGAS0$0GG4'" 0-$0G ),+04$ 2,+$3
),+04$ )$&2,+$3 8"T"(U" ),+04$ O.0$3
? V',43 L%PW <$&=(5 )$&3 1-$0 ',"
R !"#$%&'(" 3 1-(%$66'"J <$&=(53 XXXX
?DDDWDD *4 !"#$%&'(" V(4*+$3 Y=,""$4 2,+$3 XXXX
/*" O'+$3 C?WD <'"*&$6 1-(%W Y="4W >$6%-W3 XXXX
DGEDCECD?D DB3RG3CG Z<O >,&$ L%P*'-$53
>,&$ 1-(%$66$53 XXXX
Y=,""$43 CBBA Y=? CCD"+[?WC"+\ 1-(%$66$5 Y=,""$43 XXXX\ /$6*4& !53 XXXX\ 1-(%$66'"J <$&=(53 XXXX
Y=,""$43 CBBA Y=C CAD"+[?WC"+\ 1-(%$66$5 Y=,""$43 XXXX\ /$6*4& !53 XXXX\ 1-(%$66'"J <$&=(53 XXXX
L
8
DWDD
CWDD
L
8
DWDD
DWRD
?WDD
<'"*&$6
DWDD CWDD ]WDD @WDD AWDD ?DWDD ?CWDD
H--(- I(J
H--(- S 4(,5$5 &=$ U-("J &.0$ (K Y=-(+ %=,""$4 :C> 96W G>;^
Q,6'% IY 1$,T6 O,74$ J-(*0 %("&,'"6 '"K(-+,&'(" &=,&5($6"_& +,&%= &=$ 5,&, 7$'"J -$0(-&$5WChapter 6: Experimental 
194 
 
was stirred for 24 h. The reaction mixture was concentrated in vacuo and ether 
precipitated. The crude product was purified via HPLC 95:5 (water:acetonitrile) for 1 
min and then the flow was then changed to 50:50 over 10 min and held for 15 minutes 
before reducing the flow was reduced to 95:5 for 5 min, (retention time 10.4 min). The 
presence of the product was confirmed via HM ESI+ mass spectrometry: (M+H)
+ 953.7. 
 
Figure 6.13.  HPLC trace and mass spec trace of cyclic peptide 33 (protected). 
 
6.1.6.19 Peptide 32 
6.1.6.19.1 Synthesis of CRYFNV (Peptide 32) 
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The reagents in Table 6.17 were used to synthesise the linear peptide and the coupling 
(6.1.6.4) and deprotection (6.1.6.5) steps were followed as mentioned above. 
Reagent  Equivalents  Concentration  Mass (g) 
Fmoc-Tyr(tBu)-O-Wang resin  1  0.358  0.639 
Fmoc-Arg(Pmc)-OH (x2)  3  1.07  0.710 
Fmoc-Cys(Trt)-OH  3  1.07  0.543 
Fmoc-Val-OH  3  1.07  0.365 
Fmoc-Asn(Trt)-OH  3  1.07  0.460 
Fmoc-Phe(tBu)-OH  3  1.07  0.416 
PyBop  3  1.07  0.558 
DIPEA  6  2.15  374 µL 
Table 6.17.  Reagents for synthesis of linear peptide 32 (CRYFNV). 
 
On completion, peptide 32/resin (0.895 g) was placed in a flask and a mixture of 94.0% 
TFA (21 mL): 2.5% water (0.6 µL): 2.5% TIS (0.6 µL): 1% EDT (0.222 µL) was added.  
The reaction was stirred for 3 h at rt. The resin was removed via filtration and washed 
with TFA. The filtrates were combined and concentrated in vacuo and re-dissolved in 
the minimum amount of TFA and ether precipitated via the addition of an 8-10 fold 
volume of cold ether (carried out in falcon tube). The solution underwent centrifugation 
and the residual solution was decanted off leaving the peptide pellet.  
Peptide 32 (1eq, 0.34 mmol, 271 mg) was dissolved in DMF (250 mL). Aldrithiol 
(10eq, 3.4 mmol, 749 mg) was added to the reaction and stirred o/n (reaction was a lime 
green colour). The mixture was concentrated in vacuo and ether precipitated twice to 
remove excess aldrithiol. The crude product was purified via HPLC 95:5 
(water:acetonitrile) for 1 min and then the flow was then changed to 50:50 over 10 min 
and held for 15 minutes before reducing the flow was reduced to 95:5 for 5 min, 
(retention time 10.4 min). The presence of the product was confirmed via HM ESI+ 
mass spectrometry:(M+
15N)
+ 910.7. The peptide was dried o/n in the desiccator. Chapter 6: Experimental 
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Figure 6.14.  HPLC trace and mass spec trace of linear peptide 32. 
 
6.1.6.19.2 Synthesis of Cyclic-CRYFNV (cysteine protected)  
 
 
Linear peptide (1eq, 0.1 mmol 91 mg) was reacted with EDC (3eq, 0.3 mmol, 
59.31 mg) and HOBt (6eq, 0.6 mmol, 81.1 mg) in DMF. The reaction mixture was 
stirred for 24 h. The reaction mixture was concentrated in vacuo and ether precipitated. 
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The crude product was purified via HPLC 95:5 (water:acetonitrile) for 1 min and then 
the flow was then changed to 50:50 over 10 min and held for 15 minutes before 
reducing the flow was reduced to 95:5 for 5 min, (retention time 10 min). The presence 
of the product was confirmed via HM ESI+ mass spectrometry: (M+H)
+ 892. 
 
Figure 6.15.  HPLC trace and mass spec trace of cyclic peptide 32 (cysteine 
protected). 
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6.1.6.19.3 	 ﾠCyclic-CRYFNV (Removal of Aldrithiol group) 
 
 
The peptide (1eq, 2.5 mmol, 22 mg) was dissolved in degassed MeOH (44 mL) and 
propandithiol (4eq, 18.75 mmol, 2.2 µL) was added. The reaction was stirred for 6 hr. 
The crude product was purified via HPLC  95:5 (water:acetonitrile) for 1 min and then 
the flow was then changed to 50:50 over 10 min and held for 15 minutes before 
reducing the flow was reduced to 95:5 for 5 min, (retention time 12.2 min). The 
presence of the product was confirmed via HM ESI+ mass spectrometry: (M+H)
+ 783. 
The purified product was freeze dried and stored in the -80 °C freezer. 
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Figure 6.16.  HPLC trace and mass spec trace of cyclic peptide 32. 
 
6.2  In vivo effects of CtBP Dimerisation Inhibition 
6.2.1  Mammalian Cell Reagents 
Thermo scientific Griener, U.K supplied all tissue culture plastic ware. 
Invitrogen Life technologies, UK: 
  Hank’s Balanced Salt Solution (HBSS)       
    - (1X) liquid without Calcium and Magnesium  
  Dulbecco’s modified Eagle’s medium (DMEM)     
  Trypsin-EDTA 
  Peninillin/Streptomycin/L-Glutamine 100X concentration 
    Penicillin G            10 mg/mL 
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    Streptomycin            10 mg/mL 
    L-Glutamine            29.2 mg/mL 
Promega, U.K 
  CellTiter 96
® AQueous One Solution Cell Proliferation assay 20 µl/well 
PAA Laboratories, Austria 
  Foetal Calf Serum (FCS) 
   
6.2.2  Mammalian cell culture techniques 
6.2.2.1  Cell line, culture conditions and cell passage 
Cell lines MCF-7 and MDA-MB231 were cultured at 37 °C in a humidified atmosphere 
containing 10% CO2 (HERA Vell, Heraeus), with DMEM supplemented with 10% 
(v/v) FCS and 1% (v/v) penicillin/streptomycin/glutamine. All media were pre-warmed 
to 37 °C before use, and the culture media was renewed every 48-72 hr. 
Cell passaging was performed by removing the culture medium and washing the cells 
with HPSS solution. Following this cells were treated with trypsin (typically 1 mL for a 
75 cm
2 flask) and incubated at 37 °C for 5 min or until all cells had detached. Fresh 
growth medium was then added and cells plated at the required density. 
 
6.2.2.2  Cryopreservation and thawing of cells 
Monolayers were disassociated by trypsinisation as described (6.2.2.1) and cells re-
suspended in complete growth media. Cells were collected by Centrifugation at 
1399 rpm (Sorvall legend 
TM RT, Rotor 6445) for 3 min. Cells were re-suspended in 
2 mL of freezing media (50% (v/v) DMEM, 40% (v/v) FCS and 10% (v/v) Dimethyl 
Sulfoxide (DMSO) and transferred to cryovials (greiner, U.K), Cryovials were placed in 
an insulated Styrofoam box (Nalgen U.K) which was sealed and stored at -80 °C. 24 hrs 
later the vials were transferred to liquid nitrogen for long term storage. 
Cells were thawed by removing the cryovial from the liquid nitrogen and allowing rapid 
thawing at 37 °C. Once thawed the cells were added carefully to 10 mL or pre- warmed Chapter 6: Experimental 
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growth media. Cells were collected by centrifugation at 3000 rpm (Sorvall legend 
TM 
RT, Rotor 6445) for 3 min and re-suspended in the desired volume of complete media 
prior to culture and stored in the incubator. 
 
6.2.3  Transfection 
Transfection was carried out using INTERFERin
TM siRNA transfection reagent from 
Source Bioscience Lifescience. Cells were plated 24 hrs prior to transfection, typically 
in 60 mm dishes. 3.75 µL, 25 nM CtBP2 siRNA was added to an eppendorf containing 
400 µL of optimum and vortexed. 15 µL of Interferin was added and vortexed for a 
further 10 sec and left to stand for 10 min before adding to the media. Cells were then 
returned to the incubator for 4 hr. At the end of the incubation time the media was 
replaced with fresh media. 
 
6.2.4  Time-Lapse Experiments 
6.2.4.1  Peptide Microinjection Time-lapse Experiment 
6.2.4.1.1  Preparation of MCF-7 Cells for Microinjection with Peptide 6 
and Peptide 61 
The media (trypsin and DMEM) was pre-warmed in a 37 ºC water bath. The fumehood 
and gloves were sprayed with ethanol to ensure sterility. The media was removed from 
the T flask containing the cells using the aspirator and pipette. 10 mL of HPPS media 
was added to the flask. The media was then removed. 1 mL of Trypsin was added to the 
flask (ensuring that the surface was covered), and the flask was left in the incubator for 
∼5 min. The flask was checked under the microscope to see whether the cells had lifted. 
DMEM was added to the flask and transferred into a falcon tube (to prevent cells from 
adhering to the plate again). The cells were counted using a hemocytometer (require 10
5 
cells). The required amount was replated into the flask. 200 µL of cells was added to the 
centre of the 60mm dish (where the marking for microinjection was) and incubated for 
30 min at 37 ºC. 3mL DMEM was added to the plate and incubate at 37 ºC for 24 h. The 
media was removed and washed with DMEM no adds media a couple of times. 3 mL of Chapter 6: Experimental 
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DMEM no adds media was added to the plate and incubated at 37 ºC for 40 h. The 
media was removed and replaced with DMEM and incubated at 37 ºC for 30 h.    
 
6.2.4.1.1  Preparation of CtBP2 siRNA treated MCF-7 Cells for Microinjection 
with Peptide 6 
200 µL of cells was added to the centre of the 60mm dish (where the marking for 
microinjection was) and incubated for 30 min at 37 ºC. 3mL DMEM was added to the 
plate and incubated at 37 ºC for 24 h. The media was removed and washed with DMEM 
no adds media a couple of times. 3 mL of DMEM no adds media was added to the plate 
and incubated at 37 ºC for 40 h. Transfection with CtBP2 siRNA was carried out as 
described in 6.2.3. Instead of replacing the media after 4 hr, media was replaced with 
DMEM media after 8hr. The cells were microinjected 24 hr later. 
 
6.2.4.1.2  Microinjection 
Cells were plated in 60 mm dishes prior to microinjection. Media was replaced with 
Leibovitz’s L-15 medium containing serum to control pH during microinjection, which 
was performed with an eppendorf microinjection system (Femtojet and InjectMan N12), 
mounted on an Axiovert 35M microscope with heated stage. The peptide was injected 
into the Cytoplasm; Dextran-FITC was co-injected to allow cells to be followed (4 µL 
was loaded into the injection needle. The Pressure varied with the sample. Injection 
time was set to 1/2 sec.  
 
6.2.4.2  Running Time-lapse Microscopy  
Fluorescence time-lapse microscopy of MCF-7 cells was performed using an Olympus 
IX81 microscope with CO2- and temperature-controlled environmental chamber 
controlled by SIS Cell P software, for a period of 48 hr. Image J software was used for 
analysis. 
IX81 Multiple fluorescence (mFIP) set up was as follows: 
•  Switch on the microscope, stage controller, mercury bulb and computer etc 
•  Create a folder in the data folder on the hard drive (to hold images of run). Chapter 6: Experimental 
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•  Start Cell^P log into the microscope (password ‘a’) and bring up the microscope 
and camera control windows. 
•  Bring up the Define Fluorescence Acquisition window – acquire > Multiple 
fluorescence > define Fluorescence acquisition (should have phase and FITC) > 
Select phase method, click preview focus the image and the exposure time, then 
set focus level by clicking focus stop the preview by clicking on the snap shot > 
Select the FITC, click start preview, focus image and adjust exposure time, then 
click read and stop the preview > Save the method. 
•  Define ISP – acquire > define ISP > flow tab, cycle setup number of frames and 
cycle repeat times > under acquire mode select mFIP method from above > 
under save image select folder created earlier > settings tab provide a path name 
> macro tab tick sequence apply preprocessing and click define and type 
IXC::ixSetShutterOpen(TRUE,FALSE);  > Add sequence find image and then 
read image do this for all images then save and run. 
 
6.2.4.3  Tat-Tagged time-lapse experiment 
6.2.4.3.1  Testing Tat-Tagged Peptide 6, 61 and Tat 
Cells (40,000) were dosed and plated into 24 well plates. Peptides 6, 61 and Tat were 
tested at a concentration of 50 µM and 100 µM. Once the cells had adhered to the plate, 
the plate was loaded onto the time-lapse microscope using phase imaging. 
 
6.2.4.3.2  Testing Tat-Tagged Peptide 6 with CtBP2 siRNA 
MCF-7 and MDA-MB231 cells were treated with CtBP2 siRNA following the 
transfection protocol above (6.2.3). CtBP2 siRNA treated cells were then dosed and 
plated into 24 well plates. Peptide 6 and Tat were treated at a concentration of 50 µM 
and 100 µM. Once the cells had adhered to the plate, the plate was loaded onto the time-
lapse microscope using phase imaging. 
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6.2.5  Immunoflourescence analysis 
Cells were grown on coverslips in 24 well plates; the media was removed and washed 
with PBS. The cells were fixed with 4% paraformaldehyde in PBS for 10 min. Wells 
were washed with PBS, 1 mM Glycine and 0.2% Triton X-100/PBS (2 mL) was added 
and incubated for 15 min at rt, The wells were washed with PBS and then blocked for 
30 min in 10% FCS/PBS. The p53 primary antibody (1:100) in 0.6% BSA/PBS 
(100 µL) was added and incubated for 1 hr. The wells were then washed with PBS for 5 
min. The Rabbit-α-mouse FITC secondary antibody (1:50) in 0.6% BSA (100 µL) and 
DAPI (1:1000) was added and incubated in a humidified box for 90 min. Coverslips 
were mounted onto slides with fluorescent mounting medium (DakoCytomation). All 
cells were visualized using a Zeiss Axiovert 200 fluorescence microscope with a 40 xs 
or 100 xs objective. Images were collected using an Orca-ER digital camera 
(Hamamatsu) and processed using Openlab 3.5.1 Software (Improvision). Identical 
exposure times were applied for different images within the same experiment.  
 
6.2.6  3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenol)-2H-tetrazolium (MTS) assay 
For cell MTS assays, the cells were plated at 4000 cells per a well in 96 well plates. 
Cells were left to adhere for 24 hr at 37 ºC in a humidified atmosphere containing 10% 
CO2 (HERA Vell, Heareus). Media was replaced with 100 µL medium containing serial 
dilution of the peptides. The final concentration of solvent DMSO, was 1/200 in all 
wells. All conditions were assayed in triplicate. After 48 h the media was removed and 
replaced with fresh medium before performing an MTS-based assay (CellTitre Aqueous 
One Cell Proliferation assay, Promega). 10 µL of CellTitre Aqueous one solution 
reagent was added to each well, the plate was incubated at 37 °C in a humidified 5% 
CO2 atmosphere for 3 hrs to allow the colorimetric reaction to occur. The reduction of 
MTS inner salt to the coloured water soluble product formazan was measured at 490 nm 
using a plate reader (Thermo Fischer scientific Varioskan Flash).  
6.2.7  Colony forming assay 
2500 cells were dosed and plated into 96 well plates with 50 mM of peptide. Cells were 
detached with trypsin 2 days post-transfection in 96-well plates and 10% of the volume Chapter 6: Experimental 
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of harvested cells was replated into 6-well plates. The cells were grown for a further 10 
days with a change of growth medium every 3 to 4 days. Colonies were fixed with 
MeOH and stained with Giemsa (Sigma) and counted manually. 
 
6.2.8  MeOH fixing and Giemsa staining of cells 
Media was removed from the plates and washed with PBS (1 mL). MeOH (1 mL) was 
added and left for 5 min, rinsed then left to air dry. Giemsa stain (1:20 dilution) was 
added and left for 60 min. Plates were washed with water for 4 min and then with PBS 
and left to air-dry. 
 
6.2.9  Preparation of cell pellets and fixation from adherent mammalian 
cells for DNA content of cells by propidium iodide (PI) staining 
flow cytometry. 
Plates were removed from the incubator. The media was removed and added to the 
microcentrifuge tube. Wells were washed with PBS and added to centrifuge tubes. 
Trypsin was added to the plates to detach the cells. Wells were washed with the media 
in the microcentrifuge tubes. Everything was collected in the microcentrifuge tubes and 
centrifuged for 5 min at 1000g (3000 rpm). The supernatant was removed and the cell 
pellet was re-suspended in PBS (1 mL). The microcentrifuge tubes were centrifuged for 
5 min at 1000g (3000 rpm), the supernatant was removed and the cells were 
re-suspended in 70% Ethanol/water and stored at 4 °C. 
Staining and flow cytometry was carried out by Dr Charles Birts. The ethanol 
suspended cells were centrifuged at 1000g  (no breaking) and the supernatant was 
removed. PBS (1 mL) was added to the samples and mixed by pipetting up and down. 
The samples were left for 1 min and re-centrifuged. The supernatant was removed and 
the pellet was re-suspended in 0.5-1 mL PI staining solution. The sample was incubated 
at 37 °C for 15 min the at rt for 30 min. Flow cytometry was carried out according to 
the instructions in the operating manual.  
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6.3  In vitro Analysis of Peptides Developing ELISA  
6.3.1  Protein Purification Reagents 
Protease inhibitor cocktail tablets (Roche)       
Sample Buffer (for SDS-PAGE)             
                Final Concentration 
  Tri-Hydrochloric Acid pH6.8         50 mM 
  Sodium Dodecyl Sulphate          12% (w/v) 
  Bromophenol Blue            0.1% (w/v) 
  Supplemented with 10% Dithiothreitol (DTT) added fresh   
 
6.3.1.1  10X concentration Protein Running Buffer  
Tris Base              30 g 
Glycine              144 g 
Sodium Dodecyl Sulphate          10 g 
H2O                to 1 L 
6.3.1.2  10X Tris-Glycine (TG) 
  Tris Base              29 g 
  Glycine              145 g 
  H20                to 1 L 
 
6.3.1.3  Transfer Buffer 
  10X TG              100 mL 
  H2O                700 mL 
  Methanol              200 mL Chapter 6: Experimental 
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6.3.1.4  Coomassie Blue 
  Glacial Acetic acid            10% (v/v) 
  Ethanol              10% (v/v) 
  Distilled water             45% (v/v) 
  Coomassie Blue Powder          0.05% (w/v) 
 
6.3.1.5  10 mL Lysis Buffer 
(10 mL of lysis buffer per g pellet) 
Composition of lysis buffer 
  Amount   Stock  Final concentration 
TrisHCl pH 8  200 µL  1 M  20 mM 
NaCl  625 µL  4 M  250 mM 
Triton X  100 µL  20%  0.2% 
Lysozyme  2 µL  1000 x   
DNASI  50 µL  2 mg/mL  125 µg/mL 
MgCl  100 µL  1 M  10 mM0. 
Table 6.18.  Composition of lysis buffer 
 
6.3.1.6  Binding Buffer (500 mL) 
  Amount  Stock  Final concentration 
TrisHCl (Fisher) 
pH 7.4 
10 mL  1 M  20 mM 
NaCl (Fisher)  43.75 mL  4 M  350 mM 
Table 6.19.  Composition of Binding buffer. 
 
6.3.1.7  Elution Buffer (100 mL) 
Imidazole (1.7 g, 250 mM) was mixed with the binding buffer (100 mL). The pH was 
adjusted to 7.4. Chapter 6: Experimental 
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6.3.2  Protein Quantification 
6.3.2.1  Recombinant protein production and purification 
E. Coli BL21 and RIPL competent cells were used for production of recombinant GST 
fusion protein and His fusion protein as they give high-level expression and are 
protease-deficient strain. 
 
6.3.2.2  Protein Purification 
6.3.2.2.1  Cell culture and Lysis 
Cell cultures and induction was kindly set up by Dr Patrick Duriez. Competent cells 
transformed with the appropriate vector were cultured o/n at 37 °C with shaking in 
5-10 mL of LB media supplement with antibiotics. The culture was then subcultured o/n 
in LB medium (50 mL). Another subculture (500 mL) was set up and once the OD 
reached 0.6 induction was carried. IPTG (0.2 mM) was added and the culture was 
incubated for a further 2 hr at 25 °C. The culture was centrifuged at 4000 rpm at 4 °C 
for 25 min and the supernatant was discarded. The pellet was subsequently re-
suspended in 50 mL of ice-cold PBS and split into two 50 mL tubes. The samples were 
centrifuged at 4000 rpm at 4 °C for 10 min the supernatant was discarded and the pellet 
was stored at –20 °C until required.  
The pellet was thawed and lysed with lysis buffer (10 mL/mg) (kept on ice). Sample 
was left on ice for 10 min, then freezed/thawed using dry ice. Sonication was applied 
(4x 20 min pulses at 6.5) and the tubes were kept on ice. The lysed cells were 
centrifuged at 15000 rpm at 4 °C for 20 min and the sample were collected before and 
after centrifugation. The pellet (insoluble protein) was discarded and the supernatant 
(soluble protein) was kept for further purification. 
 
6.3.2.2.2  Purification on FPLC Column 
Once cells were lysed, the supernatant was filtered and loaded onto the column (GSTrap 
column (GE Healthcare) for GST-CtBP protein and HisTrap column (GE Healthcare) Chapter 6: Experimental 
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for His-CtBP protein). The column was then washed with binding buffer. Sodium 
pyruvate (50 mL, 0.25 mM) was made up in binding buffer. 15 ml was applied to fill 
line A and the column, and the FPLC was paused for 20 min. The rest of the sodium 
pyruvate/binding buffer was then washed through over 10 min (30 min of total contact 
with sodium pyruvate). Binding buffer was then applied.  Wash buffer was then applied 
in line B in a stepwise manner: first 4% (20 mM imidazole) then 8% (40 mM 
imidazole) then a10 ml gradient from 16% to 100% (20-250 mM imidazole) was 
applied to elute the purified protein. Fractions were collected throughout the run and 
then run on the SDS-PAGE gel in order to identify fractions containing the protein.  
 
6.3.2.2.3  Purification on Beads (Ni-NTA Superflow, Qiagen)) 
1.5 mL of 75% beads was washed with 15 mL of PBS (to prepare 2 mL of 50% beads). 
1 mL of 50% beads was added to 50 mL of supernatant. The beads were incubated o/n 
at 4 °C under rotation. After o/n capture the beads were centrifuged at 1300 rpm, and 
the supernatant was retained and loaded on the gel (unbound). The beads were washed 
with 50 mL binding buffer twice (saving both washes). The beads were then incubated 
with 0.25 mM sodium pyruvate in binding buffer for 30 min at 4 °C under rotation 
(wash 3). The beads were incubated with binding buffer and 20 mM imidazole for 20 
min at 4 °C under rotation (wash 4). 
The beads were then transferred onto a column and mounted onto the FPLC. Wash 
buffer was then applied in a stepwise manner: 16% (40 mM imidazole), 20% (50 mM 
imidazole) and 24% (60 mM imidazole). Finally, a 18 mL gradient from 24% to 100% 
(60-250 mM) was applied. Fractions were collected throughout the run and then run on 
the SDS-PAGE gel in order to identify fractions containing the protein. The retained 
washes collected from the beads were also run on the SDS-PAGE gel to confirm that 
the protein was not lost in the washes.  
 
6.3.2.3  Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
SDS-PAGE was used to analyse protein samples from cell extracts and protein 
purification samples. Proteins were separated by SDS-PAGE prior to further analysis Chapter 6: Experimental 
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using 12% gradient Tris-HCL SDS-polyacrylamide gels. Samples were heated to 95 °C 
for 5 min prior to loading. 20 µg of protein was loaded onto the gel in 1 x protein 
running buffer (6.3.1.1) and broad range protein marker (New England Biolabs, U.K) 
was used as a molecular weight markers. Electrophoresis was conducted at 200 V for 1 
hr or until the dye front reached the bottom of the gel in mini-protean III cells (Bio-Rad, 
U.K) 
Resolving gel (12%) 
40% Acrylamide-Bis (29:1)            3.0 mL 
Water                  5.4 mL 
1.5 M Tris pH 8.8              2.5 mL 
20% SDS                50 µL 
10% Ammonium Persulphate           100 µL 
TEMED                5 µL  
 
6.3.2.4  Coomassie Blue Stain 
Coomassie Blue Staining was used to quantify protein levels on 12% gradient Tris-HCL 
SDS-polyacrylamide gels. Coomassie blue binds non-specifically to all proteins with 
approximately 1:1 stoichiometry. After completion of SDS-PAGE, the gel was removed 
from the mini-protean III cells (Bio-Rad, U.K.). The gel was incubated with shaking in 
Coomassie blue for 1 hr at room temperature. The gel was then washed with boiling 
water to distain for 20 min at room temperature. The process was repeated 2 times to 
remove excess stain. The gel was placed on Whatmann paper 3 mm and wrapped in 
cellophane prior to drying under vacuum at 80 °C for 1 hr. 
 
6.3.2.5  Protein quantification 
Bio-Rad’s protein assay reagent, which provides a simple calorimetric assay for 
measuring total protein concentration in a sample, was used (Bio-Rad, UK). Protein was 
added into the wells of a 96 well plate at different concentrations. 50 µL of neat Bio-rad Chapter 6: Experimental 
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reagent was added. The plate was then assayed on the plate reader to measure the 
absorbance at 595 nm. Protein concentration could then be calculated using a standard 
curve of known Bovine Serum Albumin concentration against absorbance.  
 
6.3.3  ELISA  
Binding Buffer - TBS pH 7.4 (500 mL) 
  Molecular 
weight 
Mass  Final 
concentration 
TrisHCl  157.6  3.94  50 mM 
NaCl  58.44  4.38  150 mM 
Table 6.20.  Composition of Binding buffer 
 
Wash buffer – TBS + 0.05% tween-20-20 pH7.4 (200 mL)  
100 µL of tween-20 was added to 200 mL of binding buffer. 
 
6.3.3.1  CtBP1 Homodimeric assay 
The glutathione coated 96 well plate (15240 thermo Scientific) was rinsed three times 
with wash buffer (200 µL). Purified GST-CtBP1 protein was prepared in wash buffer 
(100 ng, 100 µL) and was applied to duplicate wells. GST in wash buffer (100 ng, 
100 µL) was applied to separate duplicate wells to measure background. The plate was 
covered and incubated at room temperature for 1 hr. The wells were washed three times 
with wash buffer (200 µL) for 5 min.  The wells were blocked using 3% BSA (Bovine 
serum Albumin protease free powder, Cat 700-101P, Gemini Bio Products) in TBS 
(200 µL). Dilutions of the peptide (0, 1, 5, 10, 50, 100, 500, 1000, 5000, 10000 and 
50000 nM) was mixed with purified His-CtBP1 protein (600 ng, 100 µL) and added to 
the wells for 30 min. NADH (Sigma-Aldrich, CAS Number: 104809-32-7) (0.5 mM) 
was added to the wells giving a final volume of 150 µL per well. The plate was 
incubated at room temperature for 1 hr.  Wells were washed three times with wash 
buffer (200 µL) for 5 min. A 1/5000 dilution of mouse anti-His antibody was prepared Chapter 6: Experimental 
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in 3% BSA-TBS/0.05% tween-20 and 100 µL was added to each well. The plate was 
covered and incubated at room temperature for 90 min. Plates were washed three times 
with wash buffer (200 µL) for 5 min. A 1/10000 dilution of sheep anti mouse HRP 
labelled secondary antibody was prepared in 3% BSA-TBS/0.05% tween-20 and 
100 µL was applied to each well. The plate was covered and incubated at room 
temperature for 1 hr. Wells were washed three times with wash buffer (200 µL) for 
5 min. Super signal (100 µL) (thermo Scientific) was applied to each well. The 
Luminescence measured was on the plate reader (Thermo Fischer scientific Varioskan 
Flash). 
 
6.3.3.2  CtBP2 Homodimeric assay 
The glutathione coated 96 well plate (15240 thermo Scientific) was rinsed three times 
with wash buffer (200 µL). Purified GST-CtBP2 protein was prepared in wash buffer 
(200 ng, 100 µL) and was applied to duplicate wells. GST in wash buffer  (200 ng, 
100 µL) was applied to separate duplicate wells to measure the background. The plate 
was covered and incubated at room temperature for 1 hr. The wells were washed three 
times with wash buffer (200 µL) for 5 min.  The wells were blocked using 3% BSA 
(Bovine serum Albumin protease free powder, Cat 700-101P, Gemini Bio Products) 
TBS/0.05% tween-20 (200µL). Dilutions of the peptide (0, 1, 5, 10, 50, 100, 500, 1000, 
5000, 10000 and 50000 nM) was mixed with purified His-CtBP2 protein (600 ng, 
100 µL) and added to the wells for 30 min. NADH (0.5 mM) was added to the wells 
giving a final volume of 150 µL per well. The plate was incubated at room temperature 
for 1 hr. The wells were washed three times with wash buffer (200 µL) for 5 min. A 
1/5000 dilution of mouse anti-His antibody was prepared in 3% BSA-TBS/0.05% 
tween-20 and 100 µL was added to each well. The plate was covered and incubated at 
room temperature for 90 min. The wells were washed three times with wash buffer 
(200 µL) for 5 min. A 1/10000 dilution of sheep anti mouse HRP labelled secondary 
antibody was prepared in 3% BSA-TBS/0.05% tween-20 and 100 µL was applied to 
each well. The plate was covered and incubated at room temperature for 1h. Wells were 
washed three times with wash buffer (200 µL) for 5 min. Super signal (100 µL) (thermo 
Scientific) was applied to each well. The Luminescence was measured on the plate 
reader (Thermo Fischer scientific Varioskan Flash). Chapter 6: Experimental 
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6.3.3.3  CtBP Heterodimeric assay 
The glutathione coated 96 well plate (15240 thermo Scientific) was rinsed three times 
with wash buffer (200 µL). Purified GST-CtBP2 protein was prepared in wash buffer 
(200 ng, 100 µL) and was applied to duplicate wells. GST in wash buffer (200 ng, 
100 µL) was applied to separate duplicate wells to measure the background. The plate 
was covered and incubated at room temperature for 1 hr. Plates were washed three times 
with wash buffer (200 µL) for 5 min.  The wells were blocked using 3% BSA (Bovine 
serum Albumin protease free powder, Cat 700-101P, Gemini Bio Products) in TBS 
(200 µL). Dilutions of the peptide (0, 1, 5, 10, 50, 100, 500, 1000, 5000, 10000 and 
50000 nM) was mixed with purified His-CtBP1 protein (600ng, 100 µL) and added to 
the wells for 30 min. NADH (0.5 mM) was added to the wells giving a final volume of 
150 µL per well. The plate was incubated at room temperature for 1 hr. The wells were 
washed three times with wash buffer (200 µL) for 5 min. A 1/5000 dilution of mouse 
anti-His antibody was prepared in 3% BSA-TBS/0.05% tween-20 and 100 µL was 
added to each well. The plate was covered and incubated at room temperature for 90 
min. The wells were washed three times with wash buffer (200 µL) for 5 min. A 
1/10000 dilution of sheep anti mouse HRP labelled secondary antibody was prepared in 
3% BSA-TBS/0.05% tween-20 and 100 µL was applied to each well. The plate was 
covered and incubated at room temperature for 1 hr. Wells were washed three times 
with wash buffer (200 µL) for 5 min. Super signal (100 µL) (thermo Scientific) was 
applied to each well. The Luminescence was measured on the plate reader (Thermo 
Fischer scientific Varioskan Flash). 